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Children hospitalised with severe anaemia in malaria-endemic areas are at high risk of readmission 
or death within six months post-discharge. No strategy specifically addresses this post-discharge 
period. This thesis aims to provide evidence of the burden of post-discharge mortality and 
morbidity among children less than five years of age who are admitted with all-cause severe 
anaemia and other syndromes and living in malaria-endemic areas of Africa. We also report the 
results of a malaria chemoprevention trial for the post-discharge management of severe anaemia. 
In the first study, we conducted a retrospective cohort analysis using data collected between 2008 
and 2013 from continuous paediatric in-hospital surveillance and population-based surveillance in 
western Kenya. During this period, 3,639 hospital admissions involving 4,423 different diagnoses 
were recorded. Overall, in-hospital mortality was 2.8% and the post-discharge mortality by three, 
six and twelve months among the 3,538 survivors was 7.6%, 9.4%, and 12.4%, respectively. 
Admissions with severe acute malnutrition and severe anaemia were associated with the highest 
post-discharge mortality in the first six months. Severe anaemia was associated with a significantly 
higher odds of six-month post-discharge mortality than in-hospital mortality (Mantel-Haenszel odds 
ratio [MHOR]=2.02, 95% CI 1.19-4.05, p=0.011). 
In the second study, we conducted a systematic review and meta-analysis to determine the pooled 
risks of morbidity and mortality in the post-discharge period among children admitted with severe 
anaemia versus other syndromes in malaria-endemic areas in Africa. Children admitted with severe 
anaemia were found to have higher odds of dying within six months post-discharge than during the 
in-hospital stay (N=4, MHOR=1.44, 95% CI 1.07-1.92, p<0.0157, I2=0.8%)  and they were twice as 
likely to die by 6 months post-discharge compared with children admitted without severe anaemia 
(N=4, Relative Risk [RR]=2.80, 95% CI 1.61-4.86, p<0.0001, I2=73.1%). Severe acute malnutrition was 
also associated with increased post-discharge mortality compared to children admitted without 
severe anaemia or malnutrition (N=2, RR=4.27, 95% CI 2.42-7.55, p<0.0001, I2=76.8). The risk of 
readmission was also higher among children admitted with severe anaemia compared to other 
syndromes (RR=3.05, 95% CI 1.12-8.35, p<0.001, I2=0.0%). 
The third study was a randomised placebo-controlled trial in nine hospitals in Kenya and Uganda to 
determine if three months of post-discharge malaria chemoprevention (PMC) with monthly 3-day 




readmissions and deaths by six months post-discharge (primary outcome). Children aged <5 years 
with admission haemoglobin of <5g/dL were eligible. A 3-day course with artemether-lumefantrine 
was given to all children at discharge. Children were then randomised to receive DP or placebo-DP 
at two, six, and ten weeks post-discharge and followed until week 26 inclusive. There were 184 
primary outcome events in the PMC arm and 316 in the placebo arm (HR=0.65, 95% CI 0.54-0.78, 
p<0.001). The HR was 0.30 (95% CI 0.22-0.42, p<0.001) during the PMC-intervention period (2-14 
weeks) and 1.13 (95% CI 0.87-1.47, p=0.35) during the post-intervention period (15-26 weeks), 
p<0.001).   
This thesis shows that children admitted with severe anaemia and other acute conditions are at a 
high risk of post-discharge mortality and morbidity. Admission with all-cause severe anaemia in this 
setting is associated with a doubling of the risk of post-discharge mortality compared to other acute 
conditions. Malaria chemoprevention with three monthly courses of DP is a promising tool for post-
discharge management of children recently admitted with severe anaemia in malaria-endemic 
areas.
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Statement of involvement of the PhD candidate in the PMC trial 
The PMC trial was conducted in hospitals situated in areas with moderate to intense malaria 
transmission around Lake Victoria in Kenya and Uganda between May 2016 to November 2018. 
This was one of the five major activities of the post-discharge malaria chemoprevention consortium 
funded by the Global Health and Vaccine Research program (GLOBVAC) through the University of 
Bergen, Norway. The consortium had five major objectives including the PMC confirmatory safety 
and efficacy trial; a delivery mechanisms trial and health services research in Malawi to determine 
the uptake, effectiveness, acceptability and feasibility of PMC delivery mechanisms; PMC 
intervention impact analysis involving systematic reviews, meta-analyses and mathematical 
modelling to determine the public health impact of PMC; economic evaluation of the intervention 
and a policy liaison task force with the World Health Organization (WHO).  
This thesis includes a report of the findings of the confirmatory safety and efficacy trial conducted 
in Kenya and Uganda as well as the findings of the systematic review and meta-analysis of the post-
discharge burden of severe anaemia in malaria-endemic areas of Africa. 
The study was conceived by Prof Feiko ter Kuile and Prof Kamija Phiri. The original protocol was 
drafted prior to the recruitment of the PhD candidate Dr Titus Kwambai, by Prof Feiko ter Kuile, 
Prof Kamija Phiri, Prof Chandy C John, Dr Richard Idro and Dr Robert Opoka. Additionally, Dr Titus 
Kwambai, Dr Aggrey Dhabangi, Dr Meghna Desai, Dr Simon Kariuki, Prof Michael Boele van 
Hensbroek and Prof Bjarne Robberstad helped to further develop the study design in a protocol 
workshop while Prof Duolao Wang provided statistical expertise. Dr Titus Kwambai, Dr Aggrey 
Dhabangi and Prof Feiko ter Kuile drafted the protocol amendments.  
Dr Titus Kwambai and Dr Aggrey Dhabangi were responsible for developing the study data 
collection tools, standard operating procedures, recruitment and training of study personnel and 
set up of field sites under the local supervision of Professor Feiko ter Kuile and Dr Simon Kariuki in 
Kenya and Dr Richard Indo and Dr Robert Opoka in Uganda. In Kenya, Mr Nickline Ashitiba 
supervised the daily activities of the field staff under the supervision of Dr Titus Kwambai. Mr 
Kephas Otieno and Telesphorus Odawo coordinated the laboratory work.  Prof Feiko ter Kuile had 
the overall responsibility for the trial. Dr Titus Kwambai was directly responsible for drafting the 
protocol amendments, budgeting and procurement of study supplies; staff training and appraisal, 
data collection and documentation as per good clinical practice guidelines; coordination of 
laboratory, field activities and interaction with the Ministry of Health and study hospitals in Kenya; 
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coordination of trial monitoring activities; safety monitoring and correspondence with ethics review 
committees of the Kenya Medical Research Institute (KEMRI), and the LSTM; a compilation of 
annual reports to KEMRI, LSTM and CDC.   
Dr Titus Kwambai and Mr Eric Onyango were responsible for data cleaning and reporting. Drafting 
of the data analysis plan and data analysis were conducted by the Dr Titus Kwambai and Ms Vicky 
Watson in consultation with Prof Feiko ter Kuile, Prof Duolao Wang and Dr Tao Chen.  
Dr Titus Kwambai did the data management and conducted the data analysis, for the retrospective 
cohort study (Chapter 3) and the systematic review and meta-analysis (Chapter 4). Ms Victoria 
Watson provided statistical support for Chapter 6, and Dr Sarah Nevitt provided statistical support 
and advice for Chapters 3 and 4. 
This thesis was prepared and written by the PhD candidate with guidance and support from the 
PhD supervisors.  
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Chapter 1: Preface 
General Introduction 
Severe anaemia due to severe malaria or other acute or chronic conditions is a leading cause of 
hospital admissions and mortality in the paediatrics population in malaria-endemic areas of Africa. 
Children under five years of age admitted with severe anaemia have an equal or higher risk of 
death or readmission for several months after discharge compared to the acute initial in-hospital 
period.1 This is a neglected high-risk period. Earlier studies in high malaria transmission areas of 
Kenya and Malawi showed that malaria in the post-discharge period is an important contributor 
responsible for slow haematological recovery, rebound severe anaemia and morbidity in this high-
risk population.2 Currently, there is no strategy that addresses this potentially preventable 
component of the burden of severe anaemia. A proactive approach using several months of post-
discharge malaria chemoprevention could offer substantial public health gains.  
This thesis is designed to provide further evidence of the burden of severe anaemia in the post-
discharge period in children living in malaria-endemic areas of Africa and reports the results of a 
multi-site, double-blind placebo-controlled trial of three months of malaria chemoprevention to 
reduce all-cause mortality and readmission in the post-discharge management of young children 
with severe anaemia in malaria-endemic areas in Africa. 
Thesis Outline  
• Chapter 1: Preface 
• Chapter 2: The Literature review.  
• Chapter 3: Describes the findings of a retrospective cohort analysis of historical data from a 
Health and Demographic Surveillance Site (HDSS) in western Kenya on the relationship 
between hospital admission with severe anaemia or other syndromes and the post-
discharge risk of mortality in children under five years of age. 
• Chapter 4: Presents the findings of a systematic review and meta-analysis of post-discharge 
risks of morbidity and mortality in children admitted with severe anaemia and other 
syndromes in malaria-endemic settings in Africa. 
Chapter 1: Preface 
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• Chapter 5: Presents the study protocol for the randomised controlled trial on malaria 
chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge 
management of severe anaemia in children aged less than five years in Uganda and Kenya. 
• Chapter 6: Describes the findings of the randomised controlled trial (chapter 5) and 
discusses the results.  
• Chapter 7: Provides the summary and discussions and gives recommendations based on 
the current body of knowledge. 
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Chapter 2: Literature Review 
The burden of malaria in children 
Remarkable progress in reducing under-five mortality rates globally was made between 1990 and 
2015 under the United Nations (UN) Millennium Development Goals (MDGs) agenda where under-
five mortality fell from 90.6 to 42.5 deaths per 1000 live births.3  Globally 5.5 million children died 
with sub-Saharan Africa contributing 2.8 million deaths in 2017.4 Despite being a largely 
preventable and treatable disease, malaria accounted for 219 million new cases resulting in 
435,000 deaths globally with sub-Saharan Africa disproportionately contributing 93% of these 
deaths of whom 266,000 were children under five years of age constituting 61% of global malaria 
deaths.5 Malaria is a major underlying condition and a significant contributor to severe anaemia, 
malnutrition and low birth weight in sub-Saharan Africa.6,7  
Severe malaria has been shown to lead to physical and neurocognitive impairments including 
spastic motor weakness, hearing deficits, loss of speech, blindness, epilepsy and behavioural 
problems in children which may manifest in the immediate post-discharge period or later in life as 
children are faced with more complex cognitive and linguistic demands, socially and 
educationally.8,9 Treatment of malaria has substantial direct and indirect costs to households and 
the whole economy. In Kenya, it costs up to US$ 38.95 to treat a child under five years of age with 
severe malaria anaemia,10 in Malawi this was US$ 17.48 in 2012,11 while the out-patient care in 
Ethiopia was estimated at US$ 5.06 per visit for persons with a mean age of 16 years in 2015.12 
Malaria is a leading cause of school absenteeism13 and has been estimated to reduce economic 
growth in African countries by 1.3%14 and contributes substantially to the vicious cycle of disease 
and poverty.15  
Successful strategies for the control of malaria, e.g. Insecticide-treated bed nets (ITN), Indoor 
residual spraying (IRS) and treatment with artemisinin-based combination therapy (ACT) have 
markedly contributed to the decline in the prevalence of malaria cases and deaths and the 
proportion of fevers due to malaria is decreasing in many malaria-endemic countries in Africa.5,16 
Malaria deaths in the general population in sub-Saharan Africa have decreased by 57% since 2000 
(from 12.5 to 5.4 per 10,000 population) with deaths in children under five years reducing from 25 
to less than 1 per 10,000 children17 however, the decline has stagnated since 2015.5 Estimation of 
malaria attributable deaths using severe malaria case rates and in-hospital data from malaria-
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endemic countries in Africa varies widely. This is partly reflecting the fact that in many countries 
malaria patients who are admitted do not always meet the strict WHO criteria for severe malaria 
(i.e. malaria with signs of severe illness and/or evidence of vital organ dysfunction18) while in other 
settings many severe malaria cases do not make it to the hospital and die at home (Figure 1).19  
Therefore, low in-patient malaria case-fatality rates reported in countries where uncomplicated 
malaria cases form a high proportion of hospitalised children underestimate the proportion of 
malaria-related deaths and poor-quality in-patient care or delay in accessing care may overestimate 
the malaria case-fatality rates. 
Figure 1: Estimates of the proportion of severe cases receiving in-patient 
care 
 
Adapted from Componovo et al.19 
Country estimates of the proportion of severe cases receiving in-patient care by the 
method of estimation. Colour indicates method with the prediction biased estimate 
in orange and the deaths-adjusted estimate in green. For the deaths adjusted 
estimate, the bar indicates the min and max range, and black the mean. 
 
The burden of anaemia in children  
Anaemia affects about a third of the world's population with 89% of the cases coming from 
developing countries, the majority of whom are women of reproductive age and pre-school 
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children with severe anaemia, defined as haemoglobin concentration (Hb) <5g/dL,20 constituting 
3.9% of the overall burden.21 The global estimate of the prevalence of anaemia in children under 
five years of age in 2011 was 42.6% and was higher than that for non-pregnant (29.0%) and 
pregnant women (38.2%).22 It is, however, acknowledged that these figures may be slightly 
exaggerated for children under five years of age because the authors defined any anaemia as Hb 
<12.0g/dL and not <11.0g/dL as defined by WHO.23 Regional variations in the prevalence of severe 
anaemia is apparent with malaria-endemic Africa suffering the most. However, the prevalence 
reduced from 1.1-9.7% in 1995 to 0.9-4.9% in 2011.24 The high prevalence of anaemia in the African 
region is not surprising as it mirrors the high prevalence of factors contributing to severe anaemia 
such as nutritional deficiencies, malaria, etc. and the changes over time possibly reflect the 
improvements in control measures for diseases such as malaria.  
Severe anaemia has been shown to have significant adverse health consequences and negative 
impacts on social and economic development.25,26 Severe anaemia in the acute stage causes 
fatigue, weakness, difficulty in concentrating and poor productivity due to impaired tissue 
oxygenation and in the long term it has been shown to have impairment in neurocognitive ability,27 
motor development and heart failure.28 Iron deficiency also leads to impairment of the immune 
system predisposing to infections.29 
Studies in different epidemiological settings in malaria-endemic Africa show that overall 12 to 29% 
of hospitalised children are severely anaemic30-33 as well as about a third of those hospitalised with 
fever.34 Mortality during the in-hospital period ranges from 4 to 13% in different epidemiological 
settings35-38 and post-discharge mortality is also substantial. Most cases of mild-moderate anaemia 
progress to severe anaemia if the underlying conditions are not treated in time. Because of 
ignorance about severe anaemia, community and cultural perceptions, late presentation to health 
care centres and use of traditional medicines at home contribute to the high prevalence rates of 
severe anaemia in malaria-endemic areas in Africa.39 Delay in seeking care, self-medication and 
seeking care from drug shops also contribute to high mortality and morbidity.40 
Aetiology and pathophysiology of anaemia in children 
The amount of circulating red blood cell mass and functionality of haemoglobin determines the 
efficiency to which gaseous exchange occurs in the body. Any condition, occurring singly or in 
combination, that reduces the mass of circulating red blood cells (RBC) or causes a shortage of 
functional haemoglobin causes anaemia. The aetiology of anaemia can be broadly classified into 
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decreased erythrocyte production (ineffective erythropoiesis) as a result of the impaired 
proliferation of red-cell precursors or ineffective maturation of erythrocytes; or increased loss of 
erythrocytes through increased destruction (haemolysis) or blood loss; or both. The contribution of 
these factors to severe anaemia is determined by the complex interrelationship between nutrition, 
infectious diseases and individual genetic predisposition (Figure 2).41 A more detailed review of 
these individual factors are given below  
Figure 2: Causes of anaemia in countries with low or middle incomes 
 
Adapted from: Balarajan et al.41 
Nutritional factors 
Globally, Iron deficiency accounts for approximately 50% of the cases of anaemia, though this 
varies in different geographical settings and population groups.23,24 As a result, for a long time, 
universal iron supplementation was recommended to children living in areas with a high prevalence 
of iron deficiency. Iron is a crucial component for erythropoiesis and the human immune system, as 
well as a critical element for the survival of many pathogens. Finding an equilibrium between these 
factors and the use of iron for the management of anaemia is a current dilemma.42 Iron deficiency 
is known to create a hostile environment for bacterial growth, and thus Iron supplementation 
studies in areas with a high prevalence of bacterial infections reported an increase in morbidity and 
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mortality.43,44 However, a study in Malawi in areas with perennial or seasonal malaria transmission 
found that vitamin A deficiency and not iron deficiency was the most prevalent aetiological factor 
associated with severe anaemia45 and vitamin A deficiency was found in 92.3% of participants with 
severe anaemia. In a structural equation model, the authors showed that the presence of malaria 
infection and bacteraemia potentiate the association between vitamin A deficiency and severe 
anaemia. Iron deficiency was shown to be protective for severe anaemia, likely due to its inverse 
relationship with bacteraemia (Figure 2). Because of the complex interrelationship between iron 
deficiency, bacteraemia and malaria, WHO now recommends daily iron supplementation for 
children living in malaria-endemic areas with a high prevalence of anaemia provided malaria 
prevention is guaranteed.46  
A Malawian study in 2008 in areas with seasonal or intense year-round malaria transmission 
showed that about 30% of severely anaemia children have vitamin B12 deficiency (OR=4.3, 1.9-9.9 
compared to children without severe anaemia).1 The main cause of vitamin B12 deficiency in this 
setting is an inadequate nutritional intake of the main sources of vitamin B12 (animal proteins). In 
Malawi, severely anaemic children ate fewer meals with meat compared to those without severe 
anaemia (1.9 vs 2.7 per month, P = 0.02).1 Other causes of vitamin B12 deficiency common in this 
setting include impaired gastric absorption, e.g. due to pernicious anaemia, impaired intestinal 
absorption (e.g. due to parasitic infestations: giardiasis, bacteraemia etc.) and increased 
requirements due to HIV infections or haemolysis (e.g. due to malaria).47 
The prevalence of folic acid deficiency in children in malaria-endemic areas is low1 and its 
contribution to severe anaemia is unclear.48 A 1995 trial conducted in The Gambia among children 
with malaria-associated anaemia did not find any improvements in Hb concentrations following 
folate supplementation.49 A more recent multivitamin and multimineral supplementation study in 
Uganda among children with severe anaemia did not show any significant beneficial effects in 
reducing the burden of severe anaemia in children.50 The current clinical guidelines for the 
management of malaria-associated anaemia in Kenya and Uganda which recommends routine iron 
and folic acid supplementation may need to be reviewed.51,52  
  





Malaria is recognised as the principal cause of anaemia in malaria-endemic areas of Africa. As a 
result, anaemia has been recommended by WHO as an additional indicator to monitor the 
performance of malaria control interventions such as ITNs and IRS in areas with stable malaria 
transmission.41 (see the section below on “The burden of severe malaria anaemia” for a detailed 
discussion on malaria anaemia). 
Soil-transmitted helminths 
The most prevalent soil-transmitted helminths in sub-Saharan Africa among school-aged children 
are hookworms,  Ascaris lumbricoides, and Trichuris trichiura at 16·5%, 6·6%, and 4·4% (between 
2000 and 2013) respectively. This prevalence has reduced from as high as 52% to 74% as reported 
in surveys conducted before 2000.53 Most hookworm infections are in children less than two years 
of age, with Ancylostoma duodenale being more prevalent than Necator americanus; 80.6% and 
8.3% respectively, and 11.1% of the children have mixed infections. In this setting, 15.9% of severe 
anaemia cases are attributable to hookworm infections.1 Hookworms cause iron deficiency 
anaemia with the severity being dependent on the intensity of infection and species (Ancylostoma 
duodenale is more invasive than Necator americanus).54 The ecological conditions in sub-Saharan 
Africa favour larval development with most infections occurring in areas of poverty, where poor 
water, sanitation, and infrastructure result in endemicity. Treatment with anthelminths and iron 
supplementation is the primary management strategies.55 
Schistosomiasis 
More than 90% of the global burden of schistosomiasis occurs in sub-Saharan Africa.56 About three-
quarters of the sub-Saharan African population live near water bodies and irrigation projects 
contaminated with intermediate snail hosts. Most of the burden is in Nigeria, Ghana and 
Tanzania.57 In 2011 in Zimbabwe, the prevalence of Schistosoma haematobium in 1-5-year-old 
children was 21%.58 In 2014 in Uganda, the prevalence of Schistosoma mansoni  was 39.3% in the 
shores of Lake Victoria,59 while in western Kenya, the prevalence was 14% in the 1-year-olds and 
more than 90% in children > 10 years of age.60 Schistosoma haematobium and Schistosoma 
mansoni cause the highest burden of disease.56 The mechanism of anaemia includes chronic blood 
loss leading to iron deficiency anaemia, splenic sequestration and haemolysis due to splenic 
hypertrophy, autoimmune haemolysis and prolonged pro-inflammatory cytokine-induced anaemia 
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of chronic disease.61 The primary drug for the management of schistosomiasis is praziquantel, with 
mass drug administration being the primary means of treatment in many sub-Saharan African 
countries. 
Human Immunodeficiency Virus (HIV) Infection  
Anaemia is the most common haematological complication associated with HIV infection in all age 
groups62 and has been identified as an independent risk factor for disease progression and death in 
children. The highest burden of HIV related anaemia is in sub-Saharan Africa with children being the 
most vulnerable group.63 Among children aged between 3 months to 18 years in Uganda in 2009, 
4.8% of HIV infected children were severely anaemic, and more advanced disease was associated 
with significantly lower Hb levels (p<0.0001). Other significant associated risk factors included 
younger age (p<0.0001) and low CD4 percentage (p=0.048).64 In Malawi in 2008, 6.2% of severe 
anaemia among children less than five years of age was associated with HIV infection.63 The 
mechanism of HIV/AIDS-related anaemia is multifactorial, resulting from HIV infection and the 
induced anaemia of chronic disease, AIDS-related illnesses, and antiretroviral treatment.41 Failure 
of erythropoiesis is the most prevalent mechanism of anaemia in HIV infected children.63  
Other infectious diseases 
Tuberculosis (TB) and bacteraemia have also been associated with severe anaemia in sub-Saharan 
Africa. Bacteraemia and TB are common opportunistic infections in children with HIV infection and 
bacteraemia, especially invasive non-typhoidal bacteraemia are commonly associated with malaria 
infections.65 In Malawi, 12.2% of severe anaemia cases in children less than five years of age were 
attributable to bacteraemia.63 Among children with HIV infection, TB is an independent risk factor 
for anaemia (OR 3.23, 1.10-9.70). The aetiology of anaemia in TB is likely multifactorial possibly due 
to increased IL-6 leading to anaemia of chronic illness and micronutrient deficiencies.66 
Due to geographic overlap, malaria and visceral leishmaniasis (VL) co-infection may exist, but there 
is a paucity of data on its prevalence especially in children. In 2006, about 18% of children in a 
hospital in Uganda had malaria and VL co-infection and 3.4% of patients overall had severe 
anaemia.67 VL is less widespread compared to malaria. However,t it remains an important factor to 
consider in endemic areas in terms of its contribution to severe anaemia.  
Genetic haemoglobin disorders 
Genetic disorders resulting in structural variations in Hb or reduced production of globin chains of 
Hb can result in anaemia. In the African region, about 18.2% of the population have a significant Hb 
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variant.68 Genetic conditions and haemoglobinopathies such as sickle cell disease, glucose-6-
phosphate dehydrogenase (G6PD) deficiency and thalassaemia are associated with anaemia and 
are common conditions among children under five years of age in malaria-endemic areas because 
of their partial protection against malaria. In a cross-sectional study among 6-35 months old 
children in western Kenya, Sickle cell trait (HbAS) and disease (HbSS) were found in 17.1% and 1.6% 
of children, respectively; 38.5% were heterozygotes and 9.6% were homozygotes for α+-
thalassaemia. The Hp 2-2 genotype was found in 20.4% of children, whereas 8.2% of males and 
6.8% of children overall had G6PD deficiency.69 Another cross-sectional study in Uganda among 
children less than 18 months found a prevalence of 13.2% for HbAS and 0.7% for HbSS.70 The main 
mechanism of anaemia in these conditions is intravascular or extravascular haemolysis,71,72 
sequestration of deformed RBCs in the vascular system due to increased adhesion of the red blood 
cells to the endothelium73 and RBC production failure (RCPF).74 
Figure 2: Structural equation model for severe anaemia, iron deficiency, bacteraemia and 
malaria. 
 
Adapted from Calis et al.1 
The sizes of significant (P≥0.05) factors associated with severe anaemia are indicated by the 
standardised regression coefficients (range, −1.0 to +1.0). Inverse (protective) associations are 
indicated by red lines.  
 
The pathogenesis of severe anaemia is complex and multifactorial. Acute or chronic blood loss 
through urine (e.g. schistosomiasis), stool (e.g. hookworm) or trauma, haemolysis (e.g. due to 
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malaria, bacteraemia, haemoglobinopathies), micronutrient deficiencies (e.g. vitamins A and B12) 
and RCPF (e.g. due to parasitic, bacterial or viral infections) have been documented as mechanisms 
leading to anaemia.75,76 These mechanisms act singly or synergistically to reduce the RBC mass or 
impair with the functionality of Hb (Figure 2). In a Malawian study,77 RCPF (defined as reticulocytes 
<50,000/µL and Hb of <5g/dL) was identified as the most prevalent mechanism leading to anaemia 
with 38.7%-59.7% of patients with haemolysis or blood loss having RCPF overall. For children with 
severe malaria anaemia, RCPF was identified in 40.2% and haemolysis in 17.2%, however, no 
mechanism could be defined in 43.7% of the cases (Figure 3). Known mechanisms for malarial 
anaemia include; RCPF,77 dyserythropoeiesis,78 splenic sequestrations of parasitised and uninfected 
RBCs79, and lysis of infected and uninfected RBCs.80 
 Figure 3: Pathophysiological mechanisms of severe anaemia syndrome 
 
Adapted from van Hensbroek et al.77 
Non-defined are mechanisms not fulfilling the definitions for red cell production failure, 
haemolysis or blood loss. Number and percentages denote mechanism sub-groups not 
overlapping (black) and overlapping (red). 
 
The burden of severe malarial anaemia   
The WHO defines severe malarial anaemia as Hb concentration <5 g/dL or haematocrit <15% in the 
presence of any level of malaria parasitemia.20 In high malaria transmission settings, severe malarial 
anaemia (SMA) is the major presenting syndrome of severe malaria in children aged less than five 
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years.30 Other causes of anaemia in malaria-endemic areas of sub-Saharan Africa are common, and 
malaria infection may exacerbate existing anaemia leading to SMA. Blood transfusion and 
administration of artesunate are major components of management. Access to a safe and adequate 
blood supply for transfusion is still a major challenge in developing countries where the burden of 
malaria is also high.81 
It is difficult to accurately estimate the prevalence of SMA due to variability in the methods of 
quantifying malaria burden, difficulties in accurate diagnosis of malaria and the use of presumptive 
diagnosis in the management of malaria in endemic areas. However, SMA is estimated to affect 
between 1.5 to 5 million children annually contributing up to half of all childhood deaths from 
malaria.5,82,83 In children, the risk of developing SMA generally decrease with increasing age. The 
risk is high during infancy and increases significantly until the age of two years, and then decrease 
significantly between four to ten years, this risk is also associated with the degree of malaria 
parasitaemia with the geometric mean parasitaemia being negatively correlated with Hb 
concentration.84 Malaria transmission intensity and seasonality also influence the incidence of SMA 
with a higher incidence of SMA in children aged 6 months and above in high transmission areas, 
whereas in moderate to low transmission areas SMA mainly presents in older children and adults as 
does cerebral malaria.85,86 In a prospective study in Tanzania, children with severe malaria residing 
in different altitudes were recruited into a study after admission to hospital. It was observed that 
the odds of SMA significantly reduced with increasing age (p<0.001) and decreasing intensity of 
transmission (higher altitudes) (p=0.03). At one year of age, the odds of SMA was highest in areas 
with high transmission intensity (lower altitudes) and two years for areas with low to moderate 
transmission intensity.87 These findings are consistent with reports from other studies.30,88 
However, a systematic literature review showed younger peak ages for hospitalisations with SMA in 
areas with uniform all year transmission settings compared to areas with highly seasonal malaria 
transmission (Figure 4). This pattern was not influenced by the levels of malaria transmission 
intensity. Therefore the median age of children with SMA remained the same irrespective of the 
level of transmission intensity.85 This contrasts with cerebral malaria where the burden shifts 
towards the younger age groups with increasing transmission intensity, although generally, the 
median age of patients with SMA is lower than that for cerebral malaria.86,89 The complex and 
multifactorial aetiology of anaemia likely masks the underlying relationship between SMA and 
transmission intensity. 
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The decline in the burden of SMA with increasing age is likely due to the acquisition of natural 
immunity, especially in children living in high transmission areas. The rate of acquisition of natural 
immunity in relation to the degree of exposure is still a controversial issue,90 but repeat infections 
are known to potentiate its development.86,87 However, the age of first exposure to malaria 
parasites may not affect the rate of acquisition of naturally acquired immunity.91 A modelling study 
specifically designed to analyse the relationship between acquisitions of malaria-specific immunity 
with increasing exposure concluded that physiological changes might also alter symptoms of 
malaria with increasing age.92  
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Figure 4: Age-patterns of cerebral malaria, severe malarial anaemia, and respiratory distress 
in Sub-Saharan Africa. 
 
Adapted from Roca-Feltrer et al.85 
Percentage of cerebral malaria, severe malarial anaemia, and respiratory distress admissions per 
month of age in children under ten years of age, for each cell of the transmission intensity-seasonality 
matrix. 
 
SMA mortality is high with wide variations from 1.7%93 to 23%30,88,94 in different settings depending 
on the transmission intensity, seasonality of transmission, age, accessibility to prompt medical care 
and presence of other underlying medical conditions such as malnutrition and HIV infection. Most 
SMA associated deaths occur soon after admission partly attributed to challenges in the availability 
and use of blood for transfusion and other supplies and diagnostic challenges.30 As much as there 
has been a decline in malaria attributable deaths over the last 1-2 decades, the case fatality rate for 
SMA has not changed significantly. In Kilifi, Kenya, the overall case-fatality rate for non-severe 
malaria was 2.1%  from 1990 to 2007 (p<0.0001), whereas this fatality rate fell significantly over 
time from 6.5% to 1.3%, the case fatality rate for SMA remained high (5.9%), and there was no 
significant fall in the 18 year period (as well as for cerebral malaria).86    
Children who survive SMA have been shown to have major neurological sequelae later in life.27  
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Severe anaemia and post-discharge morbidity and mortalityThe burden of in-hospital mortality due 
to severe anaemia is well recognised in malaria-endemic areas of Africa. However, the immediate 
post-discharge period is a neglected area of research. Several studies have reported the mortality 
rates in the first three to six months post-discharge to be similar to or higher than in-hospital 
mortality, likely due to a combination of environmental, behavioural, nutritional and genetic risk 
factors.36,37,45,95-98  
A case-control study in Malawi among 6-60 months old children admitted to hospital with severe 
anaemia indicated that children admitted with severe anaemia are not only at high risk of dying 
during the acute phase in hospital but also for several months after they leave hospital; 6.4% of 
cases died in-hospital and 12.6% died post-discharge. This was significantly greater than in hospital 
controls (2.9%) or community controls (1.4%) (Log-rank test, p<0.001). At six and eighteen months, 
post-discharge 8.2% and 11.6% of cases were dead compared to 1.6% and 2.7% of hospital controls. 
Furthermore, 5.9% and 9.1% of cases were readmitted with severe anaemia by six and eighteen 
months compared with 0.5% and 1.1% among the hospital controls respectively.45  
In western Kenya, a longitudinal follow-up of children admitted with severe anaemia demonstrated 
a 16% in-hospital mortality and 10% post-discharge mortality among severely anaemic children in 
the initial four weeks of follow-up and a further 4% between four and eight weeks post-discharge; 
children with severe anaemia were at a higher risk of dying (29%) than those without severe 
anaemia (RR=1.52, 1.22-1.90).99  
In Uganda, 18 months to 12-year-old children admitted with SMA were followed up for six months 
post-discharge. 2.1% of children with SMA died, and 0.7% of those with cerebral malaria died post-
discharge, with no deaths in the community controls during the same six months' follow-up 
period.100 
Malaria as a cause of post-discharge severe anaemia and mortality 
Children discharged back to the community in malaria-endemic areas are at risk of another malaria 
infection or recrudescence due to poor management or drug resistance; thus malaria is likely to be 
an important contributor to mortality and morbidity in the post-discharge period due to slow 
haematological recovery, RBC destruction, and RBCPF.101 
In an observational study in Kenya, malaria was found to be the primary diagnosis in about 33% of 
children who died after discharge following admission with severe anaemia.96 In the same cohort, 
Lackritz et al. showed that malaria parasitaemia in the post-discharge period significantly negated 
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haematological recovery99 which is known to take at least four to six weeks and maybe prolonged if 
there is inadequate parasite clearance or new malaria infections occur post-discharge due to on-
going red cell destruction and RCPF.80,102 In the same study, children who were transfused and did 
not have malaria parasitaemia had significantly higher Hb levels one-month post-discharge 
compared to those who were not transfused (least-square means of Hb: 10.2 ± 0.21 versus 9.6 ± 
0.15 g/dL, p=0.01). However, the presence of malaria parasitaemia on follow-up negated any 
beneficial gains from the blood transfusion leading to no difference in the Hb levels between 
transfused and non-transfused children a month later (8.8 ± 0.23 versus 8.9 ± 0.19 g/dL 
respectively), and a similar picture was seen two months later.99 Bloland et al. reported similar 
findings resulting from inadequate clearance of malaria parasitaemia due to continued use of 
chloroquine as first-line treatment for malaria in Kenya and Malawi in 1993 despite the widespread 
resistance to chloroquine.103  
In Uganda, Opoka et al. reported that among children previously admitted and treated for severe 
anaemia, significantly more children in this group were readmitted because of malaria (IRR=17.29, 
2.02-148.35) compared with the community controls.100  
Routine management of severe anaemia in malaria-endemic areas 
Ideally, the management of severe anaemia should be tailored towards alleviating the acute 
condition and instituting definitive management based on the underlying aetiology. Standard in-
hospital treatment of severe anaemia in many countries in sub-Saharan Africa consists of a blood 
transfusion and parenteral artesunate for severe malaria.104 In the case of severe malarial anaemia, 
this is completed with a 3-day course of artemisinin-based combination therapy (ACT), usually 
artemether-lumefantrine. Children are often discharged with a short course of iron and folate, 
typically with no further scheduled follow-up. The national clinical guidelines for the management 
of anaemia in both Kenya and Uganda advocate for the investigation into the underlying causes of 
anaemia and appropriate management. However, due to inadequate human and infrastructural 
challenges in the healthcare systems in these countries, management of severe anaemia is often 
instituted presumptively following the IMCI guidelines,105,106 without much further diagnostic 
investigation. Coupled with poor adherence to WHO guidelines for the rational use of blood for 
transfusion and the frequent acute shortage of safe blood, these children are likely to be 
readmitted because of recurrence of severe anaemia or are exposed to a higher risk of post-
discharge mortality as has been observed in previous studies.107,108 This situation is likely to worsen 
following the recent withdrawal of The President’s Emergency Plan for AIDS Relief’s (PEPFAR) 
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support of blood transfusion services in most sub-Saharan African countries. Between 2004 and 
2014, a period of consistent-PEPFAR support, there was a tremendous improvement in access to 
safe and adequate blood supplies and a decrease in the proportion of HIV positive donor blood. 
However, other transfusion-transmitted infections such as hepatitis B and C have increased in 
prevalence during the same period.109 Malaria prophylaxis is recommended for all blood recipients 
in this setting as routine screening for malaria parasites is not recommended.110 Due to frequent 
shortage of anti-malarial drugs and poor adherence to treatment guidelines, it is likely that some 
children are infected with malaria parasites following blood transfusion.  
Guidelines for in-patient management of severe anaemia in Kenya52 and Uganda51 are available and 
strict adherence has been shown to significantly reduce anaemia specific in-hospital mortality.111 
Therefore, training and supportive supervision of clinicians in this setting and the provision of an 
effective post-transfusion malaria chemoprophylaxis are likely to substantially reduce severe 
anaemia associated mortality. 
WHO recommended malaria prophylactic treatment strategies 
Malaria chemoprevention is a potential strategy for preventing new or recrudescent malaria 
infection in severely anaemic children post-discharge. When it is free from the effects of malaria 
parasitaemia, the bone marrow gets time to recover, resulting in a more sustained haematological 
recovery post-discharge.107 
Intermittent preventive therapy (IPT) could be a potential strategy for the prevention of post-
discharge malaria episodes in children diagnosed with severe anaemia in highly malaria-endemic 
and epidemic regions. IPT is the administration of a full treatment course of long-acting 
antimalarials at pre-defined time intervals irrespective of a patient’s malaria status to clear existing 
infections and provide prolonged prophylaxis against new infections.112 Currently, WHO recommends 
the following IPT strategies for control of malaria. 
Intermittent preventive therapy in pregnancy (IPTp) 
Malaria in pregnancy is associated with adverse pregnancy outcomes including severe anaemia, low 
birth weight (LBW), perinatal mortality, abortion, pre-term delivery and death especially in 
primigravidae and secundigravidae113 with about 32 million pregnancies at risk in Africa annually.114 
The population attributable risk per cent of post-neonatal infant mortality due to placental malaria 
has been estimated to be 29% among the primigravidae115 and reduction in the risk of LBW has 
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been estimated to reduce neonatal mortality among the primigravidae by 42% and post-neonatal 
mortality by 18%.116 
IPTp policies using sulphadoxine-pyrimethamine (SP) were implemented in pregnant women living 
in areas with endemic malaria transmission as a measure to reduce the adverse impact 
of Plasmodium falciparum malaria in pregnancy.117,118 Over the past decade the effectiveness of IPTp 
with SP has been threatened by increasing levels of resistance of Plasmodium falciparum to SP.119,120 
Alternative strategies using amodiaquine, mefloquine121 and azithromycin-chloroquine122 have been 
unsuccessful as better replacements for IPTp-SP because of low tolerance, but the use of IPT with 
monthly dihydroartemisinin-piperaquine (DP) is a promising alternative.123-125 Despite the high levels of 
resistance, IPTp-SP still offers substantial protection against adverse pregnancy outcomes in areas 
where the prevalence of parasites with quintuple Plasmodium falciparum dihydrofolate reductase 
(Pfdhfr) and dihydropteroate synthetase (Pfdhps) mutations is greater than 90%.114,120  More than 2-
doses of IPT during pregnancy has been shown to offer better outcomes than the previous WHO 
recommendation of 2 doses. A meta-analysis of 7 trials on pregnant women living in sub-Saharan 
Africa comparing 2-dose to 3 or more monthly doses of IPTp-SP and involving 6281 pregnancies 
showed that three or more doses of IPT-SP were associated with a higher mean birth weight and fewer 
low birth weights births since 2012 WHO recommends IPT-SP to be started in the second trimester and 
given to pregnant women at every antenatal clinic visit until delivery as long as the IPTp-SP doses are 
given at least a month apart.118,126,127 
Intermittent preventive therapy in infants (IPTi) 
Following the successful deployment of SP for IPTp, studies on IPTi were first conducted around 
2000 to take advantage of SP which is available, low-cost, well-tolerated and a long-acting anti-
malaria to reduce morbidity and mortality in infants due to malaria in malaria-endemic areas. In 
2001, Schellenberg et al. conducted a RCT in Ifakara, Tanzania, to test the safety and efficacy of SP 
in reducing the rates of clinical malaria and severe anaemia in children less than 1-year-old. The 
intervention was administered to children at the ages of 2, 3, and 9 months during their routine 
WHO's Expanded Program on Immunisation (EPI) clinic visits. The protective efficacy (PE) of SP 
against clinical malaria was 59% (95% CI, 41%-72%) and it reduced the rates of severe anaemia by 
50% (PE=50%, 8%-73%) compared to placebo during the first year of life; the drug was safe and 
well-tolerated.128 The effects against clinical malaria were sustained for another one year after 
cessation of SP administration (PE=36%, 11%-53%).129 Macete et al. did a placebo-controlled trial of 
SP among 1503 Mozambican children attending EPI clinics between 2002 and 2004 by 
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administering the intervention at 3, 4 and 9 months of age. During the first year of life, SP was 
associated with a 22% (3.7%-37.0%, p=0.020) reduction in the incidence of clinical malaria and 19% 
(4.0%-31.0%, p=.014) reduction in hospital admissions; there was no effect on the incidence of 
severe anaemia (PE=12.7%, −17.3%-35.1%, p=0.36). The PE against clinical malaria was not 
sustained in the subsequent year.129 Between 2004 and 2008 in Kenya, a comparison of SP plus 3 
days of artesunate (SP-AS3), 3 days of amodiaquine-artesunate (AQ3-AS3) and 3 days of 
chlorproguanil-dapsone (CD3) administered during EPI visits at 10 weeks, 14 weeks and 9 months 
found a PE of 25.7% (6.3%-41.1%); 25.9% (6.8%-41.0%); and 16.3% (−5.2%-33.5%) in the SP-AS3, 
AQ3-AS3, and CD3 groups, respectively.130 These studies supported the use of long-acting 
antimalarials for IPTi. The differences in the efficacy of these trials are likely due to differences in 
the intensity of malaria transmission, age of participants, levels of plasmodium falciparum 
resistance to SP and the levels of deployment of malaria control interventions especially ITN use. 
Pooled data from six RCTs in four African countries involving 7930 infants show that IPTi had a PE 
against clinical malaria of 30·3% (19·8%-39·4%, p<0·0001); against the risk of anaemia of 21·3% 
(8·2%-32·5%, p=0·002);  against all-cause hospital admissions of 22·9% (10·0%-34·0%, p=0·001) and 
against hospital admissions associated with malaria parasitaemia of 38·1% (12·5%-56·2%, 
p=0·007).131 IPTi-SP for Plasmodium falciparum control in Africa is currently recommended by WHO 
for areas with moderate to high transmission (annual entomological inoculation rates (EIR) ≥10) 
and where parasite resistance to SP is not high (Pfdhps 540 mutation of ≤50).126 WHO recommends 
the delivery of IPTi at the same time as the delivery of routine EPI vaccines. 
Seasonal malaria chemoprevention (SMC) 
Studies conducted, between 2006 and 2011, to evaluate the safety and efficacy of different 
antimalaria combinations for IPT in children living in malaria-endemic areas with seasonal 
transmission showed substantial reductions in the incidence of malaria infections, severe malaria, 
moderate anaemia and all-cause hospital admissions in children aged between 2 to 5 years.132-135 
Two systematic reviews and meta-analysis of studies reporting the safety and efficacy of 
intermittent preventive treatment in children (IPTc) arrived at similar conclusions. For studies 
conducted up to 2010, Wilson et al. showed that IPTc conferred a PE of 57% (24%-76%) against all-
cause mortality during the malaria transmission season and 82% (75%-87%) overall PE against 
clinical malaria.136 For studies up to 2011, Meremikwu reported that IPTc prevented about 74% 
(Rate Ratio [RR]=0.26; 0.17-0.38) of episodes of clinical malaria, 74% (RR=0.270, 10-0.76) of 
episodes of severe malaria and 29% (RR=0.71, 0.52-0.98) lower risk of moderate to severe anaemia, 
Chapter 3: Literature Review 
32 
 
the impact was considerable in both areas with high or low usage of ITNs.137 Since 2012, WHO 
recommends SMC (formerly called IPTc) for children 3-59 months old living in areas with highly 
seasonal malaria transmission throughout the Sahel sub-region using SP and amodiaquine (AQ) in 
areas where; more than 60% of clinical malaria cases occur in short seasons of ~4 months, SP and 
AQ efficacy is >90% and malaria clinical attack rate is >0.1 in the 3 -59 months old children.138,139 
SMC with DP is a suitable potential alternative to SMC-SP+AQ. However, currently, SP+AQ is still 
efficacious in the Sahel and sub-Sahel regions of Africa.140 
IPT and post-discharge anaemia management 
Children who have survived an episode of severe malaria anaemia have a higher risk of suffering 
another episode, and chemoprevention is a potential strategy. However, currently, there is no policy 
guiding the use of IPT in children with severe anaemia in the malaria-endemic areas. Several trials on 
IPT in children diagnosed and treated for mild to moderate anaemia in different malaria 
epidemiological settings have shown that co-administration of haematinics and IPT improves Hb 
recovery in anaemic children.  
In a RCT trial in 1998 to 2000 among 215 children with moderate anaemia (Hb between 5.0 to 8.0 
g/dL) and less than five years of age living in a refugee camp in Tanzania, Tomashek et al. 
hypothesized that administration of haematinics with a long-acting and effective antimalarial could 
induce extended periods of aparasitaemia to allow full haematological recovery. The study was 
divided into three arms, and all participants were on iron and folic acid supplementation. Arm one 
received a vitamin placebo, and symptomatic participants received chloroquine, arm two received 
thrice-weekly vitamin placebo and monthly presumptive malaria treatment with SP and arm three 
received Vit A and C (VAC) three times per week and monthly SP. Participants were followed up for 
three months. A 3.6 g/dL increase in Hb was reported with no significant differences among the 
three arms. A significant proportion of participants in arm three had normal iron stores (TfR 8.5 
g/mL) compared to arm two (p=0.012), and arm two had lower mean serum transferrin receptor 
levels than arm one. Therefore, monthly SP and VAC supplementation is more effective in the 
management of moderate anaemia in participants with iron deficiency anaemia living in areas with 
a high risk of malaria infection.141 
Another RCT conducted in an area with intense perennial transmission in western Kenya in 1999, 
evaluated the efficacy of single and combined therapies with iron supplementation and IPT with SP 
in improving Hb levels and to assess the risk of malaria infection among 2 to 36 months old 
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children. A total of 546 participants aged 2 to 36 months with Hb of 7 to 11 g/dL were enrolled, 
with a single dose of SP and a bed net being issued at enrolment. The participants were randomly 
allocated into either of the 4 arms a) IPT with SP at four and eight weeks and daily iron for twelve 
weeks, b) daily iron and IPT with SP placebo, c) IPT and daily iron placebo, or d) daily iron placebo 
and IPT with SP placebo (double placebo). Compared with double placebo, ITP with SP and iron was 
most effective in the management of mild anaemia with a mean Hb concentration gain at the end 
of follow up of 1.14 g/dL (0.82-1.47 g/dL). In terms of improvements in Hb levels, IPT with iron was 
significantly more effective than iron alone (mean difference [MD] in Hb concentration, 0.35 g/dL 
(0.03-0.68 g/dL, p=0.03), and IPT alone was not significantly more effective than double placebo 
(MD in Hb concentration, 0.17 g/dL (-0.15-0.49 g/dL, p=0.30). IPT had modest benefits on 
haematological recovery, but the incidence of malaria parasitaemia and clinical malaria associated 
with the use of IPT was reduced by 50%.142 
In 2007 in The Gambia, Cox et al. evaluated the potential use of weekly chloroquine as a possible 
intervention to induce haematological recovery in children with moderate post-malarial anaemia. 
Due to chloroquine resistance, the first-line drug for the treatment of uncomplicated malaria was 
changed in The Gambia from chloroquine-SP to co-artemether in 2008, thus children were treated 
with co-artemether before enrolment in the study. They hypothesized that the anti-inflammatory 
properties of chloroquine could enhance erythropoietic recovery by suppressing plasmodium 
induced inflammation.143 Apart from lysis of parasitised and non-parasitised erythrocytes, the 
pathogenesis of malarial anaemia includes iron sequestration in the macrophage monocyte system 
and in the hepatocytes as an outcome of inflammatory-induced iron delocalization, a process which 
reverses when inflammation wanes.144 Cox et al, randomised ninety-six children aged 12-72 months 
with uncomplicated malaria to receive either weekly chloroquine (n=50) or placebo (n=46) and 
followed them up for ninety days. There was no significant difference in Hb change between the 
two arms at the end of follow-up; CQ +1.04 g/dL (0.67-1.34 g/dL) vs placebo +0.76 g/dL (0.29-1.24 
g/dL).143 In this study, recruitment of participants over 2 malaria seasons with one season of low 
malaria transmission resulted in lower parasite densities and therefore a lowering of the effect size. 
The use of low dose chloroquine 5 mg/kg/week, as opposed to the recommended anti-
inflammatory dose of 3-4 mg/kg/day may have contributed to the inability to detect an effect of 
chloroquine on Hb change.  
A Cochrane review on the use of intermittent preventive antimalarial treatment for children mainly 
with mild-moderate anaemia in malaria-endemic areas showed a small increase in Hb levels after 
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three months of follow up but did not show an effect on mortality and hospital admission.145 A 0.32 
g/dL (MD=0.32, 0.19-0.45) increase in the mean change in Hb from baseline to 12 weeks of follow-
up was observed in 4 trials with a cumulative total of 1672 participants. The protective effect of IPT 
was found to be low in this review, possibly because half of the included trials were conducted in 
areas with low malaria transmission and in children with mild-moderate anaemia.  
However, a RCT conducted between 2006 and 2009 in areas with intense malaria transmission in 
Malawi involving children with severe malarial anaemia showed the effects of IPT post-discharge 
(IPTpd) to be significant compared to placebo. Phiri et al. recruited 1414 children under five year of 
age who were admitted with severe anaemia (Hb <5g/dL) and were randomised to either receive 
monthly IPTpd with AL or placebo for three months. Phiri et al. demonstrated an adjusted PE of 
31%, (5-50) against all-cause mortality or hospital re-admittance because of all-cause severe 
anaemia or severe malaria between one and six months after enrolment. This effect was more 
pronounced during the initial three months (PE=41%, 10-62, p=0·01) when the pharmacological 
effects of AL were active in the system than during the subsequent three months post-intervention 
(PE=17%, –27-45, p=0·395). The beneficial effect was in addition to the initial effect from the 
standard AL treatment course provided at discharge and in addition to any protective effect by 
ITNs.101 These results are consistent with earlier findings from The Gambia in a study conducted 
between 2003 and 2004, where children aged between 3 months and 9 years with a Hb 
concentration less than 7 g/dL were randomised to receive either monthly SP or placebo during the 
malaria transmission season. The proportion of children with Hb less than 7g/dL at the end of the 
malaria transmission season was similar between the two groups; prevalence ratio 0.89 (0.44-1.8, 
p=0.742). However, the PE of SP against recurrence of severe anaemia was 78% and against clinical 
malaria was 53% (37%-65%).98 Chemoprevention likely benefits children with severe anaemia more 
than those with mild or moderate anaemia. These data are scarce but indicate that IPT in the post-
discharge period provided to children treated for severe anaemia may potentially provide 
substantial health benefits.  
Other malaria chemoprophylaxis options  
Co-trimoxazole chemoprophylaxis  
Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) is an inexpensive, broad-spectrum 
antimicrobial drug that is commonly used in low-income countries. Co-trimoxazole was widely used 
for prophylaxis before the extensive use of antiretroviral therapy (ART) to reduce morbidity and 
mortality associated with malaria, Pneumocystis jirovecii pneumonia, bacterial infections, and 
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diarrhoea among HIV infected adults and children in Africa.146,147 There is widespread bacterial 
resistance against co-trimoxazole in sub-Saharan Africa, co-trimoxazole is also an inhibitor of 
dihydrofolate reductase and has been shown to act as a sulphonamide potentiator and concerns of 
cross-resistance with SP have been raised.148 However, the drug still offers a substantial 
antimicrobial activity to warrant its use as prophylaxis.149 A RCT in Zambia showed that co-
trimoxazole reduced the risk of death by 43% (HR=0.57, 0.43-0.77, p=0.0002) and hospital 
admission by 23% among HIV infected children who continued using co-trimoxazole prophylaxis for 
19 months compared to those who discontinued; most hospitalizations were due to malaria.150 Co-
trimoxazole offers beneficial protection against malaria among HIV infected individuals. In an area 
with high antifolate resistant plasmodium genotypes in Uganda, co-trimoxazole prophylaxis was 
associated with a 39% reduction in the incidence of malaria in HIV exposed infants151 and in 
another area with similar levels of resistance, co-trimoxazole was associated with a 43% reduction 
in malaria incidence or 97% when combined with the use of ITNs,152 similar findings were obtained 
in Mali.148 Two systematic reviews concluded that co-trimoxazole is safe, well-tolerated and 
efficacious for treatment and chemoprevention against malaria in HIV infected adults and children 
in Africa.153,154 WHO now recommends that in “children living with HIV in settings where malaria 
and/or severe bacterial infections are highly prevalent, co-trimoxazole prophylaxis should be 
continued until adulthood irrespective of ART provision and in settings of low prevalence for both 
malaria and bacterial infections, co-trimoxazole prophylaxis may be discontinued for children five 
years of age and older who are clinically stable and/or virologically suppressed on ART for at least 
six months and with CD4 >350 cells/mm3”.155 
There is limited information about the baseline markers of resistance for both SP and AQ collected 
in the Sahel and sub-Sahelian regions before the routine implementation of SMC.  Currently, there 
is no routine surveillance for resistance markers for SP and AQ in areas where SMC is being 
implemented. WHO recommends a baseline assessment of resistance followed by 2-3 years interval 
surveys in representative locations. The current information on the efficacy and the prevalence of 
molecular markers for resistance to SP and AQ in SMC implementing areas is only available in 
research settings. The effects of the widescale implementation of SMC on the development and 
spread of resistance to SP and/or AQ is yet to be determined. 
Intermittent preventive treatment in schoolchildren (IPTsc) 
Successful malaria control strategies in the past 2 decades have been associated with a substantial 
reduction in the overall burden of malaria, but also a shift in the burden towards older 
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children.86,156 This is the school going age children of whom the negative effects of malaria in their 
school performance and sub-optimal attendance is well recognised.13,157 The benefits of IPTp, IPTi, 
and SMC  have been demonstrated and similar benefits are likely to be achieved if the intervention 
is extended to include school going children158. However, the optimal regimen remains to be 
determined.  
In 2007-2008 in an area of seasonal malaria transmission in Mali, Barger et al. randomised 296 
school going children between 6-13 years old to receive two full treatment doses of either SP+AS, 
AQ+AS or vitamin C given two months apart during the malaria season. SP+AS and AQ+AS reduced 
the clinical malaria incidence by 66.6% and 46.5% respectively, compared to vitamin C (p<0.001). 
The prevalence of asymptomatic parasitaemia and all-cause sick child clinic visits were reduced 
significantly in both arms compared to vitamin C, (p=0.024 and <0.001 respectively). The rates of 
anaemia were similar in the SP+AS (17.7%) and AQ+AS (16.0%) at the end of the malaria season and 
were both significantly lower than for children in the vitamin C arm (29.6%; p=0.039).159 
In an area with the perennial transmission of malaria in western Kenya, Clarke et al. conducted a 
cluster-randomised placebo-controlled trial involving children aged between 5-18 years in 30 
schools. The schools were randomised to receive three courses of SP+AQ or placebo at 4-month 
intervals to determine the effects of the SP+AQ on the prevalence of anaemia (Hb<11.0 g/dL). 
SP+AQ reduced the prevalence of anaemia by about half at 12 months (RR=0·52, 0·29-0·93, 
p=0·028) and enhanced cognitive ability.160 In Tororo Uganda, children in two schools aged 8-14 
years were enrolled into a randomised placebo-controlled trial to evaluate the efficacy, safety, and 
tolerability of a single course of SP, AQ+SP or DP among school children in reducing the risk of 
malaria parasitaemia by 42 days from enrolment. DP was the most efficacious with the lowest risk 
of parasitaemia of 11.7% (7.9%-17.1%), followed by AQ+SP at 44.3% (37.6%-51.5%). There was no 
difference in the risk of parasitaemia between SP (79.7%, 73.6%-85.2%) and placebo (84.6%, 79.1%-
89.3%), p = 0.22. AQ+SP and DP were associated with a significant increase in Hb by 42 days; 0.37 
g/dL (0.18-0.56) and 0.34 g/dL (0.15-0.53) increase respectively. SP and DP were well-tolerated, but 
AQ+SP was associated with more vomiting. 161 Another trial in the same area in Uganda randomised 
6-14 years old children to either monthly DP, three monthly DP or placebo. Monthly DP reduced 
the incidence of malaria by 96% (88%-99%, p<0.0001) in 12 months, 94% (92%-96%, p<0.0001) 
reduction in asymptomatic parasitaemia and 40% (19%-56%, p<0.0001) reduction in the prevalence 
of anaemia compared to placebo. Three monthly DP reduced the prevalence of asymptomatic 
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parasitaemia by 54% (47%-60%, p<0.0001), but was ineffective against the incidence of 
symptomatic malaria or the prevalence of anemia.162 
These studies demonstrate that an IPTsc regimen using SP monotherapy may not be an optimal 
option likely due to the widespread Plasmodium falciparum resistance to SP across Africa.163 
Monthly DP provides the highest PE against malaria parasitaemia, and clinical malaria and four 
monthly courses of SP+AQ is also a good alternative. The effects of these regimens on malaria-
related anaemia are modest; however, SP+AQ has been shown to have a significant effect 
compared to placebo.160,162 IPT is likely to have less impact against malaria-related anaemia in older 
children as the effects of malaria on Hb decreases with increasing age.80 Genuine concerns about 
the spread of drug-resistant parasites and inhibition of the development of naturally acquired 
immunity to malaria have been raised158 because the large population of school-aged children,  to 
date WHO has not given policy recommendation for the use of IPTsc.  
IPT and risk of development and spread of drug resistance  
Development of anti-malarial drug resistance is a major impediment to the fight against malaria, 
and the possibility of potentiation and spread of drug resistance due to the deployment of IPT is a 
genuine concern.158  It is therefore essential to consider the impact of IPT deployment on the 
spread of drug-resistant parasites and the long-term consequences on the efficacy of the 
antimalarial drugs used for IPT or chemoprevention. There is usually a gradual decline in the anti-
malaria drug concentration in the blood following an initial peak after drug administration. 
Parasites which are fully sensitive to the antimalarial in use will be cleared by drug concentrations 
above the minimum parasiticidal concentrations (MPC), and as drug concentration declines 
parasites with increasing sensitivity will grow, but fully resistant parasites will not be cleared by 
therapeutic levels of the drug. The window for the selection of resistant parasites is the interval 
between the drug concentration threshold for partially sensitive parasites and the threshold for 
sensitive parasites.164 Resistant parasites will be transmitted to vulnerable individuals when the 
drug threshold is below the MPC and before the immune system can clear these parasites,165 this 
may be more pronounced in children and individuals who are immunologically naïve to malaria 
parasites and who mainly constitute the infectious reservoir.166 Other factors that determine the 
degree of selection pressure for drug resistance include the frequency of drug dosing, the infection 
status of drug recipients and drugs half-lives; long half-lives lead to longer duration when parasites 
are exposed to selective concentrations.167 
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Figure 5: Concentration of anti-malarial drug in the bloodstream during IPT 
 
Adapted from O'Meara et al.168 
 
SP has been used extensively for IPTp, IPTi, and IPTc in areas with varying levels of malaria 
transmission intensity. In in-vitro studies, resistance to SP has been shown through demonstration 
of substitution of alleles within the active site of target enzymes.169,170 Other methods of 
establishing drug resistance include; post-treatment analysis of recrudescent infections with the 
demonstration of the presence of specific mutations at a higher frequency than others171 or 
demonstrating the association of specific mutations to treatment failure.172 The degree of drug 
resistance is proportional to the number of allelic substitutions that confer parasitic insensitivity to 
SP with triple-mutant dihydrofolate reductase (dhfr) allele being highly resistant in comparison to 
single or double-mutant dhfr allele. The presence of both Plasmodium falciparum dhfr triple mutant 
alleles associated with pyrimethamine resistance N51I + C59R + S108N (CIRN) and Plasmodium 
falciparum dhps double mutants associated with sulphonamides resistance A437G + K540E (SGE) in 
parasite isolates from an individual is generally associated with SP treatment failure.78  
Mixed reports have emerged on the impact of IPT on the development and spread of drug-resistant 
parasite mutants. In a RCT in Senegal conducted between 2002 and 2003 to determine the safety 
and efficacy of AS+SP combination for use in seasonal IPTi, Cisse et al. observed that the proportion 
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of parasite positive children with Plasmodium falciparum dhfr and Plasmodium falciparum dhps 
mutations were significantly increased during the post-intervention survey compared to the time 
before the intervention in both the intervention and placebo groups however, the SP+AS group had 
a comparatively higher proportion of mutants than the placebo group dhfr: SP+AS 95%, placebo 
75%, p=0.01 and dhps: SP+AS 86%, placebo 44%, p=0.001. Since IPTc reduced the overall 
prevalence of parasitaemia in the SP+AS arm, the prevalence of drug-resistant parasitaemia was 
lower in the intervention arm compared to the placebo arm (dhfr: SP+AS 13%, placebo 28%, and 
dhps: SP+AS 12%, placebo16%). However, at the end of the second year of follow up there were no 
significant differences in the prevalence of dhfr and dhps in the intervention and control arms (dhfr: 
SP+AS 88%, placebo 86%, p=0.69, and dhps: SP+AS 64%, placebo 77%, p=0.10),133 similar 
observations were also reported by Sokhna et al. in 2004 in the same study area using the same 
drugs.173 
A RCT conducted in Mali in 2008, Dicko et al. reported a significantly higher frequency of dhfr-59 
and dhps-437 mutations in parasites isolated at the end of the malaria transmission season from 
children who had received SP+AQ than in those from participants in the placebo arm. The triple 
dhfr mutants and the quadruple mutant (triple dhfr+dhps 437) associated with significant 
resistance to SP in children was therefore observed more frequently in the intervention arm than in 
the control arm.132 In a study utilizing the same protocol as132 in 2008 in Burkina Faso, Konate et al. 
obtained the baseline prevalence of SP and AQ makers of resistance from 3 to 59 months old 
children from the same community who were not enrolled into the study. At baseline, 32.6% of 
children carried parasites with dhfr mutations at codons 51, 59, and 108 and 25% carried triple dhfr 
plus single dhps mutation at codon 437. In comparison to baseline, there was an overall increase in 
children with parasites carrying the triple dhfr mutations only (p=0.001) and triple dhfr plus a single 
dhps mutations (p=0.001) in the post-intervention survey. However, there was no significant 
difference in the proportion of children in the control and intervention arms who carried mutant 
parasites, and the efficacy of SP+AQ combination was not affected in the year following the 
intervention.135 
In contrast to studies conducted in west Africa132,133,135,173 which reported an increase in drug-
resistant mutants to antimalarial drugs, studies conducted in Eastern Africa did not show similar 
increases. A community randomised trial in Tanzania conducted between 2004 and 2006 to 
evaluate the effects of IPTi on antimalarial drug resistance reported that IPTi with SP neither lead to 
a rise in the selection of dhfr and dhps mutants nor an increase in drug pressure. At the beginning 
Chapter 3: Literature Review 
40 
 
of this study,174 SP was used both for treatment of symptomatic infections as well as for IPTi. The 
prevalence of SP positivity was not significantly different at baseline (in 2004) and 15 months later 
between the control and intervention arms in both the younger <1-year old (in 2004, p=0.251 and 
in 2006, p=0.186) or the older ≥1-year-old (in 2004, p=0.34 and in 2006, p=0.38) age groups. Pearce 
et al. also reported a non-significant difference in the frequency of N51I + C59R + S108-(CIRN) in 
2004 (p=0.89) or 2006 (p=0.93) and A437G + K540E (SGE) alleles in 2004 (p=0.52) and 2006 
(p=0.54) in both the intervention and control arms. In the final survey in 2007, although there was a 
non-significant increase in the A437G + K540E (SGE) allele in the intervention than control arms 
(p=0.18), the N51I + C59R + S108-(CIRN) allele frequency was higher in the intervention than 
control arm (p=0.004). It is possible, however, that a longer period of follow up could have revealed 
more changes in the dynamics of drug pressure. Different dhps alleles are found in West and East 
Africa175, and they confer different levels of resistance to antifolates and may partly be a reason for 
the differences between this study148 and the previous studies132,133,135,173 in West Africa.  
Simulated mathematical modelling studies have been designed to address the impact of IPT on the 
selection pressure for parasite drug resistance. Alexander et al. designed a model simulating 
malaria transmission dynamic of a rural Southern Tanzanian situation to predict the impact of IPTi 
with SP on selection pressure for parasite drug resistance. The relative difference in the 
reproductive success for resistant parasites (in comparison with drug-sensitive parasites), which 
determines the rate of spread of drug-resistant genotypes, defined the selection coefficient used in 
the model. The model parameters were; parasite prevalence in different ages, the prevalence of 
previous antimalarial usage (background dosing rate) and the proportion of individuals not in the 
IPT population infected with malaria and treated with anti-malarial drugs. The model showed that 
IPTi would increase the selection pressure for drug resistance by 4.4% and was unlikely to shorten 
the useful life of the drug used. However, expanding the age of children getting this intervention to 
5 years would increase the selection pressure to 31%. High prevalence of malaria parasitaemia and 
younger age were strong predictors for high selection pressure.176 The findings of this study were 
fairly consistent with an earlier composite model designed by O’Meara et al.177 This model took into 
consideration the frequency of antimalarial drug use, drug pharmacokinetics, degree of antimalarial 
immunity and transmission intensity. It was predicted that in areas with low or unstable 
transmission, IPTi would hasten the spread of both partially and fully resistant parasite mutants, 
but not in areas where partial resistance was already established. Both176 and177 predicted that 
there is a high likelihood of transmission of fully resistant parasites in high transmission areas. Use 
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of the same drug for the treatment of true infections (symptomatic individuals) as well as for IPT 
would accelerate the spread of fully resistant parasites in this setting.178  
More recently Teboh-Ewungkem et al. modified the initial model177 by adding the effects of the 
spatial structure of a population with a focus on the parasite fitness function to determine the 
effects of IPTi on the spread of antimalarial drug resistance in areas with population movements 
between low and high malaria transmission settings.179 This model showed that when areas with 
different rates of malaria transmission (low and high) are connected, the demography of infection 
shifts over time in the low transmission areas to mirror the demography of high transmission areas. 
Eventually, the fully resistant parasites spread throughout the two transmission zones. When the 
rate of movement between the two regions is high and the time spent is shorter, the two regions 
will have a strong transmission interaction; the relative rate of spread of partially susceptible 
parasites relative to fully susceptible parasites and fully resistant parasites relative to partially 
resistant parasites will be indistinguishable between the two transmission zones. Therefore, the 
proximity of areas with different transmission rates and the degree human movement activities has 
an impact in deciding on the antimalarial drug resistance monitoring policy to be used in IPTi.  
IPT and effects on the development of natural antimalarial immunity 
Partially resistant parasites survive as drug concentration declines between IPT doses, therefore 
permitting infection and the development of parasite-specific immunity.168 Naturally acquired 
immunity against malaria develops cumulatively, and each subsequent infection confers an 
increasing level of protection against severe malaria. Concerns have been raised about the 
potential effects of IPT to interfere with/or negate the development of malaria parasite-specific 
immunity, therefore, leading to rebound of severe clinical disease and mortality during the period 
immediately following cessation of IPT doses if transmission and exposure levels remained high. 
Earlier studies conducted to determine the safety and efficacy of malaria chemoprophylaxis in 
children demonstrated mixed results of rebound malaria in the transmission period following 
termination of chemoprophylaxis.180-182 In 1995 in Tanzania, Menendez et al.180 conducted a 
randomised placebo-controlled trial of iron supplementation and malaria chemoprophylaxis with 
pyrimethamine-dapsone (Deltaprim) to determine their efficacy in preventing severe anaemia and 
malaria in children. Eight hundred and thirty-two children were enrolled in the study. Passive case 
detection and a cross-sectional survey were used to evaluate the incidence of severe anaemia and 
occurrences of malaria. Compared to placebo, malaria chemoprophylaxis conferred a PE of 57.3% 
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(43·0-67·9) against anaemia and 60.5% (48·2-69·9) against malaria. However, a rebound effect was 
observed in the year following the termination of treatment, with children who had received 
chemoprevention being at a higher risk of severe anaemia RR=2.2 (1.3-3.7) and malaria RR=1.8 (1.3-
2.6) compared to children in the placebo group. In another malaria chemoprophylaxis study in 1999 
in Mali, Coulibaly et al.181 conducted a randomised cohort study among persons aged between 3 
months to 20 years. Participants were randomly assigned to receive either SP or placebo at the 
start of the high malaria transmission season. The median time to the first clinical episode of 
malaria was delayed in the SP group by 29.5 days and the incidence in the first month was reduced 
to 3% from 26%. However, later evaluation at 24 weeks post-intervention showed that the SP 
group had an increase in the incidence of the first episode of malaria to 42% compared to 17% in 
the placebo group. In Contrast to the studies above,180,181 Greenwood et al. enrolled participants 
and followed them up for five years in The Gambia. Participants aged three months to 5 years were 
randomised to 2 weekly pyrimethamine-dapsone or placebo for a maximum duration of 5 years. 
During the intervention period, malaria episodes dropped by 65% after three years of intervention. 
However, in the year following the termination of treatment five years later, there were 52% more 
episodes of malaria in the intervention arm compared to the placebo arm. Although the 
intervention arm reported an overall reduction of mortality by 15% during the intervention period, 
there was a higher risk of death in the year immediately following termination of treatment in the 5 
to 6-year-old children183,184. These trials suggest that continuous and prolonged chemoprophylaxis 
impairs the development of naturally acquired immunity against malaria.  
In contrast to the above studies on chemoprophylaxis, trials conducted to determine the safety and 
efficacy of various drugs for use in IPTi or IPTc have mostly reported no or statistically insignificant 
rebounds in malaria in the post-intervention period. In the seasonal IPT study cited above,133 85% 
of the children who were initially recruited into the study were re-recruited and followed up to the 
end of the subsequent transmission period. An incidence ratio of 0·98 (0·82-1·17) was reported 
with no significant evidence of rebound of malaria in the intervention group. In a RTC conducted 
between 2005 and 2006 in Ghana on IPTc, Kweku et al. individually randomised 3 to 59 months old 
children to receive 6-month courses of either placebo or AS+AQ combination monthly or bi-
monthly, or AS+SP combination bi-monthly. The post-intervention analysis showed that the 
incidence of malaria parasitaemia in the intervention groups among children who were >1-year-old 
was higher, but not statistically significant compared to the placebo group. However, among those 
who were < 1 year old when they received monthly AS+AQ, there was a significant increase in the 
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incidence of malaria.184 These findings contradict the results reported by Cisse et al. from a 2002-
2003 Senegalese study133 where children who had received intervention in their first year were 
better protected in the post-intervention period compared to older children. Guinovart et al.91 
conducted a randomised controlled trial between 2005 and 2009 in Mozambique to determine the 
effects of age and parasite exposure on the development of naturally acquired immunity in infants. 
Three hundred forty-nine children were randomised into early exposure group (placebo from 2.5 to 
4.5 Months and SP+AS from 5.5 to 9.5 Months) or late exposure group (SP+AS from 2.5 to 4.5 
Months and placebo from 5.5 to 9.5 Months) and the control group was put on placebo from 2.5 to 
9.5 Months. Passive follow-up was continued until the children were two years old. There was no 
significant rebound of malaria episodes, but those in the intervention arms were found to have a 
higher, but statistically insignificant increase in the risk of malaria in the second year of life; 
HR=1.35 (0.81-2.24, p=0.743) and HR=1.38 (0.83-2.28, p=0.642) in the early and late exposure 
groups respectively. Age may have a bearing on the acquisition of antimalarial immunity; however, 
this study did not find any evidence to conclude that the acquisition of naturally acquired immunity 
is dependent on the age of first exposure to malaria parasites. The different findings in these 
studies could possibly be due to the differences in the transmission intensities, seasonality of 
transmission and the duration and frequency of the interventions. A random-effect meta-analysis 
conducted on132,133,185 to determine the effects of IPTc on rebound clinical malaria in the post-
intervention period reported a summary effect measure of 1.11 (0.99-1.24, p=0.07).   
In a pooled analysis cited in 0 above, and involving six RCTs128,129,186-189 on the safety and efficacy of 
IPTi using SP, the incidence of clinical malaria, anaemia or all-cause hospital admissions were 
analysed in the five months following termination of IPTi interventions. Although there were 
inconsistencies between trials, the pooled effect estimate was non-significant. Thus the combined 
effects of the intervention were not associated with a rebound in the incidence of clinical malaria in 
the follow-up period.131 This is consistent with a study in Uganda where Bigira et al. conducted a 
RCT to determine the PE and safety of monthly SP, or monthly DP or trimethoprim-
sulfamethoxazole (TS) in 393 children aged six months of age for 18 months. A year after 
termination of the intervention, the incidence of malaria in the intervention arm was similar to that 
in children who received no intervention suggesting no apparent impairment in the development of 
naturally acquired immunity.190  
The efficacy of SP has declined over time due to the widespread resistance of the plasmodium 
parasites to SP, especially in eastern and southern Africa.191 WHO still recommends the use of SP 
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for IPTp in this epidemiological setting for lack of better alternative regimens. However, SP is still 
efficacious in west Africa where it is used for both IPTp and SMC.139 Other drug regimens such as 
dapsone and mefloquine may have good efficacy, but have not been recommended for 
chemoprevention because of low tolerance and / or potential toxicity in apparently healthy 
individuals, who are the main targets for malaria chemoprevention.192 
The available body of evidence concerning the effects of malaria chemoprevention in children <5 
years old on the impairment of antimalarial immunity is mixed.  Overall, however, most studies 
concluded that there was no significant interruption in the acquisition of antimalarial immunity. 
Age, transmission intensity, frequency and duration of chemoprevention and the half-live of the 
drug used (and type of intervention; intermittent, e.g. IPTi vs complete prophylaxis, e.g. SMC) do 
have some effects of the effectiveness of the intervention as well as the degree of rebound effects 
after the termination of treatment. In the IPTi and IPTc studies that reported some level of rebound 
in malaria, they also noted that beneficial effects of chemoprevention were not outweighed by 
rebound malaria. However, there is a need to consider the effects of chemoprevention in the 
periods immediately after the termination of interventions.  
Experience with dihydroartemisinin-piperaquine for IPT  
DP is one of the five ACTs recommended by WHO for the treatment of uncomplicated malaria 
including AS+MQ, AS+SP, AL and AS+AQ.193 DP is a very effective antimalarial with cure rates of 
≥95% in different epidemiological settings in Africa.194-196 A systematic review and meta-analysis 
showed that DP is superior to AL and is as effective as AS+MQ in preventing the recurrence of 
falciparum malaria parasitaemia.197 The piperaquine component has a long half-life of 23 days (19-
28 days) in adults and 14 days (11-18 days) in children,198 making DP an attractive candidate for IPT. 
The half-live of DP is comparable to that of mefloquine and amodiaquine-artesunate combinations 
in children, but longer than that for SP (4-11 days)199 and AL.200 A recent systematic review to 
evaluate the safety of DP when used for IPT showed that DP, when administered monthly, has a 
lower risk profile compared to daily TS, monthly SP or placebo.201  
Because of its long post-treatment prophylactic effects202 and safety profile, some studies have 
evaluated its safety and efficacy for use in IPT. In Burkina Faso, Zongo et al. conducted a RCT to 
evaluate the safety and efficacy of DP as a possible alternative to SP+AQ for use in SMC. Overall, 
1499 children aged between 3 and 59 months were randomised to either DP or SP+AQ over three 
months during the malaria transmission season. Compared to a control group involving children 
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who did not receive any intervention, both regimens were highly efficacious against clinical malaria 
at 77% (67%-84%) and 83% (74% to 89%) for DP and SP+AQ respectively.140 In western Africa, 
where SP is still highly efficacious, DP has comparable safety and efficacy profiles as SP+AQ or 
SP+PQ when used for SMC. In The Gambia, a RCT by Bojang et al. found that the incidence of 
malaria at the end of the malaria transmission season was 0.10 cases per child year (0.05-0.22), 
0.06 (0.022-0.16) and 0.06 (0.02-0.15) for DP, SP+AQ and SP+PQ arms respectively. Combination of 
two long-acting antimalarials in SP+AQ or SP+PQ combinations were more efficacious than DP of 
which only piperaquine is long-acting. The mean Hb concentration was also comparable in the 
three arms (10.1 g/dL for SP+AQ, 10.4 g/dL for DP and 10.1 g/dL for SP+PQ).203  
In East Africa where there is high resistance to SP, monthly DP has been shown to be more 
efficacious and well-tolerated compared to DP dosed every two or three months, SP alone or in 
combination with AQ for IPTsc.161,162 In Uganda, 4-weekly dosing for DP was found to be more 
efficacious against symptomatic malaria (incidence 0·018 episodes per person-year) compared to 
12-weekly dosing (incidence 0·39 episodes per person-year); adjusted incidence rate ratio [aIRR] 
0·041, 95% CI 0·012-0·150, p<0·0001), and this protection was sustained for up to one year after 
the intervention was stopped (aIRR 0·62, 0·40–0·95, p=0·028).204 DP is also a promising alternative 
to SP for use in IPTp or intermittent screening and treatment in pregnancy, possibly if used with 
rapid diagnostic tests with better sensitivity than is currently available.123  
DP and QT interval prolongation 
One of the major side effects of DP is its dose-related prolongation of the QT interval caused by the 
piperaquine component. 205 It is therefore not recommended in persons with congenital long QT 
syndrome (CLQTS). This is an arrhythmogenic disease of genetic origin caused by mutations in 
genes encoding ion channels involved in the control of ventricular repolarisation and is associated 
with sudden death. There is a paucity of data on the prevalence of CLQTS in the African population, 
but it is about 1:2534 (1:1583-1:4350) in apparently normal live births in the Caucasian 
population.206 Drugs that cause direct blockade of the rapidly activating potassium ion channels 
may induce QT interval prolongation because of delays in ventricular repolarisation.207 Drugs which 
have been shown to be associated with QT prolongation and are contraindicated when taking DP 
include; antiarrhythmics, e.g. amiodarone and quinidine, antimicrobial drugs such as macrolide 
antibiotics and fluoroquinolones, non-sedating antihistamines, e.g. terfenadine and anti-malarial 
drugs such as mefloquine, halofantrine, lumefantrine and quinine.205,208 Administration of DP with a 
high fatty meal has been shown to increase its bioavailability and subsequent risk of QT interval 
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prolongation.205,209 In rare cases, the drug-induced long-QT syndrome may potentiate the 
development of ‘torsade de pointes’, an atypical type of polymorphic ventricular tachycardia 
leading to sudden death.210 Majority of CLQTS or acquired QT prolongation are clinically silent and 
may only be diagnosed when electrocardiograms (ECG) are conducted for other reasons. A recent 
systematic review estimated the risk of sudden death due to DP intake as 1 in 757 950 (1 in 
854 490-1 in 209 114) and was not higher than the baseline rate of sudden death of between 1 in 
714 280 to 1 in 100 835 of the reference population after standardisation to 30-day risks.211 
To date, only one death regarded as potentially related to DP has been reported, an apparently 
healthy 16-year-old woman died suddenly hours after taking the 2nd dose of the first course of DP 
during a mass drug administration exercise in Mozambique.212 Clinical trials on DP that have 
conducted QT interval monitoring by ECG are scarce, but the few have reported minor, clinically 
silent QT interval prolongation with no significant differences to comparator antimalarial drugs. In 
Cambodia, a RCT to evaluate the protective efficacy of a compressed (180 mg dihydroartemisinin 
and 1,440 mg piperaquine) four, monthly 2-day treatment courses of DP was terminated early due 
to safety concerns. An unblinded review showed that the mean QTcF (using Fridericia's formula for 
correcting for heart rate) in the DP arm was 46 ms higher than the placebo arm.213 A systematic 
review by Zani et al. to determine the safety and efficacy of DP for treatment of uncomplicated 
malaria found that DP was associated with an increased frequency of prolongation of the QTc 
interval than mefloquine-artesunate and no difference was seen in prolonged QTc between DP and 
AL. No cardiac arrhythmias, sudden deaths or deaths attributed to DP were reported in this 
review.197 An open-label RCT in Asia reported a statistically significant difference in the proportion 
of patients having borderline QTcF prolongation (431-450 ms) between DP (13.0%) and AS+MQ 
(5.3%) (p<0.001) and prolonged QTcF (> 450 ms) of 4.7% vs 5.3% for DP and AS+MQ respectively 
(p<0.001). These differences disappeared by day 7 of treatment. An increase of QTcF >60 ms from 
baseline was reported in 4.6% and 2.9% for DP and AS+MQ respectively (p<0.001) and a mean 
increase from baseline to day 2 of 22.93 ms and 14.65 ms respectively (p<0.001) and these had 
fallen to 10.47 ms and 13.39 ms by day 7 for DP and AS+MQ respectively (p=0.075). No cardiac 
arrhythmias or deaths were reported in this study.214 Another study by Bassat et al. conducted in 5 
African countries reported that there was no significant difference in the borderline (431-450 ms) 
and prolonged (>450 ms) QTcF interval between DP group (1.0% and 0.2%) and the AL group (1.2% 
and 0.2%) respectively (p=0.76). About 2.7% of participants in the DP and 2.0% in the AL groups had 
a QTcB (using Bazett's formula for correcting for heart rate) increase of ≥60 ms between day 0 and 
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2 of drug administration. Two deaths occurred during the study and both were attributed to either 
severe anaemia or septicaemia.202 A post-licensure safety evaluation of DP in Ghana involving 444 
participants age <6 years conducted ECGs on participants at baseline, before dose three and 
repeated 3-4 hours post-dose three and on day seven after enrolment. Significant changes were 
reported in the mean QTcF compared to baseline; day 3 pre-dose -14.5ms (-16.3 to -12.7), day 3 
post-dose -28.2ms (-30.3 to 26.0) and day-7 post-enrollment -4.5ms (-6.1 to-2.8). Clinically 
insignificant QTcF prolongation of >60ms from baseline was reported in 7, 38 and one participant 
on day-3 pre-dose, day-3 post-dose and on day-7 post-enrollment, respectively.215 
QTcF prolongation returns to normal levels after 11 to 48 hours after the last dose of DP205 
suggesting that repeat monthly doses of DP if used for IPT is unlikely to result in dose accumulation 
and increased risk of QTcF prolongation. Studies that have assessed the cumulative effects of DP 
repeat doses report no increase in QTcF in subsequent doses compared to the first.  
An interventional study in Papua New Guinea enrolled 3 to 60 years old apparently healthy 
individuals and put them on standard 3-day treatment courses of DP over three consecutive 
months. ECGs were conducted pre-dose and 4 hours after the 3rd dose of each monthly course of 
DP. There was no evidence of cumulative cardiotoxicity in this study; the mean QTcF increase was 
19.6 ms (standard deviation [SD]=17.8 ms) and 17.1 ms (SD=17.1 ms) for the first-course and third-
course post-dosing ECGs, risk difference -2.4 (-6.9 to 2.1, p=0.285), respectively. No participant had 
QTcF of >500 ms, and 3 (4.3%) and 2 (2.9%) of participants had a QTcF prolongation of >60 ms 
between baseline and last doses of the first and the third courses (p=1.00), respectively.216 In a sub-
study in the trial by Bigira et al202 183 ECGs were conducted to monitor the effects of repeat 
monthly doses of DP on QT interval prolongation. A mean QTc of 396msec (range 278-444, 
SD=31.3) was recorded on follow up, and none was >450ms. There were no differences in the mean 
(SD) QTc intervals measured 4-6 hours post-dose 3 for children who had been prescribed 3-5, 6-10, 
or 11-18 prior doses of DP: Mean (SD) QTc 405 (26), 388 (33) and 396 (33), respectively (Dorsey, 
unpublished data). Thus, the available data suggests an absence of cumulative cardiotoxicity with 
repeated dosing in asymptomatic individuals. However, the electrocardiographic safety of monthly 
DP when provided as post-discharge chemoprevention may require further confirmations as 
children with severe anaemia may have other risk factors making them more vulnerable to QTc 
prolongation such as electrolyte disbalances. 
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The emergence of artemisinin drug resistance 
Tremendous efforts have been made in the management of malaria, but further initiatives for 
control and elimination are threatened by the emergence of artemisinin-resistant Plasmodium 
falciparum which was first reported in western Cambodia.217,218 It is in the same region where 
resistance to SP and chloroquine emerged before spreading to the rest of Asia and eventually 
Africa.219 Artemisinin resistance is characterised by the prolonged time to parasite clearance,220 
persistence of parasitaemia 72 hours after treatment,221 re-emergence of parasites within 28 
days222 and reduced in vitro susceptibility to dihydroartemisinin in the presence of adequate 
plasma concentrations of dihydroartemisinin which indicates reduced susceptibility of ring-stage 
parasites.223 In resistant parasites the cell cycle is arrested by dihydroartemisinin but resumes when 
the drug levels wane. Artemisinin drug resistance is associated with single nucleotide 
polymorphism in the “propeller” region of the Plasmodium falciparum kelch protein gene on 
chromosome 13 (kelch13).224 
Artemisinin resistance has now spread to the entire Southeast Asia region. In the Thailand-
Myanmar border, the mean parasite clearance half-live was found to be 3.7 hours (3.6-3.8) in 2010 
compared to 2.6 hours (2.5-2.7) in 2001 while in western Cambodia it was estimated to be 5.5 
hours (5.2-5.9) between 2007 and 2010; the proportion of slow clearing infections concurrently 
increased.225 The efficacy of AS+MQ has also been reported to be decreasing in this region,226 but 
the prolongation of treatment with ACTs is still an option for the management of such cases.  
A multi-country prospective study conducted between 2011 and 2013 to determine the spread of 
artemisinin-resistant Plasmodium falciparum showed that resistance is now prevalent in mainland 
southeast Asia with no evidence of spread to Africa. Day 3 post-treatment parasitaemia ranged 
from 0 to 4% in Africa and was as high as 68% in Asia. There were no significant differences in the 
median parasite clearance half-life in Kenya 2.8 hours (0.9-4.2) and Nigeria 2.6 hours (1.4-7.1) 
(p=0.75) and were significantly shorter in the Democratic Republic of Congo 1.9 hours (0.7-7.0) 
compared to Kenya and Nigeria (p<0.001); most sites in Asia had median parasite clearance of >5 
hours.227  
In addition to artemisinin resistance, the emerging resistance to partner drugs in artemisinin-based 
combination therapies could further derail efforts in the fight against malaria. The piperaquine 50% 
inhibitory concentrations (IC50s) was reported to increase significantly in Cambodia between 2011 
and 2013 and two markers of resistance to piperaquine;  exo-E415G and plasmepsin 2–3 markers 
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have been identified to be associated with DP treatment failure in Cambodia.228 In a prospective 
cohort study in Cambodia, 2-65-year-old participants with uncomplicated plasmodium falciparum 
malaria were treated with DP and peripheral parasite densities measured weekly until 63 days to 
determine recrudescence. Piperaquine plasma concentrations were measured at baseline, 7 days, 
and on the day of recrudescence. A higher prevalence of kelch13 mutations and higher 
piperaquine IC50 was found in those with recrudescent infections.229 Another study also found 
Increases in treatment failures, parasite clearance times, and piperaquine IC50 values.223 In 
Cambodia, the resistance to DP is as a result of resistance to both artemisinin and the piperaquine 
components and the presence of validated kelch13 mutations and amplification of plasmepsin-2 
have been demonstrated.223,229,230  
Patent gametocytaemia is correlated with the parasite clearance half-life, and the prevalence of 
pre-treatment and post-treatment gametocytaemia is higher in areas with the increased treatment 
failure rate. Therefore, artemisinin-resistant Plasmodium falciparum infections may have a 
transmission advantage.227,231  
Currently, artemisinin-resistant Plasmodium falciparum has not been reported in Africa.232,233 
Piperaquine associated plasmepsin-2 gene has been isolated in the west and east Africa, but the 
drug is still highly efficacious.230 However, the thread to DP resistance is real as previous resistance 
to chloroquine and SP were imported to Africa from Asia.234 Continued surveillance and monitoring 
for the emergence of resistance is, therefore, a priority in the fight against malaria. The proportion 
of children treated for severe anaemia and which would require post-discharge malaria 
chemoprevention is low compared to the overall malaria cases treated with ACTs. Therefore, PMC 
is unlikely to increase the selection pressure for drug resistance.176 
The rationale for Post-discharge Malaria Chemoprevention trial 
Children recently treated for all-cause severe anaemia are at a high risk of morbidity and mortality 
in malaria-endemic areas, and malaria has been implicated as a major contributor. Currently, no 
strategy specifically addresses this high-risk period, and a proactive approach could offer 
substantial public health gains. IPTp, IPTi and SMC have been deployed successfully and a similar 
strategy targeted on this high-risk post-discharge period is likely to be accepted by policymakers in 
malaria-endemic areas. Like SMC, PMC aims at complete prophylaxis for full haematological 
recovery to be achieved during the intervention period. The previous trial in Malawi101 showed that 
three months of post-discharge malaria chemoprevention using three full treatment courses of AL 
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prevented 31% (95% CI 5-50, P=0.02) of deaths or readmissions due to severe anaemia or severe 
malaria by six months post-discharge. These results are impressive and needed a further 
confirmatory trial before the strategy can be considered for policy by WHO and malaria control 
programs in endemic countries in Africa. PMC aims to determine if 3 months of post-discharge 
malaria chemoprevention with monthly 3-day treatment courses of DP is safe and superior to the 
standard single 3-day treatment course with AL provided as part of standard in-hospital care in 
reducing all-cause readmissions and deaths by 6 months in the post-discharge management of 
children less than 5 years of age admitted with severe anaemia. DP was chosen instead of AL for 
PMC because it is now registered as a second-line treatment for malaria in Kenya and Uganda and 
has higher efficacy and longer post-treatment prophylactic period than AL.  
Research Aim and Objectives 
Aim 
The general aim of this thesis is to generate the necessary evidence required by WHO and Malaria 
Control Programs in Africa to review whether PMC should be recommended as a strategy for the 
post‐discharge management of children with severe anaemia. 
Specific objective 1 
To conduct a retrospective cohort analysis of 5 years historical data (2008 to 2013) for children 
under five years of age from the KEMRI/CDC HDSS who were admitted with severe anaemia or 
other syndromes to the Siaya County Referral Hospital in Western Kenya, in order to determine the 
rates of post-discharge mortality. 
Specific objective 2 
To conduct a meta‐analysis of the burden of anaemia and post-discharge mortality and morbidity in 
children under five years of age in areas with moderate to high malaria transmission intensity in 
Africa order to provide the necessary data required to estimate the impact of PMC if adopted 
Specific objective 3 
To determine if 3 months of post‐discharge malaria chemoprevention with monthly 3‐day 
treatment courses of dihydroartemisinin‐piperaquine (DP) (PMC‐DP) is safe and superior to the 
standard single 3‐day treatment course with artemether‐lumefantrine provided as part of standard 
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in‐hospital care in reducing all‐cause readmissions and deaths by 6 months in the post‐discharge 
management of children less than 5 years of age admitted with severe anaemia. 
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Severe anaemia is a major public health problem in malaria-endemic areas in sub-Sahara Africa 
with up to 34% of paediatric admissions with severe malaria also suffering from severe anaemia. 
Rates of in-hospital mortality are high, and studies show that these children are vulnerable to 
further mortality after discharge. There are no policies to address this risk period, and a better 
understanding of the burden and risk factors for post-discharge mortality are needed. We aimed to 
determine the risk of post-discharge mortality among children <5 years of age admitted with all-
cause severe anaemia or other syndromes in western Kenya. 
Methods 
We conducted a retrospective cohort analysis using data previously collected from continuous 
paediatric in-hospital surveillance and population-based Health and Demographic Surveillance 
Systems in Siaya County, western Kenya. The data was analysed using Cox regression survival 
analysis and Mantel-Haenszel odds ratio (MHOR) for paired binary outcomes. The primary outcome 
was all-cause mortality in the first six months post-discharge.  
Results 
Between January 1, 2008, and December 31, 2013, inclusive, 3,639 hospital admissions involving 
4,423 different diagnoses were recorded. The primary diagnosis included: severe anaemia (n=655), 
severe malaria (n=1033), pneumonia (n=996), severe acute malnutrition (n=271) and ‘other 
syndromes’ (n=1,468). Overall, in-hospital mortality was 2.8% (101/3639) and the post-discharge 
mortality by three, six and twelve months among the 3538 survivors was 7.6%, 9.4%, and 12.4%, 
respectively. Comparison of six-month post-discharge mortality in children with versus without 
specific syndromes showed that children hospitalised with severe anaemia had higher six-month 
post-discharge mortality than other children without severe anaemia (HR=2.46, 1.69-3.56, 
p<0.001). Similarly, severe acute malnutrition was associated with higher six-month post-discharge 
mortality (HR=3.86, 2.56-5.81, p<0.001). Severe malaria, without severe anaemia, was associated 
with lower post-discharge mortality than children without severe malaria (HR=0.38, 0.22-0.67, 
p=0.001). Children admitted with severe anaemia also had significantly higher odds of six-month 
post-discharge mortality than in-hospital mortality (MHOR=2.02, 1.19-4.05, p=0.011). Younger age, 
lower socioeconomic status, living far from the hospital, lower maternal education and maternal 
HIV-positivity were associated with 6-month post-discharge mortality. 




The first six months post-discharge is a high-risk period for mortality among children admitted with 
severe anaemia and severe acute malnutrition in a malaria-endemic area in western Kenya. 
Strategies to address this risk period are needed. 
  




Severe anaemia is a major public health problem in malaria-endemic areas in sub-Sahara Africa and 
has a complex and multifactorial aetiology that includes nutritional factors, and acute and chronic 
infections such as malaria, tuberculosis and Human Immunodeficiency Virus (HIV) infection.1 In 
young children in sub-Saharan Africa, up to 34% of paediatric admission with severe malaria2-4 also 
have severe anaemia.  
Rates of in-hospital mortality due to severe anaemia range from 4 to 12% in different 
epidemiological settings5-7 and can be as high as 16% in the combined presence of respiratory 
distress and malaria.8 However, several studies have shown that the first few months after 
discharge is also a high-risk period for further mortality, which can be as high, or higher than in-
hospital mortality,9-11 particularly in malaria-endemic areas, possibly reflecting the effects of new or 
recrudescent malaria infections.11,12  
The high risk of post-discharge mortality has received little attention relative to the burden, 
diagnosis and care of children during the in-hospital stay,13 and there are currently no specific 
policies to address the post-discharge period. An improved understanding of the magnitude and 
risk factors of post-discharge mortality is needed to help inform policymakers with the 
development of risk-guided management policies to reduce paediatric mortality. In this 
retrospective cohort study, we aimed to evaluate the magnitude and predictors of increased post-
discharge mortality among young children admitted with severe anaemia or other syndromes in a 
high malaria transmission setting in western Kenya. 
Methods 
Data sources and study setting 
This study used two sources of data including data from the Kenya Medical Research Institute 
(KEMRI) and Centers for Disease Control and Prevention (CDC) Health and Demographic 
Surveillance System (HDSS) platform in Siaya County, Western Kenya (Figure 1)14 and continuous 
paediatric in-hospital surveillance in Siaya County referral hospital (formerly Siaya District Hospital). 
The HDSS provided population-based demographic information collected by trained community 
health workers through 4-monthly rounds of home visitations comprising of information on births, 
deaths, morbidity, pregnancies and delivery outcomes, and migration. The in-hospital surveillance 
provided data on all paediatric admissions up to 12 years of age. The hospital and demographic 
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surveillance data were linked using the HDSS unique personal identification numbers and 
fingerprinting14 to monitor deaths occurring after hospital discharge.  
Figure 1: Map of KEMRI/CDC Health and Demographic Surveillance System in western Kenya 
 
Adapted from Odhiambo et al.14 
 
Participants 
This retrospective cohort analysis included all children aged <5 years admitted to the paediatric 
department of Siaya County Referral Hospital from 2008-2013 inclusive who were residing within 
the HDSS study area.14 Admissions due to surgery, trauma/injury, malignancy or sickle cell anaemia 
were excluded.  
Exposure groups 
Each hospital record was examined and categorised based on the diagnosis on discharge or in-
hospital death, and the admission syndrome was used where these records were missing. The 
hospital admissions were categorised in the following primary admission syndromes: severe 
anaemia (defined as haemoglobin <5.0 g/dL or requiring a blood transfusion), severe malaria 
(defined as microscopy or rapid diagnostic test confirmed malaria infection and receipt of 
parenteral treatment with artesunate or quinine but in the absence of severe anaemia), severe 
pneumonia, and severe acute malnutrition (SAM). Diagnosis of pneumonia and SAM were as given 
by the routine hospital staff based on the Kenya Ministry of Health guidelines for clinical 
management during the study period15 as follows: Severe pneumonia for infants <2months of age 
was defined as fever (axillary temperature ≥380C), fast breathing (≥60 breaths per minute [bpm]), 
grunting, severe chest wall indrawing, refusal to feed and difficulty to wake. For children >2 months 
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to 5 years, severe pneumonia was defined as: cough, fast breathing (≥50 and ≥40 bpm for 2-12 
months and ≥12 months to 5 years respectively), lower chest wall indrawing, stridor, reduced 
conscious level. SAM was defined as a weight-for-height z-score <-3 SD or a mid-upper-arm-
circumference (MUAC) of <11.0 cm, with or without oedema. Children who did not have any of 
these four diagnoses were pooled under `other syndromes` and children admitted with conditions 
comprising more than one of the above diagnoses were categorised under `combination 
syndromes` for subgroups analyses. 
Data analysis 
The primary outcome was all-cause death. The follow-up time for the in-hospital mortality analysis 
was defined as the number of days between the date of admission and either the date of in-
hospital death or the date of discharge +1. For analysis of the post-discharge mortality, this was 
defined as the number of days + 1 between the date following the date of discharge and either the 
date of death or the date of censoring. All children were censored if they left the study because of 
out-migration, reached five years of age, date of death, or if the study ended before the event had 
occurred (December 31, 2013). 
Categorical variables were described as proportions (percentages), and continuous variables were 
described as means and corresponding standard deviations (SD) or as median with corresponding 
interquartile ranges (IQR). Univariate and multivariable Cox regression analyses were used for the 
analysis of time to the first event. Factors associated with mortality in the univariate analysis 
(p<0.2) were included in the multivariable models as covariates. These included: gender, age at 
admission, bed net use, antibiotics use, blood transfusion, mother’s education status, mother’s HIV 
status, socio-economic status, haemoglobin (Hb) levels on admission and distance from the 
hospital. There was Insufficient data for the child’s HIV status to allow the inclusion of this variable 
in any of the analyses. Hazard ratios (HR) and their 95% confidence intervals (CI) were reported 
with two-sided p-values <0.05 regarded as statistically significant. 
The Mantel-Haenszel odds ratio (MHOR) for paired binary outcomes was used to compare in-
hospital and post-discharge mortality rates.16 Forest plots were used for the graphical presentation 
of hazard ratios and Kaplan-Meier plots for the visualisation of the time to first event data. 
Data were analysed using STATA version 14 (College Station, Texas, USA). 




This study is nested under the HDSS protocol which was approved by the ethical review boards of 
the Kenya Medical Research Institute (SSC # 647) and the US Centers of Disease Control and 
Prevention (IRB # 3308). Informed written consent was obtained from compound heads for the 
participation of their families in all aspects of the HDSS.14  
Results 
Characteristics of the study groups 
Between January 1, 2008, and December 31, 2013, a total of 69,492 children living in the combined 
HDSS and hospital catchment areas met the inclusion criteria. During this period, there were 3,639 
hospital admissions involving 4,423 different diagnoses. The primary diagnosis included: severe 
anaemia (n=655), severe malaria (n=1033), pneumonia (n=996), SAM (n=271) and ‘other 
syndromes’ (n=1,468). The median (IQR) follow-up time was 23.6 (10.3-36.0) months and the mean 
(SD) age on admission was 17.8 (13.7) months (range 13.1-22.2). Over half (59.5%) of children used 
a bednet. These characteristics differed between primary exposure syndromes (Table 1), including 
the median age at admission and the median duration of follow-up. Because the duration of follow-
up varied between syndromes, the maximum duration was truncated at 12 months. Overall, 4.6% 
and 10.5% of children were lost to follow-up by three- and six-months post-discharge, respectively. 
In-hospital mortality 
The overall in-hospital crude mortality rates (MR) was 2.8% (101 of 3,639 admissions) with a 
median (IQR) length of stay in hospital of 3 (2-5) days. Children admitted with SAM had the highest 
mortality (MR=9.2%) and the longest median (IQR) stay in hospital of 7 (5-11) days. Severely 
anaemic children had the second-highest mortality (MR=5.9%) and the median (IQR) length of stay 
in hospital was 3 (2-5) days. The in-hospital MR among children admitted with pneumonia was 
2.7%, and this was 1.8% for `other syndromes` and 1.0% for severe malaria. Multi-variate models 
comparing the risk of in-hospital mortality in children with and without certain syndromes 
suggested that the in-hospital mortality was significantly higher in children admitted with severe 
anaemia compared to those admitted for other reasons (i.e. all other children admitted without 
severe anaemia, but with pneumonia, or severe malaria or SAM, etc) (hazard ratio [HR]=2.64, 1.58-
4.41, p<0.001). The in-hospital mortality was also higher among children admitted with SAM 
compared to children without SAM (HR=1.84, 1.11-3.05, p=0.018) but similar among children with 
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and without pneumonia (HR=0.86, 0.52-1.44, p=0.575) or ‘other syndromes’ (HR=0.69, 0.37-1.30, 
p=0.253). By contrast, the risk of dying in-hospital was lower among children with severe malaria vs 
those without (HR=0.38, 0.22-0.67, p=0.001) (Table 2) 
Post-discharge mortality 
The cumulative post-discharge mortality among the 3,538 survivors was 7.6%, 9.4%, and 12.4% by 
three, six- and twelve-months post-discharge, respectively (Table 2). By six months, all-cause post-
discharge mortality was highest in the SAM group (MR=37.3%), followed by severe anaemia 
(MR=24.1%), pneumonia (MR=8.3%), ‘other syndromes’ (MR=7.9%), and then severe malaria 
(MR=1.0%) (Table 2). Multi-variate models comparing the risk of post-discharge mortality in 
children with and without certain syndromes suggested the post-discharge mortality by six months 
was significantly higher in children with SAM vs without SAM (HR=3.86, 2.56-5.81, p<0.001) and 
with vs without severe anaemia group (HR=2.46, 1.69-3.56, p<0.001). By contrast, the 6-month 
post-discharge mortality was similar among children with and without pneumonia (HR=0.89, 0.60-
1.33, p=0.578) and with and without ‘other syndromes’ (HR=0.98, 0.61-1.56, p=0.917). It was lower 
in children admitted with severe malaria vs those without severe malaria (HR=0.31, 0.20-0.49, 
p<0.001) (Table 2).  
Because similar trends were seen for both in-hospital and post-discharge mortality (Figure 2), the 
cumulative all-cause mortality that combined the in-hospital with post-discharge mortality by 6 
months also showed a similar ranking by syndrome: SAM (34/71, 47.9%), severe anaemia (48/152, 
31.6%), (45/365, 12.3%), `other syndromes’ (99/943, 10.5%) and severe malaria (8/316, 2.5%) 
(Table 2) 
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Table 1: Baseline characteristics of study participants by the primary diagnosis on admission 
Characteristic Severe anaemia Severe malaria Pneumonia Malnutrition Other syndromes 
Combination 
syndromes Total 
Syndrome on index 
admission—no./total no.  255/3639  499/3639 586/3639 130/3639 1468/3639 701/3639 3639/3639 
Sex (male)—no./total no. (%) 130/255 (51.0%) 256/499 (51.3%) 302/586 (51.5%) 64/130 (49.2%) 800/1468 (54.5%) 374/701 (53.4%) 1926/3639 (52.9%) 
First admission age (months)—
mean±SD 22±14.4 22.2±14.8 13.1±11.3 16.3±10.2 18.9±14.3 15.0±12.0 17.8±13.7 
Bed net use—no./total no. (%) 97/255 (38.0%) 432/499 (86.6%) 366/586 (62.5%) 82/130 (63.1%) 636/1468 (43.3%) 552/701 (78.7%) 2165/3639 (59.5%) 
Distance—median (IQR) 
















SES—median (IQR) -0.2 (-0.6-0.3) 0.3 (-0.4-0.3) -0.1 (-0.5-0.3) -0.3 (-0.6-0.1) -0.1 (-0.4-0.3) -0.2 (-0.5-0.2) -0.1 (-0.4-0.3) 
Mother survival status—
no./total no. (%)        
Alive 244/255 (95.7%) 483/499 (96.8%) 574/586 (98.0%) 126/130 (96.9%) 1413/1468 (96.3%) 687/701 (98.0%) 3527/3639 (96.9%) 
Death 2/255 (0.8%) 1/499 (0.2%) 4/586 (0.7%) 1/130 (0.8%) 12/1468 (0.8%) 3/701 (0.4%) 23/3639 (0.6%) 
Unknown 9/255 (3.5%) 15/499 (3.0%) 8/586 (1.4%) 3/130 (2.3%) 43/1468 (2.9%) 11/701 (1.6%) 89/3639 (2.4%) 
Farther survival status—
no./total no. (%)        
Alive 227/255 (89.0%) 432/499 (86.6%) 507/586 (86.5%) 117/130 (90.0%) 1229/1468 (83.7%) 580/701 (82.7%) 3092/3639 (85.0%) 
Death 8/255 (3.1%) 16/499 (3.2%) 27/586 (4.6%) 6/130 (4.6%) 66/1468 (4.5%) 34/701 (4.9%) 157/3639 (4.3%) 
Unknown 20/255 (7.8%) 51/499 (10.2%) 52/586 (8.9%) 7/130 (5.4%) 173/1468 (11.8%) 87/701 (12.4%) 390/3639 (10.7%) 
Mother HIV status—no./total 
no. (%)        
Positive 27/255 (10.6%) 40/499 (8.0%) 83/586 (14.2%) 23/130 (17.7%) 173/1468 (11.8%) 96/701 (13.7%) 442/3639 (12.1%) 
Negative 109/255 (42.7%) 251/499 (50.3%) 256/586 (43.7%) 43/130 (33.1%) 628/1468 (42.8%) 338/701 (48.2%) 1625/3639 (44.7%) 
Unknown 119/255 (46.7%) 208/499 (41.7%) 247/586 (42.2%) 64/130 (49.2%) 667/1468 (45.4%) 267/701 (38.1%) 1572/3639 (43.2%) 
Mother Education level—
no./total no. (%)        
Lower primary 10/255 (3.9%) 10/499 (2.0%) 22/586 (3.8%) 8/130 (6.2%) 51/1468 (3.5%) 27/701 (3.9%) 128/3639 (3.5%) 
Upper primary 152/255 (59.6%) 286/499 (57.3%) 334/586 (57.0%) 68/130 (52.3%) 785/1468 (53.5%) 423/701 (60.3%) 2048/3639 (56.3%) 
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Table 1: Baseline characteristics of study participants by the primary diagnosis on admission 
Characteristic Severe anaemia Severe malaria Pneumonia Malnutrition Other syndromes 
Combination 
syndromes Total 
Secondary 85/255 (33.3%) 174/499 (34.9%) 202/586 (34.5%) 46/130 (35.4%) 528/1468 (36.0%) 226/701 (32.2%) 1261/3639 (34.7%) 
Tertiary 6/255 (2.4%) 21/499 (4.2%) 25/586 (4.3%) 5/130 (3.8%) 83/1468 (5.7%) 13/701 (1.9%) 153/3639 (4.2%) 
SES, socioeconomic status; IRQ, interquartile range; `Other syndromes` denote the undefined syndromes in children that did not have severe anaemia, severe 
malaria, pneumonia or severe acute malnutrition; `combination syndromes` comprise children with a combination of more than one syndrome including severe 
anaemia, severe malaria, pneumonia malnutrition or `other syndromes` 
 
Table 2: outcomes by the primary diagnosis on admission 
Outcomes Severe anaemia Severe malaria Pneumonia Malnutrition `Other syndromes` Total 
Duration of hospital stay 
during initial admission in 
days— median (IQR) 
3 (2-5) 3 (2-5) 4 (3-6) 7 (5-11) 3 (2-5) 3 (2-5) 
Duration of follow-up 
(months) 
22.3 (5.9-35.7) 23 (11.3-34.1) 24.4 (10.2-35.7) 15.7 (3-31) 25.2 (11.1-38.7) 23.6 (10.3-36) 
Loss to follow-up by: 
      
   3 months 10/255 (3.9%) 35/499 (7.0%) 18/586 (3.1%) 8/130 (6.2%) 65/1468 (4.4%) 169/3639 (4.6%) 
   6 months 27/255 (10.6%) 61/499 (12.2%) 56/586 (9.6%) 16/130 (12.3%) 147/1468 (10.0%) 382/3639 (10.5%) 
   12 months 47/255 (18.4%) 122/499 (24.4%) 111/586 (18.9%) 25/130 (19.2%) 290/1468 (19.8%) 728/3639 (20.0%) 
Deaths 
      
   In-hospital 15/255 (5.9%) 5/499 (1.0%) 16/586 (2.7%) 12/130 (9.2%) 27/1468 (1.8%) 101/3639 (2.8%) 
   Post-discharge deaths 
(total follow-up time) 
43/240 (17.9%) 16/494 (3.2%) 59/570 (10.4%) 28/118 (23.7%) 116/1441 (8.0%) 335/3639 (9.2%) 
   Total in-hospital and post-
discharge deaths 
58/240 (24.2%) 21/494 (4.3%) 75/570 (13.2%) 40/118 (33.9%) 143/1441 (9.9%) 436/3639 (12%) 
Median (IQR) time to post-
discharge death (months)  
1.8 (0.3-4.1) 7.5 (4.8-8.1) 1.8 (0.4-6.4) 0.6 (0.2-2) 1.1 (0.4-4) 2.1 (0.6-7.1) 
Risk of death from 
discharge to: 
      
   3 months 25/137 (18.2%) 0/311 (0.0%) 26/349 (7.4%) 21/59 (33.9%) 62/916 (6.8%) 167/2173 (7.6%) 
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Table 2: outcomes by the primary diagnosis on admission 
Outcomes Severe anaemia Severe malaria Pneumonia Malnutrition `Other syndromes` Total 
   6 months 33/137 (24.1%) 3/311 (1.0%) 29/349 (8.3%) 22/59 (37.3%) 72/916 (7.9%) 205/2173 (9.4%) 
   12 months 40/137 (29.2%) 11/311 (3.5%) 45/349 (12.9%) 23/59 (39.0%) 92/916 (10.0%) 269/2173 (12.4%) 
Cumulative risk for in-hospital and post-discharge deaths up to:     
   3 months 40/152 (26.3%) 5/316 (1.6%) 42/365 (11.5%) 33/71 (46.5%) 89/943 (9.4%) 268/2274 (11.8%) 
   6 months 48/152 (31.6%) 8/316 (2.5%) 45/365 (12.3%) 34/71 (47.9%) 99/943 (10.5%) 306/2274 (13.5%) 
   12 months 55/152 (36.2%) 15/316 (4.7%) 61/365 (16.7%) 35/71 (49.3%) 119/943 (12.6%) 370/2274 (16.3%) 
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‘Other syndromes` denote the undefined syndromes in children that did not have severe anaemia, severe malaria, pneumonia or severe acute malnutrition. 
IQR, interquartile range.  
Post-discharge mortality risk (follow-up truncated to 12 months).  
 
 




Figure 2: In-patient vs six-month post-discharge mortality by syndrome 
 
MHOR, Mantel-Haenszel odds ratio; CI, confidence interval; `Other syndromes` denote the undefined 
syndromes in children that did not have severe anaemia, severe malaria, pneumonia or severe acute 
malnutrition.  
 
The Kaplan-Meier plot (Figure 3) illustrates that. among the post-discharge deaths by 12 months 
(n=269/2173, 12.4%), the median (IQR) time to death was 2.1 (0.6-7.1) months overall (i.e. 50% of 
all death by 12 months occurred within the first 2.1 months), with 62.1% (167/269) and 76.2% 
(205/269) of these deaths occurring within the first three and six months respectively. The median 
time to death was shortest, and the proportion of the death that had occurred by three months 
was highest, for children with SAM (0.6m, 21/23 [91.3%]) followed by `other syndromes` (1.1m, 
62/92 [67.4%]), severe anaemia (1.8m, 25/40 [62.5%]), pneumonia (1.8m, 26/45 [57.8%]) and 
severe malaria (7.5m, 0/11 [0%]).  
Figure 3: Survival curves showing time to post-discharge death  
 
`Other syndromes` denote the undefined syndromes excluding severe 
anaemia, severe malaria, pneumonia or severe acute malnutrition.  




The co-presence of SAM was associated with significantly higher 6-month post-discharge mortality 
in children with severe anaemia compared to severely anaemic children that did not have SAM 
(MR=25.1% vs MR=10.0%, HR=2.49, 1.18-5.26, p=0.017) (Figure 4). The co-existence of SAM also 
significantly increased the 6-month post-discharge mortality in children with pneumonia 
(MR=14.8% vs MR=5.0%, HR=2.91, 1.41-6.01, p=0.004) and children with severe malaria 
(MR=12.2% vs 2.3%, HR=5.29, 2.11-13.24, p<0.001). The co-existence of severe anaemia did not 
significantly increase the 6-month mortality in SAM children (MR=25.1% vs 21.2%, HR=1.22, 0.56-
2.64, p=0.613), but increased it significantly in those with severe malaria (MR=6.6% vs 1.4%, 
HR=4.67, 2.07-10.58, p<0.001). The co-existence of severe malaria was associated with lower 6-
month post-discharge mortality in children with severe anaemia; i.e. children with severe malarial 
anaemia had a lower risk of dying post-discharge than children with severe non-malarial anaemia 
(MR=6.6% vs 14.8%, HR=0.45, 0.25-0.80, p=0.007) (Figure 4). 
In-hospital vs post-discharge mortality 
Overall, the odds of dying in the first six months post-discharge was higher than during the in-
hospital period (MHOR=2.08, 1.54-2.80, p<0.001) with relatively little variation between 
syndromes. The differences were statistically significant for severe anaemia, and `other syndromes` 
(Figure 2).  
Other risk factors for post-discharge mortality 
In the univariate model, post-discharge mortality by six months decreased with increasing age 
(Table 3) and Figure S1) from MR=9.5% in infants aged <6 months to MR=7.0% in the 6 to <18 
months old (HR=0.74, 0.53-1.02, p=0.067) and MR=4.1% in the 36 to <60 months old group 
(HR=0.38, 0.21-0.67, p<0.001). HIV-exposed children were twice as likely to die than HIV-unexposed 
children during the 6-month follow-up period (HR=2.61, 1.68-4.07, p<0.001). The HIV status was 
only available for 5.5% of the children, so no analysis by child’s HIV status was conducted. Post-
discharge mortality decreased with increasing socioeconomic status (SES) from MR=10.1% in the 
poorest terciles to MR=7.4% in the middle tercile (HR-0.79, 0.57-1.08, p=0.134) to MR=5.4% in the 
highest tercile (HR=0.51, 0.35-0.73, p<0.001). Maternal education was also associated with 
decreasing post-discharge mortality, but this was only significant for secondary level education 
(MR=5.3%) compared to lower primary education (MR=9.9%, HR=0.50, 0.27-0.92, p=0.027). 
Increasing distance from the admitting hospital was associated with higher post-discharge mortality 
with children with the tercile that lived furthest having a more than 2-fold higher hazard compared 
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to those in the first tercile (HR=2.66, 1.82-3.87, p<0.001). Bed net use was associated with a 
significant reduction in the six months post-discharge mortality (HR=0.65, 0.49-0.85, p=0.002). 
Treatment with antibiotics during in-patient care was not associated with post-discharge mortality 
(HR=1.10, 0.82-1.48, p=0.507). Among children with severe anaemia, lack of receipt of blood 
transfusion was not associated with a statistically significantly increased post-discharge mortality 
(HR=1.86, 0.24-14.35, p=0.553). However, a unit increase in Hb levels on admission (prior to receipt 
of any blood transfusion) was associated with about 46% decrease in the risk of 6 months post-
discharge mortality (HR=0.54, 0.38-0.77, p<0.001). Gender and discharge during malaria season 
were not associated with post-discharge mortality.  
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Figure 4: Six months post-discharge mortality by main syndrome relative to ‘co-syndromes` 
 
HR, hazard ratio; CI, confidence interval; MR, mortality rate; Other syndromes` not included, there were no deaths for overlapping syndromes between `other 
syndromes` and severe anaemia or severe malaria. Adjusted estimates were obtained from multivariate models that included the following covariates: age at 
admission, bed net use, socio-economic status, distance to hospital, maternal education level and mother’s HIV status. 
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Table 3: Risk factors for 6-month post-discharge mortality  
Univariate HR 
(95%CI) 
P Multivariate HR (95%CI) P 
Admission age (ref: <6 months) 
   
6 to <18 months 0.74 (0.53-1.02) 0.067 0.63 (0.39-1.09) 0.100 
18 to <36 months 0.42 (0.28-0.64) <0.001 0.40 (0.21-0.79) 0.008 
36 to <60 months 





0.52 (0.22-1.22) 0.134 
Haemoglobin (mean [SD]) 0.54 (0.38-0.77) <0.001 1.06 (0.97-1.15) 0.222 
Bed net (ref: no use) 0.65 (0.49-0.85) 0.002 0.76 (0.47-1.22) 0.259 
Discharge season (ref: non-malaria 
season) 
0.96 (0.49-1.26) 0.760 
  
Blood transfusion (ref: not transfused) 1.86 (0.24-14.35) 0.553 
  
Antibiotics  1.10 (0.82-1.48) 0.507 
  
Socioeconomic status (ref: first tercile-poorest) 
   
Second tercile 0.79 (0.57-1.08) 0.134 1.08 (0.66-1.75) 0.758 
Third tercile 0.51 (0.35-0.73) <0.001 0.53 (0.29-0.96) 0.037 
Distance from the hospital (ref: first tercile, closest) 
   
Second tercile 1.86 (1.25-2.78) 0.002 1.50 (0.79-2.82) 0.214 
Third tercile 2.66 (1.82-3.87) <0.001 2.00 (1.07-3.74) 0.029 
Mother education (ref: lower primary) 
   
Upper primary 0.62 (0.34-1.11) 0.108 0.48 (0.23-1.00) 0.051 
Secondary 0.50 (0.27-0.92) 0.027 0.40 (0.17-0.91) 0.028 
Tertiary 0.53 (0.22-1.30) 0.166 0.62 (0.15-2.58) 0.511 
Mother HIV status (ref: HIV negative) 2.61 (1.68-4.07) <0.001 2.06 (1.24-3.40) 0.005 
HR, hazard ratio; HIV, human immunodeficiency virus; Hb, haemoglobin; The multivariable model adjusts for 
age category, Hb levels on admission bed net use, SES terciles, distance terciles, mother`s education status 
and mother’s HIV positive status. 




In this malaria-endemic area in western Kenya, children with severe anaemia and SAM had both 
the highest in-hospital and post-discharge mortality, followed by children admitted with 
pneumonia. Except for severe malaria, children were at two-fold higher risk of dying within six 
months after discharge than during the initial hospital period. Among children admitted with severe 
anaemia half of these post-discharge deaths by 12 months occurred in the first 1.8 months and this 
was 0.6 months for children with SAM, which was similar in children admitted with pneumonia, 
where the median survival time was 1.8 months, but which was associated with lower post-
discharge mortality overall than SAM or severe anaemia. Overall, factors associated with post-
discharge mortality were comparable with earlier reports from similar epidemiological settings 
including; young age, HIV-exposure, lower maternal education, distance from the hospital and 
haemoglobin levels on admission.10,17 Unfortunately, the HIV-status of the child was not available 
for most of these children. 
Our findings are consistent with previous observational studies in the same study area in Kenya,11 
Malawi10 and Uganda9 which also reported high rates of post-discharge mortality among children 
admitted with all-cause severe anaemia. In our study, 18.2% had died by three months and 24.1% 
by six months while in the earlier observational study in Kenya, 18.8% died over two months11 and 
in Malawi, 8.8% died in six months.10 Of note is that our observed post-discharge mortality rates are 
considerably higher than those previously reported in the placebo arms of three post-discharge 
malaria chemoprevention trials in children with severe anaemia in Malawi18,19 and Kenya (Chapter 
6). It is likely that the children enrolled in these trials benefitted from access to better in-hospital 
care and closer follow-up post-discharge than can be achieved in routine settings.   
Overall, half of the post-discharge deaths by 12 months, occurred in the first 2.1 months (the 
median time to death). This pattern differed between syndromes (Figure 3) as in children with SAM, 
nearly all of the deaths had occurred by three months post-discharge, and this was approximately 
62% for children with severe anaemia and 57% for children with pneumonia. By contrast, for 
children with severe malaria, the time to death was spread over the year with a median survival 
time of 7.5 months. The first few months post-discharge has been recognised as a period of high 
vulnerability to mortality and morbidity in children with SAM and severe anaemia, possibly because 
of physiological stress and impairment of the immune system.17,20,21 In malaria-endemic areas 
Plasmodium falciparum infection has been shown to lead to endothelial inflammation which may 
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persist for more than a month even after the parasites have been cleared.22  This is likely to 
predispose to or worsen untreated bacterial infections,23 including invasive non-typhoidal 
salmonella infections (iNTS) which have been shown to have a positive correlation with 
Plasmodium falciparum infection in malaria-endemic areas in sub-Sahara Africa.24 Children with 
coexisting iNTS and falciparum malaria infections have a high in-hospital mortality rate25 which is 
even worse in children with severe malarial anaemia,26 and likely contributes to the high post-
discharge mortality in the immediate post-discharge period. 
The high risk of post-discharge mortality in children with SAM and severe anaemia was also evident 
in our analysis of the impact of co-existence of multiple syndromes. Overall, we found that children 
with pneumonia and severe malaria had the worst outcomes if they also had SAM or severe 
anaemia. For example, the 6-month post-discharge mortality was about five-fold higher in children 
with severe malaria if they also had SAM or severe anaemia. Similarly, children with severe 
pneumonia were at a threefold higher risk if they also had SAM. By contrast, the co-existence of 
pneumonia or malaria did not increase the post-discharge mortality in children with SAM or severe 
anaemia. 
Due to insufficient data, we could not explore the causes of post-discharge death, and these are 
likely to be multifactorial in this setting, including HIV infection, other acute and chronic infections, 
e.g. tuberculosis, and malnutrition or micronutrient deficiencies. However, previous studies in 
similar epidemiological settings among children admitted with severe anaemia have reported 
malaria as the main reason for morbidity and mortality in the post-discharge period. In Uganda,9 
89% of re-hospitalisations and 59% of clinic visits were due to malaria, and in previous studies in 
this same study area in western Kenya, 30% of post-discharge deaths were due to malaria.11 In a 
similar setting in Kenya, 50% of participants were parasitaemic one-month post-discharge.12 Full 
recovery from malaria-associated anaemia is known to take up to 6 weeks,27 possibly due to 
continued dyserythropoietic and bone marrow suppression28,29 and new infections or 
recrudescence due to poor parasite clearance are likely to cause further delays in recovery. 
Another noticeable finding was the relatively low risk of post-discharge mortality in children with 
severe malaria in the absence of SAM or severe anaemia. Severe malaria is an acute condition of 
which proper diagnosis and treatment result in better prognosis as opposed to the multifactorial 
aetiology of non-malaria anaemia in this setting which is difficult to diagnose and treat, especially 
due to inadequate human and structural capacity in the healthcare system.30 In this setting, malaria 
and anaemia are diagnosed clinically following the Integrated management of childhood illnesses 
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(IMCI) guidelines.31 Parenteral antimalaria treatment and blood transfusion are then administered 
presumptively, mostly without further investigation for other possible underlying conditions. 
Therefore, inadequate care during in-hospital stay due to challenges in diagnosis and treatment 
may result in disease progression and poor post-discharge prognosis among children with non-
malaria severe anaemia. Another possible reason is the misclassification of uncomplicated malaria 
as severe malaria, therefore underestimating the severe malaria-specific mortality rates; it has 
been shown that about a third of admissions for ‘severe malaria’ do not fulfil WHO’s criteria for 
severe malaria in malaria-endemic sub-Sahara Africa.32 
Almost all post-discharge deaths in this study (>95%) occurred in the community before children 
were referred or able to reach the hospital. These findings are consistent with a recent study in a 
HDSS area in Mozambique where > 80% of post-discharge deaths in children was reported to have 
occurred outside the hospital17 and in another study among children admitted with infectious 
conditions in Uganda where 67% of post-discharge deaths occurred in the community or on the 
way to the hospital.33 Delay in seeking care due to ignorance of the danger signs of severe anaemia 
and preference for traditional medicine are likely contributors to high post-discharge mortality 
among children with severe anaemia in Uganda.34 We found lower maternal education to be 
positively associated with post-discharge mortality. Thus, an intervention, including 
maternal/caretaker education on discharge on how to identify the danger signs and to seek prompt 
care, may help reduce the burden. This is further supported by the above-mentioned finding that 
the post-discharge mortality rates in the placebo arm of the PMC trial conducted in this area 
(chapter 6) were much lower than in this observational study, similar to the differences in mortality 
rates between trials and observational cohort studies in Malawi.10,18  
A major limitation of this study was the lack of data on the HIV status of participants. At the time of 
the study, testing for HIV among the paediatric population in Kenyan public hospitals was not 
offered routinely. Although the information on the maternal HIV status was available for many 
(71.4%), data on the actual HIV status of the child was available in only 5.5%. The study area is 
known to have a high prevalence of HIV infection,35 and paediatric HIV infection is a major risk 
factor for severe anaemia.36 Studies in areas with high HIV and malaria co-infection rates in Uganda 
and Kenya have reported up to 5-fold higher 6-month post-discharge mortality rates in children 
with severe malarial anaemia associated with HIV infection.36,37 Another major limitation is the lack 
of additional information about other co-morbidities associated with the primary diagnosis of 
severe anaemia. The aetiology of severe anaemia in this setting has been shown to be complex and 
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multifactorial including nutritional deficiencies, hookworm infestations, acute and chronic 
infections such as malaria, bacteraemia, tuberculosis and Human Immunodeficiency Virus (HIV) 
infection, genetic disorders such as sickle cell anaemia etc.1  There was also limited information on 
diarrhoea and bacteraemia which are generally known to cause substantial morbidity in sub-Sahara 
Africa. The latter reflects the limited diagnostic capacity in Kenyan public hospitals. Many of the 
children with sepsis may have ended up in the `other syndromes` group in our analysis.  
The results of this study add to the limited evidence from other studies in malaria-endemic areas 
and confirm that children under five years of age admitted with SAM and severe anaemia are at a 
high risk of post-discharge mortality in the first few months after discharge. Guidelines exist for the 
management of children with SAM post-discharge, but similar guidelines need to be developed for 
the post-discharge management and follow-up of children with severe anaemia. Furthermore, 
studies of predictors and the aetiology of post-discharge mortality are urgently needed to develop 
targeted management guidelines for post-discharge care.  
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Figure S1: Risk factors for 6-month post-discharge mortality 
 
HR, hazard ratio; CI, confidence interval 
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Severe anaemia is associated with high in-hospital mortality among young children. Several studies 
in malaria-endemic areas have shown that surviving children remain at increased risk of dying or re-
admission for several months after discharge from hospital. 
Methodology 
We conducted a systematic review and meta-analysis to determine the pooled risks of morbidity 
and mortality in the post-discharge period among children admitted with severe anaemia versus 
other syndromes in malaria-endemic areas in Africa. Two authors independently searched medical 
databases up to October 31, 2018, for prospective and retrospective cohort studies and clinical 
trials involving children aged <15 years. The primary outcomes were all-cause death and 
readmission within six months post-discharge. We used random-effect meta-analyses. 
Results 
Eighteen studies fulfilled the entry criteria and were included. The duration of post-discharge 
follow-up varied from 28 days to 1 year. The odds of dying within 6 months post-discharge was 
higher than during the in-hospital period for children admitted with severe anaemia (N=4, Mantel-
Haenszel odds ratio =1.44, 95% CI 1.07-1.92, p<0.0157, I2=0.8%) and they were twice as likely to die 
by 6 months post-discharge compared with children admitted without severe anaemia (N=4, 
Relative Risk [RR]=2.80, 1.61-4.86, p<0.0001, I2=73.1%). Severe malnutrition was also associated 
with increased post-discharge mortality compared to children admitted without severe anaemia or 
malnutrition (N=2, RR=4.27, 2.42-7.55, p<0.0001, I2=76.8). The risk of readmission was higher 
among children admitted with severe anaemia compared to other syndromes, but this was based 
on only one study (RR=3.05, 1.12-8.35, p<0.001, I2=0.0%).  
Conclusion 
In malaria-endemic areas of Africa, children hospitalised with severe anaemia and severe 
malnutrition are at an increased risk of dying in the first six months post-discharge compared to 
children admitted with other syndromes. There is a need to develop post-discharge management 
strategies for this high-risk group. 
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Introduction 
Substantial progress has been made in the past decade in reducing child mortality globally, but in 
sub-Saharan Africa, about 1 in 13 children still die before their fifth birthday.1 Severe anaemia and 
malaria are major contributors to morbidity and mortality in malaria-endemic areas of Africa.2,3 
Severe anaemia alone accounts for 2-29% of all paediatric hospitalisations4-6 and about a third of 
children hospitalised with fever in Africa also have severe anaemia.7 The mortality due to severe 
anaemia among children during the in-hospital period ranges from 4 to 10% in different 
epidemiological settings in Africa.8-10 The aetiology in these settings is complex and multifactorial 
and include nutritional causes,11,12 and acute and chronic infections such as malaria, tuberculosis, 
human immunodeficiency virus (HIV) infections, bacteraemia and hookworm infestations.13  
Recent studies among children with severe anaemia have focused on interventions to reduce high 
in-hospital mortality.14-16 However, it is now increasingly recognized that the excess risk of mortality 
continues even after discharge from hospital17-20 with up to 33% of the children dying or being 
readmitted during the first six months post-discharge.8,21 The post-discharge period is a well-
recognised risk period for children with severe acute malnutrition,22,23 but is less studied in children 
with severe anaemia. 
We hypothesised that children admitted with severe anaemia constitute an especially vulnerable 
group of post-discharge mortality and morbidity due to a combination of environmental, 
behavioural, nutritional and genetic risk factors.13,19 We conducted a systematic review and meta-
analysis to compare the pooled risks of post-discharge mortality and re-admissions among children 
admitted with all-cause severe anaemia versus other syndromes without severe anaemia in 
malaria-endemic areas of Africa. We also compared the in-hospital mortality against post-discharge 
mortality.  
Methods 
Search strategy and selection criteria  
This analysis was completed per the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) statement.24 The protocol was registered in PROSPERO: The International 
Prospective Register of Systematic Reviews (CRD42017079282).  
 




We identified eligible studies by performing a systematic and comprehensive electronic literature 
search using a combination of search terms (Supplement 1) in PubMed, SCOPUS, EMBASE, Web of 
Science and Cochrane CENTRAL from inception to October 31, 2018, without language restrictions. 
We identified other relevant studies by scanning reference lists of all identified articles and 
searching in Google and Google Scholar.  
Eligibility criteria 
Prospective or retrospective cohort studies and randomised-controlled trials (RCTs) were eligible 
for inclusion if they: (i) presented original data with or without comparator groups (ii) included 
children <15 years of age admitted with severe anaemia or other syndromes such as malaria, 
pneumonia, diarrhoea, malnutrition, HIV etc., alone or in combination with severe anaemia; (iii) 
defined the duration of the post-discharge follow-up and (iv) were conducted in malaria-endemic 
countries in Africa according to the World Malaria Report 2017.25  
Studies or sub-groups were excluded if they (i) involved admissions for sickle cell anaemia, 
malignancies or surgery, road accidents and other trauma cases (ii) did not report follow-up data 
for in-patients separate from out-patient.  
Study selection and data extraction 
Two independent reviewers (TKK and ATM) screened titles, abstracts and full texts of the identified 
articles and agreed on the final eligibility. Any disagreement between the two reviewers was 
resolved through consensus or after consultation with a third reviewer (FOtK). 
TKK and ATM independently extracted the data using a standardised form and database. If 
required, additional information was obtained from the authors. For each study, the following 
information was extracted: first author’s name, year of publication, recruitment site, study design, 
geographic location, study period, age range of participants, comparison groups, main syndrome on 
admission, number of enrolled participants, inpatient mortality, post-discharge mortality, post-
discharge morbidity, post-discharge follow-up time, eligibility criteria, outcomes and reported risk 
estimates. In trials or other comparative studies where interventions were provided, only the data 
from the control groups that received the standard of care were included. 
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Quality assessment 
The Cochrane Collaboration’s tool was used to assess the quality and risk of bias of clinical trials.26 
The quality of observational studies and cohort studies with comparison groups were assessed 
using the Newcastle Ottawa Scale.27 For cohort studies without comparison groups, a modified 
version of the Newcastle Ottawa Scale was used that omitted the comparability criteria and in the 
“selection criteria” the section on “selection of the non-exposed cohort”. 
Data analysis 
Two primary outcome measures were used: all-cause death or all-cause re-admissions in the post-
discharge period. 
Data were analysed using STATA version 14.0 (Stata Corporation, College Station TX). DerSimonian 
and Laird random-effects meta-analysis were used to generate pooled relative risks (RR). Pooled 
effect estimates using fixed-effects models (Mantel-Haenszel) were also provided as part of 
sensitivity analysis and are only provided in the forest plots. 
The Mantel-Haenszel odds ratio (MHOR) for paired binary outcomes was used to compare in-
hospital and post-discharge mortality rates.28 
Heterogeneity was expressed using the I2 statistic and categorised as low, moderate, substantial 
and considerable if the I2 value ranged between 0-40%, 30-60%, 50-90%, and 75-100%, 
respectively.29. We used two-tailed p-values of <0.05 to indicate statistical significance. We 
intended to perform sensitivity analysis to determine the influence of study quality on results, but 
this was not possible due to the small numbers of studies included in the meta-analysis and lack of 
heterogeneity in study quality. 
Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
Results  
Our search identified 2,972 articles; after removal of duplicates and screening of titles and 
abstracts, 73 full-text articles were further evaluated, of which 18 were eligible; this included 16 
cohort studies17,19,20,23,30-41 and 2 RCTs42,43 (Figure 1 and Table 1). The studies were published 
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between 1987 and 2018 and were conducted in Kenya (five), Malawi (four), Uganda (two), The 
Gambia (one), Guinea-Bissau (two), Democratic Republic of Congo (two) and Tanzania (two). The 
main syndromes on admission included severe anaemia (six studies), malaria (three), pneumonia 
(four), malnutrition (three) and five other studies in which the main syndromes on admission were 
not specified (unspecified syndromes). The post-discharge follow-up period ranged from 28 days to 
5 years but was truncated to a maximum of 12 months for analysis. The post-discharge mortality 
ranged from 1 to 39% (Table 1). The Cochrane Collaboration tool for RCTs scored the two RCTs as 
low risk of bias (eTable 1). Fifteen cohort studies were scored as good quality and one as poor 
quality (eTable 2, eTable 3).  
Figure 1: PRISMA Diagram 
 
IPD, in-hospital; OPD, outpatient department. Reasons for exclusion exceed the number of articles 
excluded because some articles have more than one reason for exclusion. 
*including a prospective follow-up study of children who were initially enrolled in a prospective case-
control study.20 
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Table 1: Characteristics of included studies 












Randomised Controlled Trials 
Biai et al.42 Guinea-
Bissau 
2004-06 Control ward 3m-5y Malaria 491 9.6% 1%  NR 28d 
Phiri et al.43 Malawi 2006-09 Placebo  4m-59m SMA 708 NA 2.3% 18.5% 6m 
Cohort studies without a comparator group  
Carme et al.30 Congo 1988-89 All enrolled ≤ 14 Cerebral 
malaria 
170 15% 6.7% NR 27m 
Chhibber et al.32 The 
Gambia 
2008-12 All enrolled 2m-59m Pneumonia+ 
others 
3735 3.9% 2.8% NR 180d 
Villamor et al.39 Tanzania 1993-97 All enrolled 6m-60m Pneumonia 687 3.1% 11.7% NR Mean 
24.7m Wiens et al.40 Uganda 2012-13 All enrolled 6m-5y All-cause 
(Infectious) 
1307 5.0% 4.9% 
 
Hennart et al.34 Congo 1970 All enrolled mean 
46m 
PEM 171 NR 0.18 NR 5y 
Kerac et al.23 Malawi 2006-07 All enrolled 5m-14y PEM 1024 23.2% 24.0% 7.1% 1y 
Cohort studies with comparator groups 
Moisi et al.35 Kenya 2003-08 Post-discharge 
group 




   
  




2461 5.6% 3.1% NR 1y 
Post-discharge 
group 
1m-59m No Severe 
Pneumonia 
5270 2.4% 1.3% NR 





162 12.7% 0.6% 3.1% 6m 
Admissions 
with SMA 
18m-12y SMA 138 0.4% 2.2% 9.4% 
Community 
(not admitted) 
18m-12y Healthy  133 NA 0% 0% 
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Table 1: Characteristics of included studies 












Veirum et al.38 Guinea-
Bissau 
1991-96 PD Cohort ≤15y All-cause 2950 12.5% 7.5% 15.9% 12m 
Community 
cohort 
≤15y All-cause 8184 NA *MRR  0.041 
Zucker et al.41 Kenya 1991 Exposed group  6m-5y Severe 
anemia 
293 13.0% 18.8% NR 8w 
non-exposed 
group 
6m-5y Non- Severe 
anemia 
930 8.9% 11.3% NR 
Snow et al.37 Kenya 1992-97 Post-discharge 
group 





≤6y NR 2845 NA 1.06/1000 
pm 
172 
Phiri et al.20 Malawi 2002-06 Cases 6-60m Severe 
anemia  
377 6.4% 11.6% 17.2% 18m 
Hospital control 6-60m No severe 
anemia 
377 0.0% 2.7% 9.4% 
Community 
controls 
6-60m Healthy 380 N/A 1.3% 10.0% 






499 1.0% 3.5% NR 12m 




255 5.9% 29.2% NR 
   Admitted with 
pneumonia 
≤5y Pneumonia 586 2.7% 12.9% NR  
   Admitted with 
malnutrition 
≤5y Malnutrition 130 9.2% 39.0% NR  





1468 1.8% 10.0% NR 
Chinkhumba et al.33 Malawi 2005-06 HIV Positive 6m-59m SAM 79 30.4% 7.3% NR 4m 
HIV Negative 6m-59m SAM 375 8.5% 2.0% NR 
Hau et al.31 Tanzania 2014 All-enrolled 2-12Y All-cause 537 7.7% 12.6 NR 12m 
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Table 1: Characteristics of included studies 













IP, inpatient; PD, post-discharge; FUP, follow-up period; SP, sulphadoxine-pyrimethamine; IPTpd, intermittent preventive treatment post-discharge; SpO2, 
peripheral capillary oxygen saturation; NR, not reported; SMA, severe malarial anaemia; SAM, severe acute malnutrition; NA, not applicable; MRR, mortality 
rate ratio; PEM, protein-energy malnutrition.
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Post-discharge readmission  
Seven studies reported post-discharge readmissions for periods ranging between 3 to 18 
months with wide variations in the reported readmission rates (Table 1). The crude 
proportion of children re-admitted at least once by six months was 11.6% (201/1740) 
ranging from 3.1% to 18.5% based on three studies.19,23,43 Readmissions for severe anaemia 
and non-anaemia by six months post-discharge was 17.0% and 6.4% respectively based on 
these three studies. Only two studies allowed for a direct comparison of re-admission risk by 
syndrome,19,20 but the results were not pooled because they reported readmission rates at 
different times; 6 and 18 months respectively (Figure 2). There were no studies to conduct a 
comparative meta-analysis for readmission rates for other syndromes.  
Figure 2: Post-discharge readmission between severe anaemia and other syndromes 
without severe anaemia. 
 
RR, relative risk; SA, severe anaemia; CI, confidence interval; D+L, DerSimonian and Laird; M-H, 
Mantel-Haenszel. 
 
Post-discharge mortality by syndrome 
A meta-analysis of the post-discharge mortality from 14 studies that reported this measure 
by syndrome showed that there was considerable heterogeneity between (I2=95.6%) and 
within admission syndrome groups (I2>80% for all). The crude mortality was 3.6% 
(1141/32034), but because of the high level of heterogeneity, a pooled summary proportion 
obtained by meta-analysis was not calculated (Figure 3). The mortality by six months post-
discharge ranged from 2.3%-24.1%, 2.8%-37.3%, 0.7%-9.9%, 2.3%-8.3% and 1.8%-11.8% for 
severe anaemia, malnutrition, malaria, pneumonia, and unspecified syndromes respectively. 
The 12-month post-discharge mortality by syndrome (17 studies) is shown in eFigure 1.  
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Figure 3: Mortality by six months post-discharge 
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3b. Relative Risk of six-month post-discharge mortality (excludes studies that only reported results 
for one syndrome). 
 
RR, relative risk; CI, confidence interval; D+L, DerSimonian and Laird; M-H, Mantel-Haenszel.  
Top panel a: Kwambai 2018, Zucker 1996 and Opoka, 2016 are included in more than one sub-group each 
representing a mutually exclusive group. The lower CI for Opoka, 2016 and Kwambai, 2018 and Zucker, 1996 
is negative due to the small number of post-discharge deaths reported, the lower CIs should be treated as 
zero. Due to considerable heterogeneity (as shown by the I2) between and within admission syndrome 
groups the summary statistics are not shown. The pooled I2 is 95.6%. 
Bottom panel b: Includes only studies that reported enough detail to allow direct comparisons of the post-
discharge mortality by syndrome among children from the same cohort study 
 
Among the 14 studies that reported mortality by six months, six involved cohort studies that 
reported enough detail to allow direct comparisons of the post-discharge mortality by 
syndrome (Figure 3, Table 2). This showed that children admitted with severe anaemia were 
2.80 times more likely to die in the first six months post-discharge than children admitted 
during the same study period and in the same hospitals without severe anaemia (N=4, 
RR=2.80, 1.61-4.86, p<0.001, I2=73.1%). Severe malnutrition was also associated with higher 
post-discharge mortality (N=2, RR=3.45, 1.89-6.31, p<0.001, I2=81.3%). The post-discharge 
mortality among children admitted with severe pneumonia, malaria and unspecified 
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syndromes were similar or lower compared to children admitted for other reasons. Similar 
trends were observed by 12 months post-discharge (eFigure 1, Table 2).  
When the analysis was repeated, but now excluding children (post-hoc) with either severe 
anaemia, or with severe malnutrition from the comparator group, the relative risk for 6-
month post-discharge mortality for children with severe anaemia relative to other children 
when malnourished children were excluded from the reference group was 2.43 (N=2, 
1.07-5.51, p<0.033, I2=90.5%). There was insufficient data for a similar comparison by twelve 
months (Table 2). For malnutrition, this was nearly 4-fold higher by six months when 
compared to a reference that excluded the children with severe anaemia (N=2, RR=4.27, 
2.42-7.55, p<0.001, I2=76.8%). This was 3-fold higher by twelve (N=2, RR=3.70, 2.84-4.82, 
P<0.001, I2=0.0%) (Table 2).  
Children who had both severe anaemia plus malaria (i.e. severe malarial anaemia) had a 
lower risk of post-discharge mortality than children with severe anaemia without evidence 
of malaria (N=2, RR=0.44, 0.02-0.86, p<0.040, I2=75.9%) (eFigure 2).  
Five further studies evaluated HIV status as a risk factor; HIV was associated with a 3-fold 
increased risk of post-discharge mortality (HR=3.39, 1.58-5.19, p<0.001, I2=68.2%).20,23,31,36,39 
This was observed in two studies before the widescale introduction of anti-retroviral therapy 
(ART) (HR=4.64, 0.62-8.66, p=0.24, I2=16.4%)20,39 and in three studies after the introduction 
of  ARTs (HR=3.02, 0.59-5.45, p<0.15, I2=80.6%)23,31,36 (eFigure 5). 
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Table 2: Comparison by syndrome of the risks of post-discharge mortality and re-admissions by six and by twelve months post-discharge 
 By 6 months By 12 months 
 RR (95% CI, P, I2, N) RR (95% CI, P, I2, N) RR (95% CI, P, I2, N) RR (95% CI, P, I2, N) RR (95% CI, P, I2, N) RR (95% CI, P, I2, N) 
Mortality 
Versus any other 
syndrome 
Versus any other 
syndrome, excluding 
severe anaemia 
Versus any other 
syndrome, excluding 
severe malnutrition 
Versus any other 
syndromes 
Versus any other 
syndrome, excluding 
severe anaemia 
Versus any other 
syndrome, excluding 
severe malnutrition 
Severe anaemia 2.80 (1.61-4.86), 
P<0.001, 73.1%, 4 
NA 2.43 (1.07-5.51), 
P<0.033, 90.5%, 2 
2.49 (1.53-4.06), 
P<0.001, 73.0%, 4 
NA Insufficient data 
Severe malnutrition 3.45 (1.89-6.31), 
P<0.001, 81.3%, 2 
4.27 (2.42-7.55), 
P<0.001, 76.8%, 2 
NA 3.03 (2.18-4.21), 
P<0.001, 40.6%, 2 
3.70 (2.84-4.82), 
P<0.001, 0.0%, 2 
NA 
Severe pneumonia 1.11 (0.46-2.69), 
P=0.821, 88.4%, 3 
1.25 (0.56-2.79), 
P=0.584, 85.1%, 3 
0.88 (0.48-1.63), 
P=0.690, 32.6%, 2 
1.64 (0.75-3.61), 
P=0.214, 91.6%, 2 
2.14 (0.82-5.63), 
P=0.122, 93.6%, 2 
1.16 (0.87-1.56), 
P=0.305, 60.0%, 2 
Not defined 1.00 (0.59-1.70), 
P=0.996, 79.4%, 2 
0.98 (0.52-1.85), 
P=0.951, 85.4%, 2 
1.03 (0.84-1.26), 
P=0.770, 0.0%, 2 
0.96 (0.53-1.75), 
P=0.905, 85.4%, 2 
1.10 (0.74-1.63), 
P=0.646, 64.4%, 2 
0.89 (0.60-1.34), 
P=0.591, 79.4%, 2 
Severe malaria 0.38(0.14-1.05), 
P=0.062, 88.3%, 3 
0.34 (0.03-4.10), 
P=0.393, 94.2%, 2 
0.33 (0.003-4.15), 
P=0.390, 94.3, 2 
0.50 (0.24-1.06), 
P=0.071, 85.0%, 3 
0.55 (0.16-1.87), 
P=0.336, 91.3%, 2 
0.53 (0.15-1.89), 
P=0.328, 91.9%, 2 
Re-admissions       
Severe anaemia 3.05 (1.12-8.35), 
P<0.001, 0.0%, 1 
NA Insufficient data Insufficient data N/A Insufficient data 
RR=relative risk, CI confidence interval. The effect estimates shown in the second column from the left is the same as shown in figure 3b (given for illustration 
purposes only) 
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Post-discharge versus in-hospital mortality  
During the in-hospital period 7.3% (1501/20574) of children died ranging from 0.4% to 
23.2% of all children admitted (N=15), and again a pooled summary proportion obtained by 
meta-analysis was not calculated because of the high level of heterogeneity between studies 
(I2=96.9%) (eFigure 3). The respective mortality by syndrome ranged between 0.4%-13% for 
severe anaemia and 3.0%-23.2%, 1.0%-15.1%, 2.7%-11.5% and 1.8%-12.5% for malnutrition, 
malaria, pneumonia, and unspecified syndromes respectively (eFigure 3). Eleven cohort 
studies involving a total of 18,474 admissions reported both in-hospital and post-discharge 
mortality. Overall, across all syndromes pooled, the mortality post-discharge by six months 
was lower than in hospital (MHOR=0.87, 0.62-1.20, p=0.388, I2=90.4%). However, there was 
considerable heterogeneity within and between syndrome sub-groups. Among children 
admitted with severe anaemia, the odds of mortality were consistently higher in the post-
discharge period (N=4, MHOR=1.44, 1.07-1.92, p<0.015, I2=0.8%) (Figure 4), whereas for all 
other syndromes this tended to be higher during the in-hospital period (all other syndromes 
pooled: N=16, MHOR=0.72, 0.49-1.06, p<0.099, I2=91.4%); malnutrition: MHOR=0.93, 0.27-
3.13, p=0.901, I2=93.8%; malaria: MHOR=0.34, 0.05-2.12, p=0.247, I2=84.0%; pneumonia: 
MHOR=0.69, 0.38-1.26, p=0.224, I2=85.8%; unspecified syndromes: MHOR=0.90, 0.48-1.68, 
p=0.742, I2=94.2 (p-value for difference between the effect estimates of severe anaemia 
versus all other subgroups combined p=0.003) (Figure 4).  
Post-discharge mortality vs mortality in the community 
Six prospective follow-up studies showed that relative to otherwise healthy children from 
the community, hospital admission due to any reason was associated with a 3-fold increased 
mortality rate over six months (N=6, RR=3.32, 1.83-4.82, p<0.001, I2=17.6%) (eFigure 4). The 
relative risk was 4.26 (N=2, -32.23-40.74, p=0.819, I2=0.0%) for children admitted with 
severe anaemia, 4.30 (N=1, 1.57-7.03, p=0.002) for pneumonia (only 1 study) and 4.02 (N=3, 
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Figure 4: In-patient vs six-month post-discharge mortality by syndrome on admission. 
 
PD, post-discharge deaths; D+L, DerSimonian and Laird; MHOR, Mantel-Haenszel odds ratio.  
 
Other risk factors for post-discharge mortality 
Nine studies analysed other potential risk factors for post-discharge mortality (eTable 4). 
Risk factors significantly associated with post-discharge mortality when pooled in a meta-
analysis included: discharge against medical advice (HR=6.68, 2.93-10.43), hypoxia 
(SPO2<90%) (HR=2.26, 1.51-3.01) and bacteraemia (HR=1.83, 1.18-2.49) (eFigure 5). Other 
factors significantly associated with post-discharge mortality but could not be pooled by 
meta-analyses due to differences in definitions and scales used included younger age, 
previous hospitalisation, mother HIV positive status, poor anthropometric measurements, 
reduced conscious levels, proteinuria and admission with a chronic disease. One unit 
increase in oxygen (HR=0.95, 0.92-0.98) and haemoglobin (Hb) levels on admission (HR=0.75, 
0.63-0.87) were associated with a reduction in post-discharge mortality. The presence of 
malaria parasites on admission was also associated with lower post-discharge mortality 
(HR=0.47, 0.33-0.61). Gender and axillary temperature were not associated with post-
discharge mortality (eFigure 5). 
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Discussion  
To our knowledge, this is the first systematic review and meta-analysis that compares the 
risk of post-discharge mortality in malaria-endemic Africa by syndrome on admission. The 
review shows that children with severe anaemia and malnutrition were approximately two 
and three times more likely to die during the first six months post-discharge compared to 
children admitted with other syndromes. Children with severe anaemia were also more 
likely to die in the first six months post-discharge than during their in-hospital stay as 
opposed to children admitted with malnutrition or other syndromes where the mortality 
tended to be similar or highest during the in-hospital period. Studies with longer follow-up 
periods showed that most of these events occurred in the first six months following hospital 
discharge.19,20 We also found that children originally admitted with severe anaemia were 
about three times more likely to be readmitted for any cause by six months post-discharge 
compared to children admitted with other syndromes, but this was based on only one study. 
These findings indicate that in malaria-endemic countries of Africa, children admitted with 
severe anaemia and severe malnutrition remain at a high risk of dying in the first few 
months post-hospitalisation. The World Health Organization (WHO) has developed 
guidelines for the post-discharge management and follow up of children admitted with 
severe malnutrition; similar guidelines are now needed for children admitted with severe 
anaemia in malaria-endemic areas of Africa.44  
Although the risk of post-discharge mortality was highest among those admitted with severe 
anaemia and malnutrition, the review also showed that any hospitalised child, regardless of 
admission syndrome, was at increased risk of dying during the first six months post-
discharge and the average mortality was approximately 3-fold higher during this period 
compared to apparently normal, un-hospitalised children in the same community. These 
findings are in agreement with a recent systematic review of all-cause post-discharge 
mortality among the general paediatric population, which indicated a significant global 
burden of post-discharge mortality, especially in low-income countries.18  
Recently the term “post-hospital syndrome” was proposed, which refers to an acquired, 
transient condition of vulnerability in recently hospitalized, mostly elderly patients in the 
United States of America resulting in a period of generalized risk for myriad adverse health 
events not necessarily linked to the original illness. During this period the patient is not only 
recovering from the original acute illness but also suffers continued physiological and 
immunological impairment due to the initial acute illness and other stressors following 
hospitalisation.45  
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We were unable to analyse the reasons for the high post-discharge mortality or re-admission 
rates observed in children with severe anaemia because of insufficient data, but this is likely 
to reflect the complex multifactorial nature of the aetiology of anaemia in this setting46 and 
the continued exposure to the same risk factors for severe anaemia in the community that 
resulted in the initial admission, and possible delays in seeking appropriate care due to local 
beliefs and perceptions about severe anaemia.47 Although data on HIV status was not 
reported as a standalone syndrome on admission, HIV-positive children were at 4- fold 
increased risk of post-discharge mortality compared to those who are HIV negative. 
Recurrent malaria infections have also been reported as risk factors for recurrence of severe 
anaemia among these children.19,20,41  
Malnourished children were not only at increased risk of post-discharge mortality compared 
to other children, but the co-existence of undernutrition was also reported as a significant 
contributor to post-discharge mortality among children recently admitted with other 
syndromes.23,32,35,39 A greater proportion of undernourished children in developing countries 
have an underlying medical condition either directly causing or significantly contributing to 
malnutrition.15 By contrast, to severe anaemia, malnutrition is recognised as a major risk 
factor for post-discharge mortality in resource-poor countries with guidelines for further 
follow-up and care at home and periodic monitoring to avoid relapse.22,48,49  
Children with severe malaria per se (e.g. cerebral malaria) had lower post-discharge 
mortality than children with severe anaemia. We also found a significantly lower risk of post-
discharge mortality among children with severe malarial anaemia compared to children with 
severe anaemia without malaria. It is possible that the attribution of multiple and more 
chronic causes of severe anaemia such as micro-nutrient deficiencies or chronic infections 
such as tuberculosis and HIV was greater among the children without malaria. They would 
require multiple and long-term interventions post-discharge. This may not be the case for 
children with malaria as the main cause of severe anaemia, in particular, if the initial event 
was successfully treated with blood transfusion and antimalarials.  Alternatively, the in-
patient population treated for ‘severe’ malaria may reflect a heterogeneous group of 
patients as in many countries large numbers of uncomplicated malaria patients are admitted 
as in-patients to health facilities.50 
Although in-hospital severe malaria was not a major risk factor for post-discharge death, in 
highly endemic areas, malaria may become an important risk factor for readmissions or 
mortality post-discharge in all groups, as children experience new or recrudescent malaria 
infections after discharge3,41 leading to continued dyserythropoietic and bone marrow 
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suppression that may last for several weeks.51,52 In children initially admitted with severe 
anaemia this may negate the initial rise in Hb achieved by blood transfusion leading to slow 
haematological recovery resulting in rebound severe anaemia, poor immunological response 
to bacterial and other infections and even death. 
Other significant factors reported across studies irrespective of the initial exposure 
syndrome include; hypoxia, bacteraemia/sepsis, jaundice, hepatomegaly, splenomegaly, 
prolonged hospitalisation, lower socio-economic status, reduced consciousness on 
admission (Blantyre coma scale <5), delay in seeking care, history of previous hospitals 
admissions, young age and discharge against medical advice.  
These findings support the need for post-discharge management strategies for recently 
discharged children especially those with severe anaemia and severe acute malnutrition in 
malaria-endemic areas of Africa. Post-discharge Interventions that have been shown to be 
effective include; preventive zinc supplementation to reduce morbidity and mortality due to 
diarrhoea and pneumonia,53 prophylaxis with co-trimoxazole to reduce morbidity and 
mortality in HIV-positive individuals. Evidence from Malawi shows that 3 months of Post-
discharge Malaria Chemoprevention (PMC) prevented 31% of deaths and readmissions in 
recently discharged children with severe malarial anaemia.43 A confirmatory PMC trial 
comparing 3 monthly full courses of PMC with dihydroartemisinin-piperaquine against 
placebo was recently concluded in Uganda and Kenya.54  
The findings from this review will also be used to model the potential post-discharge 
mortality and morbidity among children recently hospitalised with severe anaemia to 
estimate the potential impact of PMC in different malaria-endemic areas in sub-Saharan 
Africa. 
There are important limitations to this type of secondary analysis that should be considered. 
Some limitations are common to many meta-analyses. First, there was considerable 
variation in the duration and/or reporting of follow-up data; e.g. some studies followed 
children only for one month, whereas others followed them for much longer than 6 months 
but did not report results by 6 months and could thus not contribute to our primary analysis. 
Second, variations in the design of observational studies and RCTs and their reporting 
contributed to observed heterogeneity. Third, few studies reported both on in-hospital and 
post-discharge mortality, and few studies reported post-discharge mortality by admission 
syndrome, and those that did had relatively modest sample sizes and the number of events. 
Fourth, we were not able to analyse the causes of post-discharge deaths due to insufficient 
data. Fifth, included studies that recruited children with severe anaemia did not report on 
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the aetiology of anaemia on admission, therefore we could not determine cause-specific 
severe anaemia mortality burden in-hospital or link the aetiology to post-discharge mortality 
burden. The inconsistency in reporting the risk factors for post-discharge mortality and 
scarcity of data on the causes of post-discharge mortality is an important consideration for 
future research necessary to develop a comprehensive post-discharge management plan.  
Conclusions 
This review reveals the scarcity of data on post-discharge morbidity and mortality. Despite 
the small number of studies, it confirms that children <5 years of age recently hospitalised 
with severe anaemia or severe malnutrition who survive the initial in-hospital period are at 
excess risk of dying during the first six months post-discharge compared to children 
admitted for other causes such as malaria. There is a need to develop post-discharge 
management strategies for these high-risk groups. 
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Post-discharge risks of morbidity and mortality in children admitted with severe anaemia 
and other syndromes in malaria-endemic settings in Africa: A systematic review and meta-
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Supplemental methods 
Supplement 1: Search terms used in PubMed 
(((((((((child) OR childhood) OR infant) OR paediatric)) AND ((((((((((anemia) OR "severe 
anemia") OR "severe malaria") OR "severe malaria anemia") OR "severe malarial anemia") 
OR "severe malarial anaemia") OR "severe pneumonia") OR "severe malnutrition") OR 
diarrhea) OR sepsis)) AND (((((((death) OR admission) OR readmission) OR mortality) OR 
morbidity) OR survival) OR post-discharge syndrome)) AND ((((((post-discharge) OR post-
discharge) OR post hospitalization) OR longitudinal) OR follow-up) OR discharge follow-up)) 
AND (((((((((((((((((((((((((((((((((((((((((((((((((((cape verde) OR Gambia) OR Mauritania) OR 
guinea bissau) OR liberia) OR togo) OR sierra leone) OR benin) OR senegal) OR guinea) OR 
cote d'ivoire) OR mali) OR ghana) OR burkina fasso) OR niger) OR nigeria) OR zimbabwe) OR 
zambia) OR swaziland) OR south africa) OR namibia) OR mozambique) OR malawi) OR 
mauritius) OR madagascar) OR botswana) OR angola) OR egypt) OR uganda) OR tanzania) OR 
sudan) OR somalia) OR rwanda) OR mayotte) OR kenya) OR ethiopia) OR eritrea) OR djibouti) 
OR comoros) OR burundi) OR "sao tome") OR ("sao tome and principe")) OR "equatorial 
guinea") OR gabon) OR "central african republic") OR congo) OR chad) OR cameroon) OR 
"democratic republic of congo")) OR ((africa) OR sub-saharan africa))) NOT (((((((("aplastic 
anemia") OR "severe aplastic anemia") OR "acquired aplastic anemia") OR "Fanconi anemia") 
OR "megaloblastic anemia") OR "maternal anemia") OR "pregnant women") OR "sickle cell 
anemia"). 
Supplement 2: Outcome definitions 
Primary outcomes 
All-cause death or all-cause readmission in the first six months post-discharge  
Secondary outcomes 
• Deaths due to severe anaemia in the first six months post-discharge 
• Deaths due to syndromes other than severe anaemia in the first six months post-
discharge 
• In-hospital deaths due to severe anaemia 
• In-hospital deaths due to syndromes other than severe anaemia 
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• Readmission due to all-cause severe anaemia (defined as Hb <5 g/dL or PCV <15% or 
requirement for blood transfusion based on other clinical indication irrespective of 
the Hb level). 
• Readmission due to syndromes other than severe anaemia 
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Supplemental Figures 
eFigure 1: Mortality by twelve months post-discharge 
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1b. Relative Risk of 12-month post-discharge mortality (excludes studies that only reported 
results for one syndrome). 
 
RR, relative risk; CI, confidence interval; D+L, DerSimonian and Laird; M-H, Mantel-Haenszel.  
Top panel a: Kwambai 2018, Zucker 1996 and Opoka, 2016 are included in more than one sub-group 
each representing a mutually exclusive group. The lower CI for Opoka, 2016 and Ngari, 2017 are 
negative due to the small number of post-discharge deaths reported, the lower CIs should be treated 
as zero. Due to considerable heterogeneity (as shown by the I2statistic) between and within admission 
syndrome groups the summary statistics are not shown. The pooled I2 is 96.6%. 
Bottom panel b: Includes only studies that reported enough detail to allow direct comparisons of the 
post-discharge mortality by syndrome among children from the same cohort study. 
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eFigure 2: Post-discharge mortality between severe malaria anaemia vs severe anaemia 
due to other causes. 
 




eFigure 3: Proportion of in-hospital mortality by syndrome. 
  
Kwambai 2018, Zucker 1996 and Opoka, 2016 are included in more than one sub-group each 
representing a mutually exclusive group. The lower CI for Opoka, 2016 and Zucker, 1996 are 
negative due to the small number of post-discharge deaths reported, the lower CIs should be 
treated as zero. Due to considerable heterogeneity (as shown by the I2statistic) between and within 
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eFigure 4: Post-discharge mortality between post-discharge and community cohorts. 
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eFigure 5: Risk factors for post-discharge mortality 
 
CI, confidence interval; HR, hazard ratio; Hb, haemoglobin 
*Unadjusted HR 
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Supplemental tables 




















































































































+ + + + + + + 
Phiri et 
al, 2012 
+ + + + + + + 
+ Low Risk of Bias  ? Unclear Risk of Bias - High Risk of Bias 
 
Risk of bias assessment for included studies with authors’ judgements for each included trial. 
Adapted from the Cochrane Library. 
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eTable 2: Newcastle Ottawa scale for quality assessment of cohort studies with comparison groups 




























































































Selection             
Representativeness of exposed cohort 1 1 1 1 1 1 1 1 1 
selection of the non-exposed cohort 1 1 1 1 1 1 1 1 1 
Ascertainment of exposure 1 1 1 1 1 1 1 1 1 
Demonstration that the outcome of interest was not present at the start of the 
study 1 1 1 1 1 1 1 1 1 
Comparability           
Comparability of cohorts based on the design or analysis 2 2 2 2 1 1 1 2 2 
Outcome           
Assessment of outcome 1 1 1 1 1 1 1 1 1 
Was follow up long enough for outcomes to occur? 1 1 1 1 1 1 1 1 1 
Adequacy of follow up of cohorts 0 1 0 1 0 0 0 0 1 
Total starts awarded out of 9 8 9 8 9 7 7 7 8 9 
Quality Assessment  Good Good Good Good Good Good Good Good Good 
The Newcastle Ottawa scale is based on a star system where one star is awarded for each item under selection and outcome categories and a maximum of two stars for 
comparability. A maximum of nine points is assigned for the least risk of bias in three domains: 1) selection of study groups (four points); 2) comparability of groups (two 
points); and 3) ascertainment of outcomes (three points) for cohort studies. The quality of studies was rated based on the Newcastle Ottawa scale of 0 to 9 as; poor quality 
(0 -3), fair quality (4 -6) and good quality (7 -9). 
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eTable 3: Modified Newcastle Ottawa scale for quality assessment of cohort studies without comparison  
 
 






































































Selection   
       
Representativeness of exposed cohort 1 1 1 1 1 1 1 
selection of the non-exposed cohort NA NA NA NA NA NA NA 
Ascertainment of exposure 1 1 1 1 1 1 1 
Demonstration that outcome of interest was not present at the start of the study 0 1 1 1 1 0 1 
Comparability 
       
Comparability of cohorts on the basis of the design or analysis NA NA NA NA NA NA NA 
Outcome 
       
Assessment of outcome 0 1 1 1 1 1 1 
Was follow up long enough for outcomes to occur? 1 1 1 1 1 1 1 
Adequacy of follow up of cohorts 0 1 0 1 1 1 1 
Total starts awarded out of 6 3 6 5 6 6 5 6 
Quality Assessment  Poor Good Good Good Good Good Good 
This tool was used for cohort studies without a comparison group. A single group of participants with an exposure of interest were followed up over to 
determine the outcome. In the “selection” criteria of the Newcastle Ottawa scale, the “selection of the non-exposed cohort” and the comparability criteria 
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eTable 4: Risk factors for post-discharge mortality 
Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
Moisi34  Age 1–5 months (ref: <1 month) HR 1.34 (0.93-1.92) Yes 
 
Age 6–11 months (ref: <1 month) HR 0.82 (0.57-1.18) Yes 
 
Age 2–5 years (ref: <1 month) HR 0.57 (0.36-0.90) Yes 
 
Weigh for age z-score < −3  HR 3.42 (2.50-4.68) Yes 
 
Weigh for age z-score < −4 HR 6.53 (4.85-8.80) Yes 
 
Parasitaemia (ref: no parasitaemia) HR 0.45 (0.29-0.71) Yes 
 
Hypoxia (ref: no hypoxia) HR 2.3 (1.64-3.23) Yes 
 
Bacteraemia (ref: no bacteraemia) HR 1.77 (1.15-2.74) Yes 
 
Jaundice (ref: no jaundice) HR 1.77 (1.08-2.91) Yes 
 
Hepatomegaly (ref: no hepatomegaly) HR 2.34 (1.60-3.42) Yes 
 
Hospitalization > 13 d (ref: <13 days) HR 1.83 (1.33-2.52) Yes 
 
1 prior discharge (within a 1 year of index discharge) (ref: no prior discharge) HR 2.83 (2.04-3.92) Yes 
 
2 prior discharges (within a 1 year of index discharge) (ref: no prior discharge) HR 7.06 (4.09-12.21) Yes 
 
≥ 3 prior discharges (within a 1 year of index discharge) (ref: no prior discharge) HR 23.55 (10.70-51.84) Yes 
 
Mild pneumonia (ref: no pneumonia) HR 2.3 (1.00-5.28) Yes 
 
Severe pneumonia (ref: no pneumonia) HR 1.37 (1.05-1.79) Yes 
 
Very severe pneumonia (ref: no pneumonia) HR 4.09 (2.25-7.46) Yes 
 
Severe malnutrition (ref: no malnutrition) HR 4.37 (2.73-7.01) Yes 
 
Meningitis (ref: no meningitis) HR 2.29 (1.57-3.32) Yes 
 
Sick young infant HR 2.67 (1.98-3.58) Yes 
Wiens39  Male sex (ref: female) OR 0.90 (0.54-1.51) No 
 Age (months) (per unit increase)  OR 0.97 (0.97-0.97) No 
 
MUAC (per mm increase) OR 0.97 (0.96-0.98) No 
 
Weight for age z-score (per unit increase) OR 0.66 (0.57-0.76) No 
 
Weight for length/height z-score (per unit increase) OR 0.81 (0.72-0.91) No 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 
Length/height for age z-score (per unit increase) OR 0.79 (0.7 -0.89) No 
 
Heart rate for age z-score OR 0.86 (0.74-0.99) No 
 
Heart rate (raw) OR 1.00 (0.99-1.01) No 
 
Respiratory rate for age z-score OR 0.99 (0.92-1.06) No 
 
Respiratory rate (raw) OR 1.01 (1.00-1.03) No 
 
Systolic blood pressure z-score OR 0.94 (0.79-1.12) No 
 
Systolic blood pressure (raw) OR 0.98 (0.96-1.00) No 
 
Diastolic blood pressure (raw) OR 0.99 (0.97-1.01) No 
 
Temperature (transformed) OR 1.02 (0.90-1.16) No 
 
Temperature (raw) OR 0.76 (0.62-0.93) No 
 
SpO2 (raw) (per 1% increase) OR 0.94 (0.92-0.96) No 
 
SpO2 (transformed) (per 1% increase) OR 1.04 (1.02-1.05) No 
 
HIV positive (ref: negative) OR 5.21 (2.55-10.65) No 
 
Hb (g/dL) OR 0.95 (0.87-1.03) No 
 
Blantyre Coma Scale <5 (ref: 5) OR 2.40 (1.27-4.57) No 
 
Positive blood smear (vs negative) OR 0.33 (0.16-0.68) No 
 
Illness >7 days prior to admission OR 0.50 (0.30-0.83) No 
 
Time since last hospitalisation (Ordered as <7 days, 7 to 30 days, 30 days to 1 year, >1 year 
and never (analysed as continuous and coded and 1–5, respectively) 
OR 0.75 (0.62-0.90) No 
 
Sibling deaths OR 1.54 (0.89-2.65) No 
 
Number of children in family  OR 1.02 (0.92-1.13) No 
 
Boil all drinking water OR 0.82 (0.47-1.42 No 
 
Maternal age (years) OR 1.00 (0.97-1.04) No 
 
Mother HIV positive (ref: negative) OR 1.79 (0.87-3.67) No 
 
Mother HIV status unknown (ref: negative)) OR 1.27 (0.64-2.52) No 
 
Maternal education (Primary) (ref: <primary 3) OR 1.18 (0.62-2.23) No 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 
Maternal education (Some) (ref: <primary 3) OR 0.72 (0.31-1.70) No 
 
Maternal education (Postsecondary) (ref: <primary 3) OR 1.18 (0.41-3.36) No 
 
Bed net use (Sometimes) (ref: never) OR 1.00 (0.48-2.09) No 
 
Bed net use (always) (ref: never) OR 0.85 (0.46-1.58) No 
 
Distance from hospital (30–60 minutes) (ref: <30 min) OR 0.71 (0.31-1.64) No 
 
Distance from hospital (>60 minutes) (ref: <30 min) OR 1.30 (0.70-2.41) No 
Phiri20 Unit increase in age (months) HR 0.92 (0.87-0.97) Yes 
 
Rural residency (ref: urban) HR 1.63 (0.63-4.20) Yes 
 
Sex (Male) HR 1.54 (0.68-3.52) Yes 
 
Maternal education (Some) (ref: none) HR 1.63 (0.72-3.70) No 
 
Parents unemployed (ref: employed) HR 4.15 (1.61-10.74) Yes 
 
Weight-for-height <-2 Z-score (≥-2 Z-score WHZ) HR 0.74 (0.31-1.80) No 
 
Height-for-age <-2 Z-score (≥-2 Z-score HAZ) HR 0.61 (0.30-1.22) No 
 
Splenomegaly (ref: no splenomegaly) HR 0.36 (0.16-0.80) Yes 
 
Iron deficiency ≥5.6 sTfR/Log ferritin (ref: <5.6 sTfR/Log ferritin) HR 0.91 (0.41-2.03) No 
 
Any malaria parasite/µL blood (ref: no parasitaemia) HR 1.25 (0.67-2.34) No 
 
HIV Positive (ref: HIV negative) HR 10.49 (4.05-27.20) Yes 
 
Bacteraemia (ref: no bacteraemia) HR 2.17 (0.84-5.64) Yes 
Ngari35 Age 12–23 months (ref: ≥24 months) HR 1.02 (0.1-9.6) Yes 
 
Age 6–11 months (ref: ≥24 months) HR 5.8 (0.8-40.5) Yes 
 
Age <6 months (ref: ≥24 months) HR 4.8 (0.7-34.1) Yes 
 
Sex (male) HR 1.45 (0.75-2.83) Yes 
 
Reported preterm/low birthweight (LBW) (ref: no preterm/LBW) HR 0.7 (0.2-2.8) Yes 
 
Residence distance (from study site per KM) HR 1.0 (0.9-1.1) Yes 
 
Duration of hospitalisation per day HR 1.1 (1.0-1.2) Yes 
 
Hypoxia (SaPO2 <90%) (ref: SaPO2 >90%) HR 1.9 (0.7-5.4) Yes 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 
Capillary refill >2 seconds (ref: <2seconds) HR 2.4 (0.5-12.1) Yes 
 
Impaired consciousness (ref: normal consciousness) HR 1.1 (0.2-7.8) Yes 
 
Wheezing (ref: no wheezing) HR 0.5 (0.1-2.4) Yes 
 
Cough for >14 days HR 0.2 (0.1-5.5) Yes 
 
Jaundice (ref: no jaundice) HR 12.5 (1.1-13.7) Yes 
 
Severe anaemia (Hb <5g/dL) (ref: Hb≥5) HR 0.8 (0.1-7.5) Yes 
 
Axillary temperature <36°C (ref: axillary temperature 36 to 39oc) HR 0.3 (0.1-2.8) Yes 
 
Axillary temperature >39°C (ref: axillary temperature 36 to 39oc) HR 1.1 (0.4-3.0) Yes 
 
HIV antibody test positive (ref: HIV negative) HR 6.5 (2.3-18.4) Yes 
 
HIV test not performed (ref: HIV negative) HR 0.4 (0.1-3.6) Yes 
 
Respiratory Syncytial Virus test positive (ref: RSV test negative) HR 0.3 (0.1-1.2) Yes 
 
Respiratory Syncytial Virus test not performed (ref: RSV test negative) HR 2.7 (1.2-6.3) Yes 
 
Malaria slide positive (ref: negative) HR 0.5 (0.1-5.2) Yes 
 
Bacteraemia (ref: no bacteraemia) HR 0.8 (0.1-5.2) Yes 
 
MUAC per cm increase HR 0.6 (0.5-0.8) Yes 
 
Year of admission 2008 (ref: Year of admission 2007) HR 0.9 (0.3-3.1) Yes 
 
Year of admission 2009 (ref: Year of admission 2007) HR 0.5 (0.1-2.1) Yes 
 
Year of admission 2010 (ref: Year of admission 2007) HR 0.7 (0.2-2.5) Yes 
 
Year of admission 2011 (ref: Year of admission 2007) HR 1.7 (0.5-5.3) Yes 
 
Year of admission 2012 (ref: Year of admission 2007) HR 1.8 (0.2-15.7) Yes 
Villamor38  HIV Positive (ref: HIV negative) HR 3.92 (2.34-6.55) Yes 
 
Sex Male HR 0.98 (0.65-1.48) No 
 
Age 6–11 months (ref: ≥24 months) HR 3.70 (1.72-7.95) Yes 
 
Age 12–23 months (ref: ≥24 months) HR 3.14 (1.44-6.88) Yes 
 
Height-for-age <-2 Z-score (ref: HAZ>-2 Z-score) HR 2.12 (1.31-3.42) Yes 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 
Low MUAC at baseline (MUAC <25th percentile of the population age-specific distribution) 
(per cm increase) 
HR 1.88 (1.16-3.03) Yes 
 
Hb ≤7.00 g/dL (ref: Hb >10.00g/dL) HR 2.55 (1.13-5.77) Yes 
 
Hb 7.01–8.50 g/dL (ref: Hb >10.00g/dL) HR 2.81 (1.24-6.37) Yes 
 
Hb 8.51–10.00 g/dL (ref: Hb >10.00g/dL) HR 1.76 (0.75-4.10) Yes 
 
Severe pneumonia on admission (ref: no pneumonia on admission) HR 2.47 (1.59-3.85) Yes 
 
Maternal education (Elementary) (ref: None/illiterate) HR 0.84 (0.48-1.49) No 
 
Maternal education (Secondary or higher) (ref: None/illiterate) HR 0.27 (0.06-1.17) No 
 
Tap in compound (ref: tap in house) HR 1.40 (0.60-3.29) Yes 
 
Tap outside compound (ref: tap in the house) HR 2.27 (1.02-5.03) Yes 
 
Public well (ref: tap in the house) HR 2.92 (1.03-8.30) Yes 
 
Mother works outside home-yes (ref: no) HR 0.61 (0.36-1.03) No 
 
Mother lives with a partner (ref: mother lives without a partner) HR 1.60 (1.00-2.57) No 
 
No household amenity (ref: 1 household amenity) (from a list of five items: car, refrigerator, 
radio, bicycle, and television) 
HR 1.58 (0.92-2.69) No 
 
2≤ household amenities (ref: 1 household amenity) HR 0.95 (0.56-1.60) No 
Kerac23 Sex (Male) HR 0.89 (0.73-1.08) Yes 
 
Age >=60 months (ref: age 48 to 60 months) HR 1.22 (0.63-2.36) Yes 
 
Age 36 to 48 months (ref: age 48 to 60 months) HR 1.66 (0.84-3.29) Yes 
 
Age 24 to 36 months (ref: age 48 to 60 months) HR 1.38 (0.76-2.49) Yes 
 
Age 12 to 24 months (ref: age 48 to 60 months) HR 1.57 (0.89-2.78) Yes 
 
Age <12 months (ref: age 48 to 60 months) HR 2.49 (1.38-4.51) Yes 
 
Oedema (ref: no oedema) HR 0.58 (0.47-0.72) Yes 
 
MUAC per cm increase HR 0.80 (0.74-0.86) Yes 
 
weight-for-height (per 1-unit z-score increase) HR 0.75 (0.68-0.83) Yes 
 
Weight for age (per 1-unit z-score increase) HR 0.73 (0.66-0.81) Yes 
 
height for age z-score (per 1-unit z-score increase) HR 0.92 (0.86-0.99) Yes 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 
HIV Positive (ref: HIV negative) HR 4.03 (3.08-5.25) Yes 
 
HIV status unknown (ref: HIV negative) HR 16.9 (12.1-23.7) Yes 
Chhibber31  Sepsis with clinically severe malnutrition (ref: pneumonia without clinically severe 
malnutrition) 
HR 18.4 (11.3-30.0) Yes 
 
Meningitis with clinically severe malnutrition (ref: pneumonia without clinically severe 
malnutrition) 
HR 13.7 (4.2-44.7) Yes 
 
Pneumonia with clinically severe malnutrition (ref: pneumonia without clinically severe 
malnutrition) 
HR 8.1 (4.4-14.8) Yes 
 
Meningitis without clinically severe malnutrition (ref: pneumonia without clinically severe 
malnutrition) 
HR 2.6 (1.2-5.5) Yes 
 
Sepsis without clinically severe malnutrition (ref: pneumonia without clinically severe 
malnutrition) 
HR 2.2 (1.1-4.3) Yes 
 
Age in months (mean [SD]) HR 1.00 (0.98-1.03) Yes 
 
Neck stiffness (ref: no neck stiffness) HR 10.4 (3.1-34.8) Yes 
 
Non-medical discharge (i.e. discharge against medical advice) (ref: medical discharge) HR 4.68 (2.01-10.85) Yes 
 
Axillary temperature (oC) (mean [SD]) HR 0.71 (0.58-0.87) Yes 
 
Oxygen saturation (% increase) HR 0.96 (0.93-0.99) Yes 
 
Hb in g/dL (mean [SD]) HR 0.82 (0.73-0.91) Yes 
 
MUAC 11.5–13.0 cm (ref: MUAC>13cm) HR 7.19 (3.04-17.01) Yes 
 
MUAC 10.5–11.4 cm (ref: MUAC>13cm) HR 24.2 (9.4-61.9) Yes 
 
MUAC <10.5 cm (ref: MUAC>13cm) HR 43.7 (17.7-108) Yes 
Veirum37 Discharge age 5 years+ (ref: 1-12 months) RR 0.15 (0.05-0.30) Yes 
 
Discharge age 4 years (ref: 1-12 months) RR 0.23 (0.09-0.48) Yes 
 
Discharge age 3 years (ref: 1-12 months) RR 0.14 (0.04-0.39) Yes 
 
Discharge age 2 years (ref: 1-12 months) RR 0.52 (0.25-0.76) Yes 
 
Discharge age 1 year (ref: 1-12 months) RR 0.82 (0.67-1.41) Yes 
 
Neonatal (ref: 1-12 months) RR 0.69 (0.21-1.77) Yes 
 
Mothers’ education (ref: no education) RR 0.74 (0.56-1.14) Yes 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 
Non-medical discharge (against medical advice) (ref: medical discharge) RR 8.51 (5.32-13.59) Yes 
 
Other (ref: malaria) RR 1.65 (1.02-2.92) Yes 
 
Anaemia (ref: malaria) RR 1.97 (0.97-4.00) Yes 
 
Diarrhoea (ref: malaria) RR 1.82 (0.83-2.35) Yes 
 
Bronchopneumonia (ref: malaria) RR 0.98 (0.66-1.74) Yes 
 
Measles (ref: malaria) RR 0.77 (0.43-2.22) Yes 
Hue et al41 Age 5 – 12 years (ref: <5 years) HR 1.75 (1.15-2.68) No 
 Age 5 – 12 years (ref: <5 years) HR 1.01 (1.00-1.01) Yes 
 Pit latrine at home (ref: none) HR 1.58 (1.00-2.50) No 
 Sex (ref: female) HR 0.84 (0.55-1.28) No 
 Lake or pond as a water source (ref: no) HR 1.10 (0.71-1.69) No 
 HIV Status (HIV negative) HR 1.38 (0.60-3.16) No 
 Decreased urine output (ref: no) HR 4.95 (2.83-8.66) No 
 Diarrhea (ref: no diarrhoea) HR 0.114 (0.39-1.11) No 
 Fever (ref: none) HR 0.86 (0.54-1.36) No 
 Vomiting (ref: none) HR 1.02 (0.63-1.63) No 
 Oxygen saturation: per % increase HR 0.93 (0.91-0.95) No 
 Oxygen saturation: per % increase HR 0.93 (0.89-0.98) Yes 
 Glasgow coma scale 13-14 (ref: <13) HR 0.66 (0.60-0.73) No 
 Bilateral lower extremity edema (ref: none) HR 2.31 (1.40-3.81) No 
 Respiratory Rate-bpm (per unit increase) 2-5 years HR 1.04 (1.02-1.06) No 
 Respiratory Rate-bpm (per unit increase) 6-12 years HR 1.02 (1.00-1.04) No 
 Diastolic blood pressure, mean mm Hg (per unit increase) 2-5 years HR 0.99 (0.96-1.02) No 
 Diastolic blood pressure, mean mm Hg (per unit increase) 6-12 years HR 0.94 (0.91-0.98) No 
 Heart rate, beats per minute, mean (SD) (per unit increase) 2-5 years HR 1.00 (0.99-1.02) No 
 Heart rate, beats per minute, mean (SD) (per unit increase) 6-12 years HR 1.01 (0.99-1.02) No 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 Systolic blood pressure, mean mm Hg (per unit increase) 2-5 years HR 1.00 (0.98-1.02) No 
 Systolic blood pressure, mean mm Hg (per unit increase) 6-12 years HR 0.97 (0.95-1.00) No 
 Severe Malnutrition (ref: normal) HR 1.49 (0.83-2.70) No 
 Moderate Malnutrition (ref: normal) HR 1.07 (0.57-1.98) No 
 Mild Malnutrition (ref: normal) HR 0.99 (0.55-1.77) No 
 Temperature, Celsius, mean (SD)  HR 1.05 (0.84-1.30) No 
 Hb level, g/dL, mean (SD) (per unit increase) HR 0.82 (0.75-0.88) No 
 Hb level, g/dL, mean (SD) (per unit increase) HR 0.79 (0.70-0.88) Yes 
 Proteinuria by urinalysis (ref: none) HR 2.38 (1.51-3.74) No 
 Proteinuria by urinalysis (ref: none) HR 2.13 (1.12-4.05) Yes 
 Hematuria by urinalysis (ref: none) HR 2.81 (1.35-5.81) No 
 Glomerula filtration rate < 60 ml/min/1.73m2 (ref: no) HR 1.91 (1.21-3.02) No 
 Random blood glucose, mg/dL, mean (SD) (per unit increase) HR 0.98 (0.90-1.05) No 
 Cancer (ref: respiratory infections & malaria) HR 11.79 (4.95-28.03) No 
 Heart disease (ref: respiratory infections & malaria) HR 7.11 (2.89-17.51) No 
 Sickle cell disease (ref: respiratory infections & malaria HR 3.32 (1.44-7.68) No 
 Neurologic diseases (ref: respiratory infections & malaria) HR 3.51 (1.35-9.11) No 
 Septic shock (ref: respiratory infections & malaria) HR 4.64 (1.42-15.08) No 
 Severe malnutrition (ref: respiratory infections & malaria) HR 3.19 (1.18-8.57) No 
 Anemia (ref: respiratory infections & malaria) HR 2.03 (0.75-5.46) No 
 Diarrheal diseases (ref: respiratory infections & malaria) HR 1.94 (0.75-5.04) No 
 Diarrheal diseases (ref: respiratory infections & malaria) HR 0.49 (0.20-1.17) Yes 
 Other (ref: respiratory infections & malaria) HR 1.96 (0.73-5.27) No 
 Decreased urine output (ref: no) HR 4.95 (2.83-8.66) No 
 Diarrhea (ref: no diarrhoea) HR 0.114 (0.39-1.11) No 
 Fever (ref: none) HR 0.86 (0.54-1.36) No 
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Author Risk factor  Effect 
Measure 
(EM) 
EM (95% CI) Adjusted 
 Vomiting (ref: none) HR 1.02 (0.63-1.63) No 
 Oxygen saturation: per % increase HR 0.93 (0.91-0.95) No 
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eTable 5: PRISMA checklist 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  90 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
91 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  92 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
93 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
92 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving a rationale.  
93  
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
93 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
Supplement 1 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in a systematic review, 
and, if applicable, included in the meta-analysis).  
93 
Data collection process  10 Describe the method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
93 and 94 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
93 and 94 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing the risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be used 
in any data synthesis.  
94 
Summary measures  13 State the principal summary measures (e.g., risk ratio, the difference in means).  94 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
94 
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of the risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
94 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), 
if done, indicating which were pre-specified.  
94 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
94 and 95 and Figure 
1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
94 and 95 and Figure 
1 
Risk of bias within studies  19 Present data on the risk of bias of each study and, if available, any outcome level assessment 
(see item 12).  
95 and eTable 1 to 
eTable 3 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
Table 1 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
99-101, 103, 104, 
105, 116-120 eFigure 
2 to 4 and 
supplemental 
content 
Risk of bias across studies  22 Present results of any assessment of the risk of bias across studies (see Item 15).  eTable 1 to eTable 3 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
94 
DISCUSSION   
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policymakers).  
106 to 107 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
108 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence and implications 
for future research.  
109 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., the supply of 
data); the role of funders for the systematic review.  
109 to 110 
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Children hospitalised with severe anaemia in malaria-endemic areas in Africa are at high risk of 
readmission or death within 6 months post-discharge. Currently, no strategy specifically addresses 
this period. In Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly 
treatment courses of artemether-lumefantrine given at discharge and at 1 and 2 months prevented 
30% of all-cause readmissions by 6 months post-discharge. Another efficacy trial is needed before a 
policy of malaria chemoprevention can be considered for the post-discharge management of 
severe anaemia in children under 5 years of age living in malaria-endemic areas. 
Objective 
We aim to determine if 3 months of post-discharge malaria chemoprevention with monthly 3-day 
treatment courses of dihydroartemisinin-piperaquine is safe and superior to a single 3-day 
treatment course with artemether-lumefantrine provided as part of standard in-hospital care in 
reducing all-cause re-admissions and deaths (composite primary endpoint) by 6 months in the post-
discharge management of children less than 5 years of age admitted with severe anaemia of any or 
undetermined cause. 
Methods 
This is a multi-centre, 2-arm, placebo-controlled, individually randomized trial in children under 5 
years of age recently discharged following management for severe anaemia. Children in both arms 
will receive standard in-hospital care for severe anaemia and a 3-day course of artemether-
lumefantrine at discharge. At 2 weeks after discharge surviving children will be randomized to 
receive either 3-day courses of dihydroartemisinin-piperaquine at 2, 6 and 10 weeks or an identical 
placebo and followed for 26 weeks through passive case detection. The trial will be conducted in 
hospitals in malaria-endemic areas in Kenya and Uganda. The study is designed to detect a 25% 
reduction in the incidence of all-cause re-admissions or death (composite primary outcome) from 
1,152 to 864 per 1000 child years (power 80%, α=0.05) and requires 520 children per arm (1040 
total children).  
Results 
Participant recruitment started in May 2016 and was on-going by the time this article was 
published. 
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Trial registration:  
ClinicalTrials.gov NCT02671175, Registered January 28, 2016. 
https://clinicaltrials.gov/ct2/show/NCT02671175  
Keywords: Malaria, severe anaemia, chemoprevention, post-discharge, readmission, mortality, 
dihydroartemisinin-piperaquine, protocol, cost-effectiveness 
  




Severe anaemia, defined as haemoglobin (Hb) concentration level below 5.0 g/dL or haematocrit 
below 15.0%,1 is a major public health problem in low and middle-income countries. Severe 
anaemia is associated with approximately one-third of hospital admissions among febrile children 
in sub-Saharan   Africa contributing substantially to paediatric morbidity and mortality, especially in 
malaria-endemic areas.2,3 Children under 5 years of age are most vulnerable to the long term 
effects of severe anaemia including decreased cognitive performance, mental and motor 
development.4 Rates of in-hospital mortality due to severe anaemia ranging from 4 to 12% have 
been reported in different epidemiological settings.5-7 In addition, these reports indicate high post-
discharge mortality and morbidity, especially in the first 3 to 6 months. Longitudinal follow-up of 
children aged less than 5 years admitted with severe anaemia in Malawi showed that 8.2% died by 
6 months post-discharge and 5.9% was readmitted with severe anaemia, compared to those 
without severe anaemia among whom 1.6% died and 0.5% were readmitted.8,9 Similar high rates of 
post-discharge mortality (10% by 8 weeks) were observed in malaria-endemic areas of western 
Kenya10 and in Uganda, where 12% died or were readmitted within 6 months.11 
Standard in-hospital treatment of severe anaemia in many countries in sub-Saharan Africa consists 
of a blood transfusion and parenteral artesunate for severe malaria.12 In the case of severe malarial 
anaemia, this is completed with a 3-day course of artemisinin-based combination therapy (ACT), 
usually artemether-lumefantrine. Children are often discharged with a short course of iron and 
folate, typically with no further scheduled follow-up. Haematological recovery from malaria-
associated anaemia takes at least 6 weeks.13,14 However, many children in these areas experience 
episodes of new or recrudescent malaria infections after discharge which negates the initial rise in 
haemoglobin achieved by blood transfusion resulting in delayed haematological recovery and 
potentially rebound of severe anaemia and death in some.10,15-17 Furthermore, delayed haemolytic 
anaemia occurring 1 to 3 weeks after artesunate treatment of falciparum malaria has been 
reported in non-immune traveller,18,19 although more recent studies show this to be rare in African 
children.20 
Malaria control strategies in endemic and epidemic-prone areas include Intermittent Preventive 
Therapy (IPT). IPT is the administration of a full treatment course using long-acting antimalarials at 
pre-defined time intervals irrespective of a patient’s malaria status to clear existing infections and to 
provide prolonged prophylaxis against new infections.21 The World Health Organisation (WHO) 
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recommends IPT as a malaria control strategy in malaria-endemic areas for pregnant women 
(IPTp),22,23 infants (IPTi)24 and for children in areas with seasonal malaria transmission (‘seasonal 
malaria chemoprevention’, or SMC).25 Currently, no control strategy specifically addresses the high-
risk post-discharge period for children previously treated for severe anaemia in malaria-endemic 
areas. In Malawi, three months of malaria chemoprevention with three full treatment courses of 
artemether-lumefantrine, given in-hospital to children under five years of age admitted with severe 
malarial anaemia, and at one and two months post-discharge, prevented 31% of deaths or 
readmissions by six months post-discharge, and 30% of all-cause readmissions.17 These results are 
consistent with earlier findings from The Gambia which showed that in children with severe 
anaemia, chemoprevention targeted during the malaria transmission season halved the rate of 
clinical malaria and reduced all-cause hospital readmission by 78% in one trial, and recurrence of 
severe anaemia by 78% in the other.26,27 These data indicate that malaria chemoprevention in the 
post-discharge period may provide substantial health benefits. 
We are conducting an efficacy trial in Kenya and Uganda to determine the efficacy and safety of 
three months of malaria chemoprevention post-discharge as a potentially cost-effective strategy to 
reduce all-cause readmissions and deaths in children admitted with severe anaemia. We 
hypothesize that by creating a prophylactic-time-window post-transfusion for malaria, more time is 
assured for bone-marrow recovery, resulting in a more sustained haematological recovery post-
discharge.  
We refer to this strategy as post-discharge malaria chemoprevention, PMC, to illustrate the 
similarities with SMC rather than with IPT in pregnancy as it aims to provide complete, rather than 
intermittent prophylaxis. 
Study Design and Methods  
Design overview 
This will be a multi-centre, parallel-group, two-arm, placebo-controlled, individually randomized, 
superiority trial with 1:1 allocation ratio comparing the safety and efficacy of three courses of 
monthly PMC-DP or placebo post-discharge provided in addition to the standard single 3-day 
treatment course with artemether-lumefantrine given as part of routine in-hospital care 
(ClinicalTrials.gov: NCT02671175. Registered January 28, 2016). Randomisation to PMC with DP or 
placebo will occur at 2 weeks after enrolment, and PMC treatments will be administered at 2, 6 and 
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10 weeks. The primary outcome will be the number of all-cause deaths or all-cause re-admissions 
between 2-26 weeks after enrolment (composite outcome). The study will be conducted in Uganda 
and Kenya, using randomisation stratified by weight and study centre. The study will include a total 
of 1040 children (520 per study arm) less than 5 years of age who have been admitted for severe 
anaemia and have successfully completed the standard in-hospital treatment. 
Primary objective 
The primary objective is to determine if 3 months of post-discharge malaria chemoprevention with 
monthly 3-day treatment courses of DP is superior to the single 3-day treatment course with 
artemether-lumefantrine provided as part of standard in-hospital care in reducing all-cause 
readmissions and deaths by 6 months in the post-discharge management of children less than 5 
years of age admitted with severe anaemia.  
Secondary objectives 
The secondary objectives include the determination of the safety of 3 courses of monthly DP and 
the cost-effectiveness of PMC-DP compared to the current standard of care. 
Design Considerations 
The rationale for the choice of DP for PMC 
Optimal antimalarial prophylaxis with maximum compliance would be provided by a regimen that is 
long-acting so that administration is not required more frequently than monthly. Sulphadoxine, 
mefloquine, and DP have sufficiently long half-lives to be considered.28 However, there is high-level 
resistance to sulphadoxine in many parts of east and southern Africa, precluding its use for this 
purpose in these malaria-endemic areas.29 Both amodiaquine30 and mefloquine are poorly 
tolerated; which is an important consideration when providing drugs for malaria prevention to 
recipients with few or no symptoms31,32 DP is very effective, well-tolerated, and provides 4 to 5 
weeks of post-treatment prophylaxis, and is therefore currently the drug of choice for use for 
evaluation as part of IPT and malaria chemoprevention in areas with high-grade parasite resistance 
to sulphadoxine.33-38 Furthermore, recent studies show that artemether-lumefantrine and DP exert 
inverse selective pressure on P. falciparum drug sensitivity,39 suggesting that the use of DP may be 
a good choice for chemoprevention in areas where artemether-lumefantrine is the first-line drug of 
choice for case-management.  
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Why in this study population? 
The primary study population involves children with severe anaemia, rather than only children with 
severe malarial anaemia, which was the study population in the previous trial in Malawi.17 This is 
based on observational studies in Malawi, Uganda and western Kenya showing that children 
admitted with severe anaemia appear to be at increased risk of readmission and death regardless 
of whether they had evidence of malaria infection at the time of admission or not [Desai et al, 
unpublished observations; Richard Opoka, unpublished observations].17 Reliable diagnosis of the 
presence of malaria is difficult and the differentiation between severe anaemia and severe malaria 
anaemia is not always feasible as it is common practice in many hospitals in sub-Saharan Africa to 
start parenteral treatment with antimalarials before the laboratory diagnosis of malaria is available. 
Furthermore, the interpretation of malaria diagnostic tests on admission may be complicated in 
children who received antimalarial treatment just prior to admission.40 
Efficacy and effectiveness of delivery mechanisms 
This current trial is an efficacy trial and each treatment course will be provided by study staff 
directly. The first dose of each course will be observed, and where feasible, doses on day 2 and 3 
will also be given under supervision, or compliance verified by home visits or contacting caretakers 
by mobile phone. A separate trial, focusing on the effectiveness of different delivery mechanisms is 
being conducted by our consortium members in Malawi (NCT02721420). 
Why this composite primary outcome? 
Use of clinical malaria as the primary outcome would require a smaller study, however, the 
composite outcome is used because it is more likely to drive policy. We use a composite outcome 
rather than a single severe outcome, such as death, to keep sample size requirements manageable. 
The rationale for assessment by 6 months after enrolment 
The period 2-26 weeks, instead of 0-26 weeks is used for the primary efficacy analysis because 
children will not be randomized until 2 weeks after enrolment. Prior to 2 weeks, all children, 
including those in the placebo arm, will receive a 3-day course of artemether-lumefantrine as part 
of standard in-hospital care, which will be started before discharge and completed at home after 
discharge. The duration of post-treatment prophylaxis in our previous trial with artemether-
lumefantrine is about 2 to 3 weeks17 and we, therefore, do not anticipate any differential effect 
between the arms until children receive their first study-specific intervention upon randomisation. 
The protective drug levels have waned in many children by 14 weeks (i.e. about 4 weeks after the 
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last PMC course of DP), but we follow the children for a total of 26 weeks to capture any potential 
prolonged benefits or rebound effects.  
Study settings 
The study will be conducted in hospitals in Kenya and Uganda located in areas with moderate to 
intense malaria transmission.41,42 The annual entomological inoculation rates vary widely, in 
western Kenya from 31.1 to 108.6 infective bites/person/year43,44 in areas around Kisumu and Siaya 
respectively, while in Uganda from 2.8 to 4 infective bites/person/year45,46 in areas around Jinja and 
Mubende respectively. In western Kenya, we will recruit participants from hospitals located in areas 
around Lake Victoria with well-documented malaria transmission intensity, including the Jaramogi 
Oginga Odinga Teaching and referral hospital, Siaya, Kisumu, Homa Bay and Migori County referral 
hospitals. In Uganda, we will recruit from Jinja, Hoima, Masaka and Mubende regional referral 
hospitals as well as Kamuli mission hospital (Figure 1).  
Figure 1: Map of study setting in Kenya and Uganda 
 
Study sites in both western Kenya and Uganda are in the lake endemic region. These are large referral 
hospitals in the region with adequate diagnostic and treatment capacities for malaria and other conditions. 
 
Post-discharge Malaria Chemoprevention Safety and Efficacy Study Design 
146 
 
Inclusion and exclusion criteria  
The inclusion and exclusion criteria for pre-study screening, enrolment and for randomisation 2 
weeks later are shown below. 
Eligibility criteria 
Eligibility criteria for pre-study screening 
Inclusion criteria for enrolment into pre-study screening period 
1. Haemoglobin <5.0 g/dL or parked cell volume < 15.0%, or requirement for blood 
transfusion for other clinical reasons on or during admission to the hospital 
2. Aged less than 59.5 months 
3. Bodyweight ≥5 kg 
4. Resident in the catchment area 
Exclusion criteria for enrolment into pre-study screening period 
1. Recognised specific other cause of severe anaemia e.g. trauma, haematological malignancy, 
known bleeding disorder 
2. Known sickle cell disease 
3. The child will reside for more than 25% of the 6 months study period (i.e. 6 weeks or more) 
outside of catchment area 
Eligibility criteria for enrolment into the study 
Inclusion criteria for enrolment: 
1. Fulfilled the pre-study screening eligibility criteria 
2. Aged less than 59.5 months 
3. Clinically stable, able to take oral medication  
4. Subject completed blood transfusion(s) or became clinically stable without transfusion 
5. Able to feed (for breastfeeding children) or eat (for older children) 
6. Provision of informed consent by parent or guardian 
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Exclusion criteria for enrolment: 
1. Previous enrolment in the present study 
2. Known hypersensitivity to study drug  
3. Use or known need at the time of enrolment for concomitant prohibited medication 
including drugs known to prolong the QTc interval during the 14 weeks PMC treatment period 
(Additional file 1), section 8.5.7, page 34) 
4. Ongoing or planned participation in another clinical trial involving ongoing or scheduled 
treatment with prohibited medicinal products or active follow-up during the study 
5. A known need for scheduled surgery during the subsequent course of the study 
6. Anticipated non-compliance with the follow-up schedule 
7. Know heart conditions, or family history of congenital prolongation of the QTc interval 
Eligibility criteria for randomisation into the study (at 2 weeks post-discharge) 
Inclusion criteria for randomisation:  
1. Fulfilled enrolment eligibility criteria and was enrolled during a recent admission 
2. Aged <60 months 
3. Still clinically stable, able to take oral medication, able to feed (for breastfeeding children) 
or eat (for older children) and able to sit unaided (for older children who were already able to do so 
prior to hospitalisation) 
Exclusion criteria for randomisation: 
1. Used DP since enrolment 
2. Use or known need at the time of randomisation for concomitant prohibited medication 
(Additional file 1) section 8.5.7, page 34). 
3. Enrolled, or known agreement to enrol into another clinical trial involving ongoing or 
scheduled treatment with medicinal products during the study. 
4. Withdrawal of consent since enrolment 




Trial Medication and Interventions 
Children will be randomized to one of the two treatment groups: DP or placebo. Children in both 
arms will receive standard in-hospital care and, at discharge (enrolment) a 3-day course of 
artemether-lumefantrine regardless of whether they were admitted with severe malarial anaemia 
or severe anaemia without evidence of malaria. 
Artemether-lumefantrine  
The study will use a Good Manufacturing Practice (GMP) formulation of artemether-lumefantrine 
(Coartem®, Novartis Pharmaceuticals). The recommended treatment is a 6-dose regimen over a 3-
day period with dosing per bodyweight following WHO dosing recommendations as provided for in 
the latest WHO malaria treatment guidelines12 (see Additional file 1, Table 3, page 29).  
Dihydroartemisinin-piperaquine 
The study will use the Eurartesim® brand of DP from Alfasigma (formerly Sigma Tau), Italy, a co-
formulated tablet containing 40 mg dihydroartemisinin and 320 mg piperaquine phosphate or as 
20/160 (paediatric formulation). Dosing will be per bodyweight according to the schedule 
recommended by current WHO’s Guidelines (Additional file 1), Table 4, page 30). 
Placebo DP 
Placebos for DP will be manufactured by Alfasigma, Italy. The dosage regimen for DP-placebo will 
be identical in the number of tablets per day and timing of the dose to that of the active DP 
product. The drug administration procedures will also be identical to that for the active drugs.  
Other medication 
Standard in-hospital and post-discharge care 
Except for the full 3-day course of artemether-lumefantrine all care provided prior to and following 
enrolment of the participants in the study (at convalescence) will be according to local (hospital) or 
national guidelines, and therefore not subject to this study. Treatment for malaria in both Kenya 
and Uganda conforms with the current WHO malaria treatment guidelines,12 which includes 
artemether-lumefantrine as first-line treatment for uncomplicated malaria and parenteral 
artesunate for severe malaria. Details of non-study specific care provided by the hospital staff will 
be recorded.  
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Iron and folate supplementation 
All children will receive 28 days iron and folate supplementation at 2 weeks -post-discharge as part 
of routine care for severe anaemia. A standardized prophylactic dose of iron supplementation 
(about 2 mg/kg) will be given as monotherapy or as part of the fixed-dose formulation with folic 
acid.  
Outcomes 
The Primary and secondary efficacy outcomes are shown below: 
Primary efficacy outcome 
The number of all-cause deaths or all-cause re-admissions between 2-26 weeks after enrolment 
(composite outcome).  
Key secondary efficacy outcomes 
1. Readmission due to severe malaria (defined as any treatment with parenteral quinine or 
artesunate, or presence of severe anaemia and treatment with oral antimalarials) by 26 weeks from 
randomisation 
2. Readmissions due to severe anaemia (defined as Hb <5.0g/dL or Packed Cell Volume 
<15.0% or requirement for blood transfusion based on other clinical indication) by 26 weeks from 
randomisation 
3. Readmission due to severe malarial anaemia (severe anaemia plus parenteral or oral 
antimalarial treatment) by 26 weeks from randomisation 
4. Readmission due to severe anaemia or severe malaria (composite outcome) by 26 weeks 
from randomisation 
5. All-cause mortality by 26 weeks from randomisation 
6. All-cause hospital readmission by 26 weeks from randomisation 
7. Clinic visits because of smear or malaria rapid diagnostic test (RDT)- confirmed non-severe 
malaria by 26 weeks from randomisation 
Other secondary efficacy outcomes 
1. Readmission due to severe malaria-specific anaemia (severe anaemia plus parenteral or 
oral antimalarial treatment and parasite density >5000/microlitre) by 26 weeks from randomisation 
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2. Readmission due to severe disease other than severe anaemia and severe malaria by 26 
weeks from randomisation 
3. Non-severe all-cause sick-child clinic visits by 26 weeks from randomisation 
4. Non-malaria sick child clinic visits by 26 weeks from randomisation 
5. Malaria infection at 26 weeks 
6. Hb at 26 weeks 
7. Any anaemia (Hb<11 g/dL), mild anaemia (Hb 8.0-10.99 g/dL) moderate anaemia (Hb 5.0-
7.99 g/dL) and severe anaemia (Hb<5 g/dL) at 26 weeks 
8. Weight-for-age, height-for-age, and height-for-weight Z-scores [standard deviation (SD) 
scores of reference population] at 26 weeks 
Tolerability and safety outcomes 
1. Serious adverse events, excluding primary and secondary efficacy outcomes, by 26 weeks 
from randomisation 
2. Serious adverse events within 7 days after the start of each course of PMC, excluding 
primary and secondary efficacy outcomes 
3. Adverse events by 26 weeks from randomisation 
4. Adverse events within 7 days after the start of each course of PMC 
5. QTc prolongation measured by electrocardiogram (ECG) 4-6 hours after 3rd dose of each 
course (in a subset of patients) 
Participants timeline  
Overview of study phases and scheduled visits (Table 1 and Additional file 2) 
The study timelines consist of an in-patient pre-study screening period while the patient is acutely 
ill (visit 1), followed by a screening, consent and enrolment visit (visit 2). During the convalescence 
phase in the hospital, patients receive artemether-lumefantrine (visit 3), prior to discharge. The 
patient returns to the study clinic 14 days later (visit 4) for randomisation. Home treatment visits 
are made at 6 (visit 5) and 10 (visit 6) weeks. The PMC period starts at 2 weeks and ends at 14 
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weeks, but participants are followed up for an additional 12 weeks through passive follow-up and 
then seen at 26 weeks (visit 7) for an end of study assessment.  
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Table 1: Study Design and Schedule of Assessment (Spirit figure) 


































AL treatment visit 







End of study 
Assessment 
Study Time 









2 weeks  
(day 14[11-28])c 
6 weeks  
(day 42 [38-56])c 
10 weeks  
(day 70 [66-84])c 
6 Month 




















Recruitment                
  Pre-screening eligibility X               
  Prior consent discussion X               
Enrolment                
  Eligibility screen  X              
  Informed Consent  X              
  Study code issued  X              
  Allocation      X          
Interventions                
  PMC-Placebo arm   AL1&2b AL3&4b AL5&6b Plac1 Plac2 Plac3 Plac1 Plac2 Plac3 Plac1 Plac2 Plac3  
  PMC-Active arm   AL1&2b AL3&4b AL5&6b DP1 DP2 DP3 DP1 DP2 DP3 DP1 DP2 DP3  
  Iron supplement. 
     
Iron for 28 days from t=14-42 
days 
      
Assessments                
Baseline                
  Copy Clinic/Lab data from hospital records X    X          
  Physical Exam.  X    X          
  Blood sample 
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Efficacy Outcomes                
  Physical exam/growth               X 
  Hb & Malaria & PCR               X 
  Clinic visits 
  
Passive surveillance in clinics in the catchment area, 26 weeks from 0-26 weeks (clinical malaria and other acute 
illnesses) (RDT/smear, Hb, dried blood spots for parasite genetics) 
  Hospitalisation   Passive surveillance for hospital admission in the catchment area, 26 weeks from 0-26 weeks 
  Vital status   X X X X X X X X X X X X X 
  Pf genetics/resistance Xf X    X         X 
  Host genetics  X             X 
  Patient costs     X          X 
Safety Outcomes                
  Adverse events   X X X X X X X X X X X X X 
  ECGd      X  X X  X X  X  
Visit #1: Pre-study Screening (around admission or shortly thereafter) 
Visit #2: Screening Consent & Baseline (during convalescence) 
Visit #3: Oral artemether-lumefantrine (AL) consisting of 6 doses (2x daily for 3 days); first dose provided in the hospital. Subsequent doses may be administered at home or in hospital. 
Visit #4: 2 weeks after enrolment. Participants will be randomised to one of the two treatment groups during this visit. They will also be given the first dose of PMC under observation. 
Doses of day 2 and 3 can be taken at home. All participants will get a 1-month supply of iron during this visit. 
Visit #5 #6: Home visits at 6 and 10 weeks after enrolment to issue participants with the 2nd and 3rd course of the PMC study drugs.  
Visit #7: at 6 months after enrolment. This is the closeout assessment. 
a. Children can be pre-study screened at any time between hospital admission and enrolment. The figure of -4 days is provided for illustration purposes only. 
b. AL: Some children may have received AL as part of standard in-hospital care prior to enrolment (e.g. during days -1 or -2 and not as part of the study). They will have their 
number of study AL doses adjusted to ensure that no more than a cumulative total of 6 AL doses are provided. The day of enrolment is always considered as Day-0 regardless of when 
the first dose of AL was received. 
c.  Visit window= number of days an actual subject visit may fall outside of the planned protocol schedule visit to still meet protocol requirements. DP should be given at least 4 
weeks apart.  
d. ECG, Electrocardiogram, to be conducted in a sub-sample only. A capillary sample will be taken at the same time as the ECG for piperaquine drug levels. 
e. MS, malaria smear. This will be collected for research purposes only and read days to weeks later. Malaria smears will not be used for point of care. If participants are 
symptomatic (e.g. fever) an RDT will be taken for point of care. 
f. Uses leftover samples from blood-group typing and cross-matching or other clinical samples that were taken as part of routine care that would otherwise be discarded. The 
sample will only be used after consent has been obtained in the subsequent visit 2. 
VP=vena puncture. FP=finger prick, Plac=Placebo DP, DP=dihydroartemisinin-piperaquine, AL=artemether-lumefantrine, Hb=haemoglobin, MS=malaria smear, Pf=Plasmodium 
falciparum 
 




Unscheduled Visits (passive follow-up) 
A passive surveillance system is in place to monitor intercurrent illnesses during the observation 
period. Parents are instructed to bring their child to the study clinic for any suspected illness. Blood 
samples for Hb, malaria diagnosis (RDT and smear) and filter paper dry blood spot (DBS) for 
parasite genetics are obtained. Verbal autopsy is conducted for children who die at home during 
the follow-up period. Adverse events and vital status are assessed during all scheduled or 
unscheduled visits.  
Sample Size 
Original sample size 
The initial estimate of the required sample size of 2212 children (1106 per arm) across both 
countries pooled was designed to detect a 30% reduction in the incidence rate of the composite 
primary outcome (death or all-cause readmission) from 469 per 1000 child years in the control arm 
to 328 per 1000 child years in the intervention arm (power 90%, α=0.05), which allowed for one 
interim analysis and 15.7% loss to follow-up. For these estimations, we assumed an average pooled 
event rate of 399 per 1000 child years across the two arms, with 328 and 469 events per 1000 child 
years in the intervention and control arms, respectively (RR=0.70). We based this assumption on 
observations in western Kenya (Desai et al, unpublished) and Malawi.17 However, the observed 
event rate, pooled across both arms, during the first year of the study was 1,120/1000 child years, 
which is almost three times higher than the assumed event rates. The higher rate is consistent with 
the recently published observations in Uganda.11 Furthermore, the observed rate of loss to follow-
up in the first 533 participants recruited and followed up for 6 months was 7% rather than the 
assumed 15%.  
Sample size re-estimation 
Following recommendations from the Data Monitoring and Ethics Committee (DMEC) and The Trial 
Steering Committee (TSC), a blinded interim sample size re-estimation was conducted to take into 
account the lower than expected rate of loss to follow-up and the higher than expected pooled 
incidence rate of the composite primary endpoint (death or all-cause readmission). This was 
favoured over an interim analysis because the available funding did not allow an extension of the 
recruitment period, even if the results of any interim analysis had suggested that this would be 
required.  
 




The revised sample size calculations show that a total sample size of 1040 children (520 per arm) is 
required to detect a 25% reduction in the incidence of the composite primary outcome from 1,152 
per 1000 child years (530 events per 1000 children) in the control arm to 864 per 1000 child years 
(398 per 1000 children) in the intervention arm (power 80%, α=0.05), allowing for 10% loss to 
follow-up. The same sample size also provides 90% power to detect a 28.7% reduction in the 
primary endpoint from 1,152 to 822 events per 1000 children years. 
Assignment of interventions 
Allocation  
Eligible children are randomly assigned (1:1) to either PMC-DP or placebo by a computer-generated 
randomisation schedule stratified by weight (per DP dosing schedule) and study site using 
permuted blocks of random sizes (see Additional file 1, page 30, Table 4)12 Recruitment is 
‘competitive’ between the sites in the trial. 
Blinding  
The study is double-blinded to both participants/caretakers and study staff. Allocation concealment 
is achieved by the use of sealed opaque envelopes, with each envelope containing 3 other small 
envelopes (one for each PMC course). The envelopes containing active DP or placebo look identical, 
and the appearance and consistency of the tablets are also identical. 
Laboratory Procedures 
Hb is measured using HemoCue201 (Angelholm, Sweden) photometers. Thick and thin blood films 
for parasite counts is obtained and examined. The films are read by two independent microscopists 
by counting any malaria parasites against 200 high power fields before a slide is declared 
negative.47 Point of care malaria diagnosis will be conducted using First Response® Malaria Ag. 
pLDH/HRP2 Combo Card Test 
Statistical Methods 
A detailed study statistical analytical plan for the final analysis, that will supersede the study 
protocol, will be developed during the study before the unblinding of data. 
Analysis Populations 
The intention-to-treat population (ITT) is defined as all randomized subjects allocated to one of the 
two treatment arms and will be analysed in the group to which they were randomized, regardless 
 




of the type (placebo or active PMC) or the number of courses received. The per-protocol (PP) 
population is a subset of the ITT population; excluding participants with major protocol deviations.   
Missing Data 
Every effort is being made to minimise the amount of missing data in the trial, and whenever 
possible, information on the reason for missing data is obtained. No adjustments will be made for 
missing outcome data, but missing data may be imputed for co-variates.  
Assessment of efficacy 
The primary analysis will be by intention to treat and include all primary endpoint events (i.e. first 
and repeat events). The follow-up time will be measured as the time in days from the date of 
randomisation to the end of follow-up (around 26 weeks), death or drop-out. The incidence rate 
will be calculated per arm and the incidence rate ratio (IRR, PMC to placebo) and 95% CI estimated 
using Poisson regression models with treatment (as randomised) as the only covariate. The results 
will also be expressed as the relative rate reduction (RRR) (95% CI). (However, in the final analysis, 
we used cox regression for repeated events as this takes time to each event into account. The 
results were expressed as hazard ratio (RR) and 95% confidence interval).  
Subgroup analysis 
We will use stratified analysis to assess to what extent the effect of the intervention on the primary 
outcome is influenced by country, demographic parameters (e.g. age, ethnicity and socioeconomic 
status), clinical parameters, malaria transmission variables (malaria transmission intensity, 
residence (urban/rural), season, insecticide-treated nets use, site), time of assessment and 
potential intervention modifiers. Because we did not power the study for subgroup analyses, we 
will interpret the results of the subgroup analysis cautiously. No adjustment will be made for 
multiple comparisons.  
Sensitivity analysis 
A number of sensitivity analyses will be conducted to assess the robustness of the primary endpoint 
analysis. These include analysis of the per-protocol subject population and covariate-adjusted 
analysis. Other regression models will also be explored. Additional post-hoc analyses may also be 
conducted if deemed appropriate. In addition, we will compare the results of the covariate-
adjusted analyses with and without imputation for missing values for co-variates values at baseline.  
 




Analysis of adverse events 
Adverse events and serious adverse events are monitored, managed, and recorded during the 
study. They will be recorded and tabulated for each treatment arm, overall, and per body system. 
Treatment-emergent adverse events are defined as adverse events that had an onset day on or 
after the day of the first dose of study medication. No formal statistical testing will be undertaken.  
Enrolled children who are clinically unstable 2 weeks post-discharge (i.e. at the time eligibility is 
assessed for randomization) and/or have rebound severe anaemia, are re-admitted and become 
eligible for randomization if they fulfil the entry criteria two weeks after the subsequent discharge. 
Procedures for Assessing Efficacy and safety Parameters 
Primary Efficacy outcome 
All-cause Mortality  
This will be assessed during visits 4 (2 weeks), 5 (6 weeks), 6 (10 weeks), and 18 weeks (by phone) 
and during the end of study assessment at 26 weeks.  
All-cause and Disease-Specific Re-admissions 
This will be assessed through passive case detection and through a questionnaire administered 
during visits 4-7 at 2, 6, 10, 26 weeks and during unscheduled sick visits. Details of admissions and 
treatment that the participants received are recorded, including malaria diagnostic test results and 
use of antimalarials to allow for differentiation between malaria, severe anaemia, and other 
syndromes. 
Secondary Efficacy Outcomes 
All-Cause and malaria-specific Clinic Visits 
This will be assessed through passive case detection and through questionnaires administered 
during visits 4-7 at 2, 6, 10, 26 weeks and during unscheduled sick visits. Details of clinic visits are 
recorded including malaria diagnosis results to allow for differentiation between malaria and non-
malaria clinic visits. 
Adverse Events  
We will adhere to the International Conference on Harmonisation (ICH) good clinical practice (GCP) 
principles in recording, reporting and managing adverse events and serious adverse events for all 
participants in both arms (see Additional file 1, page 51, section 9.6.2). 
 




Cardiac monitoring sub-study 
The main safety concern with DP is its dose dependent QTc prolongation induced by the 
piperaquine component. Transient QTc prolongation has been confirmed in clinical trials but there 
are no data suggesting that the treatment is associated with clinically significant arrhythmias.38,48,49 
A trial in Uganda among children 6 to 24 months old included monthly DP for up to 18 monthly 
courses. A detailed sub-study of the effect of DP on cardiac repolarization was conducted in 26 
children and concluded that DP is not associated with a trend toward increasing QTc prolongation 
with an increasing number of DP courses.38 This type of safety data is limited and we will, therefore, 
conduct a nested cardiac monitoring sub-study at Jinja Regional Referral Hospital in Uganda among 
66 children who will be selected through convenience sampling. Separate written informed consent 
will be sought for inclusion in this sub-study. Approximately half of these children are expected to 
have received PMC with DP. The primary objective is to determine whether transient QTc 
prolongation increases in magnitude with subsequent courses of DP. Children enrolled in the sub-
study will have an ECG taken prior to the first dose of each course and again 4-6 hours after taking 
the 3rd dose of each course of DP (anticipated maximum drug concentration).  
Discussions 
Severe anaemia and severe malaria are major public health problems in malaria-endemic areas of 
Africa.  Evidence suggests that a major, potentially preventable, component of the burden occurs 
after discharge and that a proactive approach is needed. Currently, no strategy specifically 
addresses this high-risk post-discharge period. This study seeks to determine the efficacy, safety 
and cost-effectiveness of 3 months of malaria chemoprevention post-discharge as an innovative 
strategy to reduce all-cause readmissions and deaths among children admitted with severe 
anaemia in malaria-endemic areas. The study settings in Kenya and Uganda are representative of 
the main epidemiological settings appropriate for this intervention. Members from our consortium, 
under the leadership of the College of Medicine in Malawi, are concurrently conducting a trial in 
Malawi, under a separate protocol, on potential delivery mechanisms and health services research 
to determine the uptake, effectiveness, acceptability and feasibility of different mechanisms for 
delivering PMC (clinicaltrials.gov: NCT02721420). This strategy builds on existing approaches used 
for seasonal malaria chemo-prevention in west Africa and experience with IPT in pregnant women 
and infants 50,51. Should PMC prove to be effective, cost-effective and feasible, PMC may be a 
 




promising strategy to reduce all-cause readmissions and deaths in children admitted with severe 
anaemia in malaria-endemic areas of Africa. 
Trial status 
Recruitment started in May 2016 and is ongoing. Unblinding and analysis will begin after 
recruitment and follow up is completed, the database has been completed, cleaned, and locked. 
Additional files 
Additional file 1: Full study protocol (including SPIRIT figure): v4.0, dated 06-Feb-2018. 
Additional file 2: Summary of study design and schedule of assessment (SPIRIT checklist) 
Additional file 3: Ethics Approvals KEMRI, SOMREC, LSTM, REK vest and CDC 




This protocol, the informed consent documents and patient information sheets have been 
reviewed and approved by KEMRI Scientific and Ethics Review Unit (SERU) (protocol #2965), 
Makerere University School of Medicine Research and Ethics Committee (SOMREC) (protocol 
#2015-125), LSTM Research Ethics Committee (protocol #14.034), Regional Committee for Medical 
and Health Research Ethics, Western Norway (REK Vest) (protocol #2014/1911).  The Centers for 
Disease Control and Prevention gave approval for reliance on the KEMRI SERU (CDC Protocol 
#6919) (see Additional file 3, Ethics Approvals KEMRI, SOMREC, LSTM, REK vest and CDC). 
Consent for publication 
 Not applicable 
Availability of data and material 
Not applicable 
 





The study has a trial steering committee (TSC) and a Data Monitoring and Ethics Committee 
(DMEC). 
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Children hospitalized with severe anaemia in malaria-endemic areas are at high risk of readmission 
or death within six months post-discharge. No strategy specifically addresses this post-discharge 
period. We conducted a multi-centre, two-arm, placebo-controlled, randomised trial in nine 
hospitals in Kenya and Uganda to determine if three months of post-discharge malaria 
chemoprevention (PMC) with monthly 3-day treatment courses of dihydroartemisinin-piperaquine 
(DP) reduced the rate of all-cause readmissions and deaths by 6 months post-discharge (primary 
outcome). 
Methods 
Children aged <5 years with admission haemoglobin of <5g/dL were eligible. They received 
standard in-hospital care for severe anaemia and a standard 3-day course with artemether-
lumefantrine at discharge. At two weeks post-discharge, they were randomised to receive DP or 
placebo-DP at two, six, and ten weeks post-discharge and followed until week 26 inclusive using 
passive case-detection. Conditional risk set modelling for repeated events (Prentice-Williams-
Peterson total-time) was used to obtain hazard ratios (HR). 
Results 
Between May 2016 and November 2018, 1049 participants were randomised (PMC=524, 
control=525). Between 2-26 weeks post-discharge, there were 184 primary outcome events in the 
PMC arm and 316 in the placebo arm (Hazard Ratio [HR]=0.65, 95% CI 0.54-0.78). The HR was 0.30 
(0.22-0.42) during the PMC-intervention period (2-14 weeks) and 1.13 (0.87-1.47) during the post-
intervention period (15-26 weeks), p<0.001). The median time to the first event was delayed from 
47 to 110 days. 
Conclusion 
In areas with intense malaria transmission, three months of malaria chemoprevention in children 










Severe anaemia is a substantial contributor to child mortality in malaria-endemic Africa. A third of 
children aged <5 years admitted with fever are severely anaemic comprising 4 to 12% of in-hospital 
mortality.1,2 
In the past 2-3 decades, most research on severe anaemia in Africa focused on reducing in-hospital 
mortality. However, observational studies show that in areas with intense malaria transmission a 
significant, potentially preventable component of the burden of severe anaemia occurs in the first 
few months post-discharge with similar or higher mortality than during the in-hospital period.3,4 
These observations suggest that strategies that reduce the risk in this post-discharge period could 
offer substantial public health gains. 
Data from Malawi show that children in malaria-endemic areas with severe anaemia require at 
least two to three months to achieve haematological recovery.3 In areas with intense malaria 
transmission, delay in haematological recovery due to new or recrudesced malaria infections is 
common and may contribute to the high post-discharge burden.4,5 We hypothesized that by 
creating a prophylactic-time-window post-transfusion, the bone marrow gets time to recover, 
resulting in a more sustained haematological recovery post-discharge. Currently, there are no 
specific prevention strategies provided post-discharge to address this in malaria-endemic areas. 
The World Health Organization (WHO) recommends seasonal malaria chemoprevention (SMC) with 
monthly treatment courses of antimalarials to reduce the burden of malaria during the 
transmission season,6 and intermittent preventive therapy (IPT) for pregnant women (IPTp).5 In 
Malawi, three months of post-discharge malaria chemoprevention (PMC) with monthly treatment 
courses of artemether-lumefantrine prevented 31% of deaths or readmissions by six months post-
discharge in children aged <5 years who had been admitted with severe malarial anaemia and were 
successfully treated with blood transfusion and parenteral antimalarials.7  
In this study, we aimed to establish the safety and efficacy of 3 months of post-discharge malaria 
chemoprevention with monthly 3-day treatment courses of the long-acting antimalarial 
dihydroartemisinin-piperaquine (DP) in reducing all-cause readmissions and deaths by six months in 
the post-discharge management of children aged <5 years admitted with all-cause severe anaemia. 
 





Design and Oversight 
We did a randomised, double-blind, placebo-controlled, parallel two-arm superiority trial. The trial 
was conducted in nine hospitals in Kenya and Uganda located in areas with moderate to intense 
perennial malaria transmission.8 It was approved by the ethics committees of the Kenya Medical 
Research Institute (KEMRI), the Makerere University School of Medicine, the Regional Committee 
for Medical and Health Research Ethics, Western Norway and the Liverpool School of Tropical 
Medicine (LSTM). Dihydroartemisinin-piperaquine and placebo were supplied by Alfasigma 
(formerly Sigma-Tau), Italy which had no role in the design of the trial; the collection, analysis, or 
interpretation of the data or the writing of the manuscript. Trial oversight and monitoring were 
provided by a trial steering committee and by an independent data and safety monitoring 
committee, who archived a signed copy of the statistical analysis plan before the database was 
locked and the data were unmasked. The trial methods were published previously.8 Additional 
details are provided in the Supplementary Appendix and the protocol and statistical analysis plan 
will be available at nejm.org after publication. The authors TK, VW, DW and FOtK vouch for the 
accuracy and completeness of the data and analyses and all authors vouch for the fidelity of the 
trial to the protocol. 
Randomisation and masking 
Children who had been admitted with severe anaemia and fulfilled the other eligibility criteria 
(Supplementary Appendix) were randomly assigned (1:1) 2 weeks after discharge to receive either 
PMC or placebo using a computer-generated randomisation schedule stratified by study site and 5 
weight bands (Table S2) using permuted blocks of random sizes generated by an independent 
statistician. 
Allocation concealment was achieved using sequentially numbered sealed identical-looking opaque 
envelopes prepared by the independent study pharmacist. Each envelope contained three other 
envelopes containing the study drug for each PMC course. Participants were enrolled and followed 
up by study staff. Throughout the trial, the investigators, caretakers, and study staff were unaware 
of the trial-group assignments. 
  
 





Participants received standard in-hospital care for severe anaemia and any other conditions based 
on the Kenya/Uganda Ministry of Health treatment guidelines and a 3-day course of artemether-
lumefantrine at discharge, irrespective of their malaria status on admission, as soon as they were 
able to take oral medication. Two weeks later, surviving participants were randomised to receive 
either standard 3-day courses of DP (Eurartesim®, Sigma-Tau, Italy) or placebo, at two, six, and ten 
weeks after enrolment. Participants also received a 28-day course of iron supplementation at 
randomisation as per the national treatment guidelines in each country.9,10 and were encouraged to 
sleep under an insecticide-treated net. The artemether-lumefantrine and DP doses were based on 
the current WHO guidelines (Table S1 and Table S2). The first dose of each course was administered 
by study staff in the hospital or during home visits and the remaining doses by the guardians at 
home. Adherence to the study medication was ascertained by daily telephone contact with 
caretakers and random home visits. 
Outcomes 
All participants were followed passively for a total of 24 weeks after randomisation (i.e., 26 weeks 
after discharge; Figure S1). The primary outcome was a composite of all-cause mortality or all-cause 
readmission. Key secondary outcomes included the individual components of the primary outcome; 
hospital readmissions due to severe anaemia or malaria; and all-cause and malaria-related out-
patient clinic visits (see Supplementary Appendix for additional efficacy outcomes). Tolerability and 
safety outcomes included adverse events reported by study clinicians and QTc prolongation 
measured by electrocardiogram (ECG) 4-6 hours after the third dose of each course. 
Statistical Analysis 
The initial sample size was 2212 children (1106 per arm) across both countries pooled. For these 
estimations, we assumed an average pooled event rate of 399 per 1000 child years across the two 
arms. We based this assumption on observations in western Kenya (Desai et al, unpublished) and 
Malawi.7 However, the observed event rate, pooled across both arms, during the first year of the 
study was 1,120/1000 child years. The higher rate is consistent with the recently published 
observations in Uganda.11 Furthermore, the observed rate of loss to follow-up in the first 533 
participants recruited and followed up for 6 months was 7% rather than the assumed 15%.  
 




Following recommendations from the Data Monitoring and Ethics Committee (DMEC) and The Trial 
Steering Committee (TSC), a blinded interim sample size re-estimation was conducted to take into 
account the lower than expected rate of loss to follow-up and the higher than expected pooled 
incidence rate of the composite primary endpoint. 
The revised sample size calculations show that a total of 1,040 (520 per arm) participants are 
required to detect a 25% reduction in the incidence of the composite primary outcome from 1,152 
to 864 per 1000 child years with 80% power and a two-sided p-value of 0.05 allowing for 10% loss 
to follow-up.8  
Analyses were performed using STATA, version 15.1 (StataCorp). The primary outcome was 
analyzed as recurrent time-to-event data using the Prentice Williams Peterson-Total Time (PWP-
TT),12 and results expressed as the hazard ratio (HR), 95% confidence interval (CI) and p-value 
(based on the z-score). Models included site and weight category as covariates to adjust for 
stratification factors. The primary analysis was based on the intention-to-treat population (ITT), 
defined as all participants randomised and included the primary outcome events occurring during 
24 weeks starting from the day of randomisation (14 days after enrolment) until the end of week-
26 (day 181 inclusive), henceforth referred to as week 3-26. The analysis was also stratified a priori 
by the PMC-intervention period (weeks 3-14) and the post-intervention period when the direct 
pharmacological protective effect of DP has waned (weeks 15-26). 
Supportive analyses using covariate-adjusted analysis (Supplementary Appendix) and per-protocol 
analysis were also performed. Further sensitivity analyses to assess the robustness of the primary 
analysis were conducted using the negative binomial model and Prentice Williams Peterson–Gap 
Time (PWP-GT) model.12 Similar analyses were used for secondary time-to-event outcomes. The 
Kaplan-Meier survival plots were drawn for time to first event and forest plots to present the 
results of the PWP-TT models for primary and secondary outcomes and subgroup analyses. The p-
values for the interaction terms were obtained using the Altman and Bland method.13  
Results  
Trial population 
During the in-hospital period, 1,366 participants were screened, and 1,125 assessed for eligibility of 
whom 1,049 were randomised and included in the ITT population (PMC=524, Placebo=525, Figure 
 




1). The baseline characteristics were similar between groups (Table 1). Overall, 96.8% of 1,041 
participants received all three intended courses or had died before the third course, and 7.6% 
(80/1049) withdrew or were lost-to-follow-up. This was equally divided between the study arms. 
The median (IQR) follow-up time was 168 days (161-168) (Table S 4). 
Primary outcome  
Overall, 315 (30.0%) of 1,049 participants had 500 primary events: 184 and 316 in the PMC and 
placebo groups, respectively (Figure 2). PMC was associated with a 35% lower hazard of the 
primary outcome by 26 weeks (HR=0.65, 95% CI 0.54-0.78, p<0.001), and this was 70% during the 
PMC-intervention period from 3-14 weeks post-discharge (HR=0.30, 0.22-0.42, p<0.001), and -13% 
during the post-intervention period (15-26 weeks) (HR=1.13, 0.87-1.47, p=0.37), (p-value 
interaction term <0.001 [Figure S2]). Similar results were obtained with co-variate adjusted 
analysis, sub-group analysis (Figure 2 and Figure S3), per-protocol analysis (Figure S4), and 
sensitivity analysis using alternative extended Cox-regression models or negative binomial 
regression models (Figure S5).  
The PMC intervention delayed the median time to first event from 47 (IQR=20-71) to 110 (IQR=53-

















Figure 1: CONSORT diagram 
 
PMC, post-discharge malaria chemoprevention. 
  
 




Table 1: Baseline Characteristics of Study Participants. * 
 PMC Placebo 
Child characteristics     
Study site     
Uganda—no./total no. (%) 347/524 (66.2) 345/525 (65.7) 
Kenya 177/524 (33.8) 180/525 (34.3) 
Sex (male)—no./total no. (%) 280/524 (53.4) 265/525 (50.5) 
Mean age in months 26.8±15.5 26.3±14.8 
Distance (km) to clinic 27.5±22.6 29.1±23.8 
SES—no./total no. (%)     
poor 173/524 (33.0) 177/525 (33.7) 
poorer 164/524 (31.3) 189/525 (33.0) 
poorest 187/524 (35.7) 159/525 (30.3) 
Mean Hb Level (g/dL) before transfusion 4.1±1.1 4.2±1.2 
Mean Hb level (g/dL) at baseline 8.1±4.5 8.0±2.0 
Mean weight (Kg) at randomisation  11.1±3.2 11.0±3.1 
SMA—no./total no. (%) 436/524 (83.2) 454/525 (86.5) 
Non-SMA—no./total no. (%) 74/524 (14.1) 61/525 (11.6) 
Number of previous hospitalizations—no./total no. (%)    
1 339/521 (65.1) 330/522 (63.2) 
2 94/521 (18.0) 98/522 (18.8) 
>=3 88/521 (16.9) 94/522 (18.0) 
Parent characteristics     
Marital Status—no./total no. (%)     
Single 41/524 (7.8) 29/525 (5.5) 
Married 425/524 (81.1) 435/525 (82.9) 
Other 58/524 (11.1) 61/525 (11.6) 
Father unemployed—no./total no. (%) 32/134 (23.9) 22/117 (18.8) 
Mother education level—no./total no. (%)     
None 36/349 (10.3) 33/366 (9.0) 
Completed primary 224/349 (64.2) 248/366 (67.8) 
Completed secondary 84/349 (24.1) 72/366 (19.7) 
Tertiary/University 5/349 (1.4) 13/366 (3.6) 
*Plus-minus values are means ±SD. PMC, post-discharge malaria chemoprevention; SES=socio economic 
status, RDT=rapid diagnostic test, HIV=human immune deficiency virus, SMA=severe malaria anaemia. 
There were no significant differences between the study groups in any characteristic. Percentages may not 
total to 100 because of rounding. 
 
 





Figure-2: Primary and other efficacy outcomes 
 
* N=total number contributing per time period, PY=person years, IR=Incidence rate per 100 person-years. 
† Median and interquartile range (IQR) of the time to any event (i.e., first, second, third event, etc. pooled). 
‡ Adjusted for site, bodyweight, previous hospital admissions, the syndrome on admissions, age, haemoglobin level at randomization, distance to hospital, 
number of previous admissions, and socio-economic status. 
PMC=Post-discharge malaria chemoprevention 









Figure-3: Efficacy outcomes by sub-group 
 
*N=total number contributing per time period, PY=person years, IR=Incidence rate per 100 person-years, 
HR=hazard ratio, CI=confidence interval, PMC=post-discharge malaria chemoprevention. 
  
 





PMC was associated with a 37% (HR=0.63, 0.52-0.77, p<0.001) reduction in the number of all-
cause hospital re-admissions by 26 weeks. The effect was only evident during the PMC period 
(HR=0.31, 0.22-0.43, p<0.001), not during the post-intervention period (HR=1.09, 0.83-1.42, 
p=0.54) (Figure 2). Hospital readmissions due to severe malaria, severe anaemia, severe malarial 
anaemia, and other severe diseases were also significantly reduced, overall, and during the PMC 
period. All-cause mortality was similar overall by 26 weeks (HR=0.74, 0.35-1.56, p=0.43). There 
was a 92% reduction in mortality during the intervention period (HR=0.08, 0.01-0.64, p=0.02), 
but this was higher (not significant) during the post-intervention period (HR=2.67, 0.85-8.40, 
p=0.09) (Figure 2). 
Among the non-severe outcomes, PMC was associated with significantly lower risks of all-cause 
sick-child out-patient clinic visits mainly reflecting reductions in uncomplicated malaria (Figure 
2) during the PMC period (HR=0.31, 0.23-0.41, p<0.001). There was no effect on non-malaria 
sick-child clinic visits. At the cross-sectional survey at 26 weeks, the groups did not differ in the 
prevalence of malaria infection, haemoglobin concentrations, or severe or moderate anaemia. 
Adherence and tolerance outcomes 
All 1,049 participants received the first course at randomisation, and 98.4% (1,031/1,048) and 
96.8% (1,008/1,041) received the second and third PMC course at approximately six- and ten-
weeks post-discharge. This was equally divided by the two arms (Table S4). The study 
medications were well tolerated; 153 (29.2%) of children in the PMC arm and 168 (32.0%) in the 
placebo arms experienced an adverse event (AE) on days 1-5 after drug intake. The proportion 
of participants who vomited the study medication at least once within 60 minutes during the 
three courses after drug intake was higher in the PMC (65/524, 12.4%) than the placebo 
(20/525, 3.8%) arms. 
Safety outcomes 
In the safety population severe adverse events (SAEs), other than the primary efficacy 
outcomes, occurred in 245 of 524 (46.8%) participants in the PMC arm compared with 319 of 
525 (60.8%) participants in the placebo arm (Table S6). No severe adverse events were judged to 
be related to the trial drugs. Severe malaria was the most frequent adverse event reported in 
both arms. The incidence of adverse events did not significantly differ between the two groups. 
 




Verbal autopsy and clinical notes suggested that none of the 28 deaths was attributed to the 
study medication; eight were due to severe malarial anaemia, nine were due to severe anaemia, 
and eleven were due to other causes. 
ECG monitoring in 66 children showed that DP (N=33) was associated with an 18.6ms (95% CI 
15.6-21.8) increase in the QTcF interval after the third dose of each course, whereas placebo-DP 
(N=33) was not (-1.8ms, -5.3-1.7) (p<0.001). The mean QTcF prolongation decreased with each 
subsequent course and was significantly lower after the third compared to the first courses of 
PMC with DP (p=0.02, Table S7). None of the 33 children in the DP arm experienced QTcF values 
>480ms. Sensitivity analysis using Bazett’s method showed that 1 out of 33 children (3.0%) had 
an asymptomatic QTcB value >500ms (503ms) (Table S7). 
Figure 4: Survival curve comparing time to the first event in PMC and Placebo arms over the 26 
weeks period after discharge 
 
Kaplan–Meier Estimates of time to event. Time (0 days) denotes the day of discharge. The dashed 
vertical lines denote the day of randomisation at 14 days post-discharge, and the end of the PMC 
intervention period at the end of week 14.  
 
 





About one-third of participants enrolled in the placebo arm died or were readmitted at least 
once during the 24 weeks after randomisation and many of them were readmitted multiple 
times confirming the high burden of post-discharge morbidity seen in previous studies in similar 
settings.3,4,11,14,15 Most readmissions in the placebo arm were due to severe malaria or severe 
malarial anaemia and explain the impressive 35% protection against all-cause readmissions and 
deaths conferred by three months of malaria chemoprevention. The effect was restricted to the 
12-week intervention period when the reduction was 70%, and not sustained after waning of 
the direct pharmacodynamic effects of the protective drug levels. Similar conclusions could be 
drawn from covariate-adjusted analyses, per-protocol analyses, and sensitivity analyses using 
alternative methods such as count or alternative time-to-event models. 
We chose dihydroartemisinin-piperaquine for use in PMC because it is safe and well-tolerated 
by children and very effective as seasonal malarial chemoprevention or monthly intermittent 
preventive therapy in children.16-19 The piperaquine component, which is eliminated slowly, 
provides at least four weeks of post-treatment prophylaxis allowing for the pragmatic 4-weekly 
or monthly administration used in this study. The previous PMC trial used three monthly courses 
of artemether-lumefantrine, which provided approximately three weeks of prophylaxis after 
each monthly course and 41% reduction in the same primary outcome during the 3-month 
chemoprevention period.7 One other PMC trials in The Gambia, also conducted in recently 
hospitalized children with severe anaemia, showed that near-complete malaria prophylaxis 
provided post-discharge for the remainder of the malaria transmission season with weekly 
malaria prophylaxis with pyrimethamine-dapsone,20 or monthly sulphadoxine-pyrimethamine21 
reduced all-cause readmission20 or readmission due to severe anaemia21 by 78%.  
We continued follow-up for three months after the protective drug-levels had waned to 
determine the duration of any initial beneficial effect of PMC and whether this was cancelled 
out by a subsequent increased risk of events, e.g., through the loss or delayed acquisition of 
premunition. There was no evidence of either long-term protection or increased risk of 
uncomplicated clinical malaria following cessation of the intervention. However, there was an 
increase, albeit non-significant, in all-cause mortality (HR 2.67, p=0.09) consistent with previous 
seasonal malaria chemoprevention studies in children.22,23 This could reflect an effect on 
 




premunition but also an artifactual increase due to frailty effects because, by contrast to the 
placebo arm, the most vulnerable children in the PMC arm may have survived the intervention 
period. Overall, however, the protection conferred by PMC during the intervention period far 
outweighed any increased risk of events during the extended follow-up period. The effects of 
this intervention are restricted to malaria-associated morbidities, and there was no impact of 
non-malaria associated events, reflects that malaria was the predominant, but not the only 
cause of severe anaemia in this setting. Additional interventions such as antibiotics, 
micronutrient and multivitamins supplementations that target other aetiological factors may 
improve the efficacy of the intervention and address the complex and multifactorial nature of 
the aetiology of severe anaemia in this setting. 
DP was well tolerated, and no serious adverse events attributable to the study drug were 
reported during the intervention period. The incidence of mild adverse events was also similar in 
the PMC and placebo groups, except for asymptomatic corrected QT interval prolongation, 
which, as expected, was significantly higher with dihydroartemisinin-piperaquine than placebo. 
However, no episode of QTc prolongation was associated with arrhythmias or clinical adverse 
events, consistent with other studies using monthly dihydroartemisinin-piperaquine in pregnant 
women24 or other groups.18 Only a few mothers/caretakers withdrew their children because of 
perceived adverse events associated with the intervention, and this was equally divided 
between both arms. 
Nevertheless, like SMC,22 when PMC is implemented, clear health education messages would 
need to be delivered to PMC providers and the target population to achieve effective coverage 
of PMC under programmatic conditions. Recent health services research show that PMC is likely 
to be highly acceptable by mothers/caretakers and that community delivery (i.e. all PMC doses 
are given to the mother/caretaker on discharge), ideally when combined with SMS reminders, is 
more likely to achieve high coverage than facility-based delivery that requires 
mothers/caretakers to return to the clinic for the 2nd and 3rd PMC course.25,26 Modeling studies 
to determine the epidemiological and geographical settings where PMC would be a cost-
effective intervention are merited. 
Potential limitations include the relatively short post-intervention follow-up period. Another 
potential limitation is the use of a composite primary endpoint; the relative risk reduction, and 
 




particularly the reduction in absolute risk differed considerably between the two components 
(i.e., death vs. non-fatal hospital admissions), which combined with the fact that they may be of 
different importance to policymakers and mothers/caretakers, makes the interpretation of the 
composite endpoint more challenging than the individual components. This study was not 
designed to assess the effect of iron supplementation on the potential risk of adverse events 
due to bacterial infections or malaria because both arms received iron as per national 
guidelines. 
The results of this trial are very encouraging and suggest that in areas with intense malaria 
transmission, three months of malaria chemoprevention in children recently admitted with 
severe anaemia is a highly effective intervention resulting in substantial benefits in reducing all-
cause readmissions or death post-discharge. 
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Monthly malaria chemoprevention for the post-discharge management of severe anaemia in 
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Children aged <5 years, weighing ≥5 kg, who had been admitted with severe anaemia 
(haemoglobin <5g/dL/haematocrit<15% or clinical indication for blood transfusion) and had 
received the standard in-hospital care were eligible during their convalescence period if their 
post-transfusion haemoglobin concentration was >5g/dL, they were clinically stable and able to 
take oral medication and if their caretakers agreed to the follow-up schedule. Exclusion criteria 
included severe anaemia due to blood loss/trauma, malignancy, known bleeding disorders or 
sickle cell disease. Children with these specific causes of severe anaemia were excluded because 
currently there are clear guidelines for their management in-hospital and during the follow-up 
periods, both in Uganda and Kenya. Other exclusion criteria included known hypersensitivity to 
study drug, known heart conditions or need for drugs that may be associated with QTc 
prolongation, non-resident in the study area, enrolled into another clinical trial or previous 
participation in this trial. 
Outcomes 
Efficacy outcomes  
Primary efficacy outcome  
The composite primary outcome of all-cause mortality or all-cause hospital readmissions 
determined by the time from randomisation around two weeks post-discharge until week-26 
inclusive. A composite outcome was chosen to increase the power of the study and because the 
two components were expected to follow a similar biological pathway and have similar relative 
risk reductions. 
Secondary efficacy outcomes  
• The composite primary outcome of all-cause mortality or all-cause hospital readmissions 
by study period (PMC-intervention period and PMCpost-intervention period)  
• All-cause hospital readmissions (overall and by study period)  




• Hospital readmissions due to severe anaemia or malaria (composite) (overall and by 
study period)  
• All-cause mortality (overall and by study period)  
• All-cause sick clinic visits (overall and by study period)  
• Uncomplicated clinical malaria (overall and by study period)  
Tertiary efficacy outcomes  
• Hospital readmissions due to severe anaemia (overall and by study period)  
• Hospital readmissions due to severe malarial anaemia (overall and by study period)  
• Hospital readmissions due to severe malaria (overall and by study period)  
• Hospital readmission due to severe disease other than severe anaemia and severe 
malaria 
• Non-severe all-cause sick-child clinic visits (overall and by study period)  
• Non-malaria sick child clinic visits (overall and by study period)  
• Malaria infection (overall and by study period)  
• Malaria infection (at 26 weeks)  
• Hb (at 26 weeks)  
• Any anaemia (Hb<11 g/dL), mild anaemia (Hb 8.0-10.99 g/dL) moderate anaemia (Hb 
5.0-7.99 g/dL) and severe anaemia (Hb<5 g/dL) (at 26 weeks)  
• Weight-for-age, height-for-age, and height-for-weight z-scores (standard deviation [SD] 
scores of reference population) and as categories <2SD and <3SD from references 
population (at 26 weeks).  
Tolerability and safety outcomes  
• Mean QTc and mean increase in QTc prolongation measured by electrocardiogram 
(ECG) 4-6 hours after 3rd dose of each course (mean SD) and QTC prolongation >480ms 
and >500ms and >60ms increase in QTc at any course (binary; yes/no)  





Definition of study time intervals 
Participants were randomised about 14 (11-28) days after discharge. This was delayed if the 
child was readmitted before day 14 or was found to be acutely ill on the scheduled day of 
randomisation. The survival or incidence data analysis cut-off date for a participant was; the 
date of last study visit if no follow-up contact was available thereafter or last known survival 
status date or end of study visit at 182 days (26 weeks) post-discharge (i.e. enrolment).  
The study period was divided into three periods; 1) pre-randomisation screening period of 
approximately 2 weeks from the time the participant was formally enrolled (day 0) until the day 
of randomisation when the first dose of the first course of PMC or PMC-placebo was given, 2) 
PMC-intervention period (week 3-14) of approximately 12 weeks starting from the date of 
randomisation and ending 4 weeks (28 days inclusive) after the date of the first dose of the last 
3-day course of PMC or 14 weeks from enrolment (98 days inclusive), whichever came last and 
3) PMCpost-intervention period (weeks 15-26) of approximately 12 weeks from the end date of 
the subject PMC intervention period plus one day until 26 weeks after enrolment (182 days). 
The analysis for each outcome was presented as the overall effect during the entire on-study 
period (3-26 weeks) and stratified by study period (the PMC intervention period and the PMC 
post-intervention period). 
Covariate adjusted analysis 
Secondary covariate-adjusted analysis of the primary outcome was conducted to determine 
whether the treatment effect estimates, or standard errors were affected by the inclusion of 
covariables. In addition to stratification factor, site and weight, the following pre-specified 
covariates were included: previous hospital admissions, the syndrome on admissions (non-
malaria severe anaemia vs. severe malarial anaemia, age, Hb level at randomisation, distance to 
hospital, readmission during the pre-randomisation screening period, and socio-economic 
status. The same covariates were used in the sub-group analysis of the primary outcome defined 
a priori. 




Subgroup analysis of the primary outcome 
Subgroup analysis of the primary outcome using PWP-TT model was conducted to determine 
the extent to which the study effect varied by sub-groups. The treatment, subgroup variable, 
and their interaction term were used as predictors and the P-value for the interaction term 
obtained from the interaction term models (for those variables not involving period) or using 
Altman and Bland’s method for models involving interaction with the period of assessment. Sub-
group variables considered a priori included; period of assessment, adherence to the number of 
courses taken, malarial season on admission based on microscopy or RDT positivity among 
participants, country, dose in mg/kg received, the severity of anaemia on initial admission, blood 
transfusion status on initial admission, Hb level at randomisation, distance to nearest study 
hospital and socioeconomic status. 
Cause of death 
Data on cause of deaths was collected at least one month after the death had occurred using 
standardized WHO verbal autopsy forms,1 to gather information on symptoms and any 
treatments or care sought prior to death. The forms were reviewed independently by two 
clinical officers and a probable cause of death assigned. The number (%) of participants with 
cause-specific death was then summarized by treatment group. 
Results of cardiac monitoring 
A total of 66 children were recruited; 33 per arm. All 66 received three courses of PMC. A total 
of 1,188 ECGs were taken consisting of 396 timepoints in triplicate, 2 per course for three 
courses each. There were no clinical cardiac adverse events. 
The Fridericia’s method resulted in a better rate correction than the Bazett’s method in the PMC 
arm. In the PMC arm, the mean (SD) QTcF was 400ms (14) at baseline and increased to 422ms 
(15), 4-6 hours after the last dose of the first course (Table S7), representing a mean (SD) 
increase of 22ms (14) (95% CI 20 to 24) (range -6 to 54), p<0.0001 (paired t-test). No increase in 
QTc values was seen in the placebo arm.  
Significant increases were also seen after the second and third course. Comparison of the delta 
QTc between the courses suggested a significant decline in QTcF prolongation from a mean (SD) 
of 22ms (14) after the first course to 14ms (17) after the third course (mean difference [MD], 




8ms, 95% CI 1-15, p=0.02, by paired t-test). None of the children had QTcF values exceeding 
480ms. 
Supplemental references 
1. World Health Organization. Verbal Autopsy Standards: 2012 WHO Verbal Autopsy 
instrument. 2012. 
https://www.who.int/healthinfo/statistics/verbalautopsystandards/en/index2.html.  
2. Van Eijk A, Adazu K, Ofware P, Vulule J, Hamel M, Slutsker L. Causes of deaths using 
verbal autopsy among adolescents and adults in rural western Kenya. Tropical Medicine & 
International Health 2008;13:1314-24. 
 





Figure S1: Overview study flow and periods of assessment 
 
Children who fulfil the enrolment criteria but not the randomisation criteria will not be randomised, 
but where feasible will continued to be followed until the end of study at 26 weeks 
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Figure-S2: interaction terms for period and treatment 
 
N=total number contributing per period, PMC=post-discharge malaria chemoprevention, IR=incidence rate per 100 person-years, PY=person years, 
HR=hazard ratio, CI=confidence interval.  
* Incidence rates obtained from two separate models; one per period. § Ratio of the hazard ratio in the intervention period and the post-intervention period obtained using 
the method described by Altman and Bland.4 ‡ Adjusted for site, bodyweight, previous hospital admissions, the syndrome on admissions, age, haemoglobin level 
at randomization, distance to hospital, number of previous admissions, and socio-economic status. 
 
 




Figure-S3: sub-group analysis by participant characteristics 
 
PMC=post-discharge malaria chemoprevention; IR=incidence rate per 100 person-years; PY=person-years; HR=hazard ratio; 
CI=confidence interval. 




Figure-S4: Per protocol analysis 
 
* N=total number contributing per period, PY=person years, IR=incidence rate per 100 person-years, HR=hazard ratio 
† Median and interquartile range (IQR) of the time to any event (i.e., first, second, third event, etc. pooled). 
‡ Adjusted for site, bodyweight, previous hospital admissions, the syndrome on admissions, age, haemoglobin level at randomization, distance to hospital, 
number of previous admissions, and socio-economic status. 
PMC=Post-discharge malaria chemoprevention 
Confidence intervals for secondary outcomes have not been adjusted for multiple testing, and inferences drawn from the intervals may not be reproducible. 
 




Figure-S5: Sensitivity analysis of the primary outcome using alternative models 
 
HR=hazard rate, IRR=incidence rate ratio, AIC=Akaike information criterion, BIC=Bayesian information criterion. 
 
  







Table S1: Artemether-lumefantrine weight-based dosing schedule 
Weight in 
Kg 
Number of pediatric tablets of artemether (20 mg)-and lumefantrine (120 mg) 
per dose 
  
 Day 1 Day 2 Day 3 
 1st dose 8 hours 24 hours 36 hours 48 hours 60 hours 
5 to <15 1 1 1 1 1 1 
15 to<25 2 2 2 2 2 2 
25 to ≤34 3 3 3 3 3 3 
>34 4 4 4 4 4 4 
 
 
Table S2: Dihydroartemisinin-piperaquine weight-based dosing schedule 
Weight in Kg 
Daily dose (mg) Tablet strength and number of 
tablets per dose Piperaquine DHA 
5 to <8 160 20 
1 x 160 mg / 20 mg tablet or 
½ x 320 mg / 40 mg tablet 
8 to <11 240 30 
1.5 x 160 mg / 20 mg tablet or 
¾ x 320 mg / 40 mg tablet 
11 to <17 320 40 1 x 320 mg / 40 mg tablet 
17 to <25 480 60 1.5 x 320 mg / 40 mg tablet 
25 to<36 640 80 2 x 320 mg / 40 mg tablet 












Table S3: Full list of baseline characteristics of study participants by country. * 
 Uganda  Kenya 
Child characteristics PMC (N=347) Placebo (N=345) PMC (N=177) Placebo (N=180) 
Sex (male)—no./total no. (%) 181/347 (52.2) 168/345 (48.7) 99/177 (55.9) 97/180 (53.9) 
Age—Mean (SD) 27.4±14.8 27.3±14.5 25.7±16.7 24.5±15.3 
Distance (KM)—Mean (SD) 31.4±23.9 31.4±23.4 19.2±17.0 24.2±23.8 
SES—no./total no. (%)         
poor 95/332 (28.6) 72/325 (22.2) 30/124 (24.2) 25/125 (20.0) 
poorer 147/332 (44.3) 172/325 (52.9) 65/124 (52.4) 73/125 (58.4) 
poorest 90/332 (27.1) 81/325 (24.9) 29/124 (23.4) 27/125 (21.6) 
Hb Level (g/dL) pre-transfusion- Mean (SD) 4.2±1.0 4.1±1.2 4.1±1.2 4.2±1.2 
Hb level (g/dL) at enrolment-Mean (SD) 7.7±1.7 8.0±1.8 8.9±7.3 8.0±2.4 
Weight (Kg) at randomization- Mean (SD) 11.0±3.0 10.9±3.0 11.3±3.5 11.1±3.4 
Malaria RDT at enrolment—no./total no. (%)       
Positive 250/347 (72.0) 238/345 (69.0) 7/177 (4.0) 10/180 (5.6) 
Negative 40/347 (11.5) 36/345 (10.4) 5/177 (2.8) 5/180 (2.8) 
Not Done 57/347 (16.4) 71/345 (20.6) 165/177 (93.2) 165/180 (91.7) 
HIV status—no./total no. (%)        
Positive 2/347 (0.6) 1/345 (0.3) 3/177 (1.7) 0/180 (0.0) 
Negative 104/347 (30.0) 107/345 (31.0) 142/177 (80.2) 134/180 (74.4) 
Not known 239/347 (68.9) 234/345 (67.8) 27/177 (15.3) 39/180 (21.7) 
Exposed 2/347 (0.6) 3/345 (0.9) 5/177 (2.8) 7/180 (3.9) 
Bednet use—no./total no. (%) 206/251 (82.1) 199/250 (79.6) 111/129 (86.0) 119/135 (88.1) 
SMA—no./total no. (%) 303/347 (87.3) 307/345 (89.0) 133/177 (75.1) 147/180 (81.7) 
Non-SMA—no./total no. (%) 37/347 (10.7) 36/345 (10.4) 37/177 (20.9) 25/180 (13.9) 
Previous hospitalizations—no./total no. (%)       
1 206/347 (59.4) 203/344 (59.0) 133/174 (76.4) 127/178 (71.3) 
2 69/347 (19.9) 65/344 (18.9) 25/174 (14.4) 33/178 (18.5) 




>=3 72/347 (20.7) 76/344 (22.1) 16/174 (9.2) 18/178 (10.1) 
Treated with antibiotics—no./total no. (%) 346/347 (99.7) 343/345 (99.4) 174/177 (98.3) 176/180 (97.8) 
Difficulty in breathing—no./total no. (%) 133/347 (38.3) 137/345 (39.7) 31/177 (17.5) 24/180 (13.3) 
History of fever—no./total no. (%) 334/347 (96.3) 338/345 (98.0) 170/177 (96.0) 173/180 (96.1) 
HAZ—Mean (SD)-Mean (SD) -1.0±3.9 -1.3±3.1 -0.1±4.9 -0.4±5.2 
WAZ—Mean (SD) -0.7±2.0 -0.9±2.0 -0.3±2.1 -0.6±1.3 
WHZ—Mean (SD) -0.2±1.2 -0.2±1.3 -0.1±1.7 -0.1±2.0 
HAZ <-2 z score 88/233 (37.8) 104/221 (47.1) 36/123 (29.3) 39/128 (30.5) 
HAZ <-3 z score 31/233 (13.3) 43/221 (19.5) 19/123 (15.4) 18/128 (14.1) 
WAZ <-2 z score 33/233 (14.2) 44/221 (19.9) 16/123 (13.0) 15/128 (11.7) 
WAZ <-3 z score 8/233 (3.4) 17/221 (7.7) 7/123 (5.7) 5/128 (3.9) 
WHZ <-2 z score 12/231 (5.2) 16/220 (7.3) 13/120 (10.8) 14/122 (11.5) 
WHZ <-3 z score 3/231 (1.3) 5/220 (2.3) 7/120 (5.8) 4/122 (3.3) 
Parental characteristics         
Marital Status—no./total no. (%)        
Single 11/347 (3.2) 15/345 (4.3) 30/177 (16.9) 14/180 (7.8) 
Married 295/347 (85.0) 290/345 (84.1) 130/177 (73.4) 145/180 (80.6) 
Other 41/347 (11.8) 40/345 (11.6) 17/177 (9.6) 21/180 (11.7) 
Father employment status—no./total no. (%) 26/109 (23.9) 15/94 (16.0) 6/25 (24.0) 7/23 (30.4) 
Mother education level—no./total no. (%)       
None 28/209 (13.4) 25/226 (11.1) 8/140 (5.7) 8/140 (5.7) 
Completed primary 125/209 (59.8) 143/226 (63.3) 99/140 (70.7) 105/140 (75.0) 
Completed secondary 53/209 (25.4) 56/226 (24.8) 31/140 (22.1) 16/140 (11.4) 
Tertiary/University 3/209 (1.4) 2/226 (0.9) 2/140 (1.4) 11/140 (7.9) 
SD, standard deviation; SES, socioeconomic status; RDT, rapid diagnostic test; HIV, human immune deficiency virus; SMA, severe malarial anaemia; 
HAZ, height for age z-score; WAZ, weight for age z-score; WHZ, weight for age z-score. There were no significant differences between the study 
groups in any characteristic. Percentages may not total to 100 because of rounding. 





Table S4: Adherence table 
 Uganda Kenya Overall 
 PMC Placebo PMC Placebo PMC Placebo Pooled 
 N=347 N=345 N=177 N=180 N=524 N=525 N=1049 
Achieved¶/expected€ (%)        















  PMC2 
345/347 
(99.4) 342/344 (99.4) 171/177 (96.6) 173/180 (96.1) 516/524 (98.5) 515/524 (98.3) 1031/1048 (98.4) 
  PMC3 
345/347 
(99.4) 336/341 (98.5) 164/176 (93.2) 163/177 (92.1) 509/523 (97.3) 499/518 (96.3) 1008/1041 (96.8) 
Total person-days        
  Overall (week 3-26) 56,042 54,226 26,830 26,740 82,872 80,966 163,838 
  PMC intervention period (week 3-14) 29,245 28,665 15,077 15,227 44,322 43,892 88,214 
  Post intervention period (week 15-26) 26,589 25,318 11,505 11,406 38,094 36,724 74,818 
Median (IQR) person-days        
  Overall (week 3-26) 168 (163-168) 166 (159-168) 168 (163-168) 168 (159-168) 168 (163-168) 168 (159-168) 168 (161-168) 
  PMC intervention period (week 3-14) 84 (84-86) 84 (81-86) 85 (84-93) 85 (84-95) 84 (84-87) 84 (82-88) 84 (83-88) 
  Post intervention period (week 15-26) 82 (76-83) 81 (74-83) 80 (69-83) 78 (64-83) 81 (75-83) 80 (71-83) 81(73-83) 
Lost/withdrawn by 26 weeks (%)        
  Overall (week 3-26) 7 4 37 32 44 (8.4) 36 (6.9) 80 (7.6) 
  PMC intervention period (week 3-14) 3 4 21 17 24 (4.6) 21 (4.0) 45 (4.3) 
  Post-intervention period (week 15-26) 4 0 16 15 20 (3.8) 15 (2.9) 35 (3.3) 
PMC=post-discharge malaria chemoprevention, IQR interquartile range.  
PMC1, PMC2 AND PMC3 are the first, second and third PMC courses respectively provided at approximately 2, 6, and 10 weeks post-discharge. 
¶Number of participants who received the PMC courses 
€Number expected to receive the PMC course excluding the death 
  





Table-S5: End of study cross-sectional survey* 
Characteristic PMC (N=473) Placebo (N=472) RR or MD (95% CI)* p-value 
Fever documented or in last 48h 67/470 (14.3) 80/471 (17.0) 0.84 (0.62-1.13) 0.25 
Malaria RDT positivity 116/461 (25.2) 137/464 (29.5) 0.85 (0.69-1.05) 0.14 
Anemia (Hb <11.0 g/dL) 197/458 (43.0) 188/463 (40.6) 1.06 (0.91-1.23) 0.46 
Moderate anemia (Hb≥5.0 and ˂8.0 g/dL) 48/458 (10.5) 39/463 (8.4) 1.24 (0.83-1.86) 0.29 
Hemoglobin in g/dL, mean (SD) 11.0 (2.1)  11.0 (2.2)  -0.03 (-0.31-0.24) 0.83 
HAZ, mean (SD) -1.0 (3.0)  -1.0 (3.2)  0.07 (-0.34-0.48) 0.74 
WAZ, mean (SD) -0.6 (1.6)  -0.7 (1.4)  0.05 (-0.14-0.25) 0.61 
WHZ, mean (SD) -0.1 (1.3)  0.0 (1.4)  -0.09 (-0.27-0.09) 0.35 
HAZ, Z-score <-2 146/448 (32.6) 157/452 (34.7) 0.94 (0.78-1.13) 0.50 
HAZ, Z-score <-3 60/448 (13.4) 73/452 (16.2) 0.83 (0.60-1.14) 0.25 
WAZ, Z-score <-2 64/448 (14.3) 59/452 (13.1) 1.09 (0.79-1.52) 0.59 
WAZ, Z-score <-3 18/448 (4.0) 12/452 (2.7) 1.51 (0.74-3.10) 0.26 
WHZ, Z-score <-2 28/446 (6.3) 20/446 (4.5) 1.40 (0.80-2.45) 0.24 
WHZ, Z-score <-3 8/446 (1.8) 6/446 (1.3) 1.33 (0.47-3.81) 0.59 
Numbers denote n/N (%) unless otherwise indicated.  
SD standard deviations, SES socioeconomic status, RDT rapid diagnostic test, Hb haemoglobin, HAZ height (or length) for age z score, 
WAZ weight for age z score, WHZ weight for height (or length) age z score, CI confidence interval. 
* RR=relative risk for binary variables, MD=mean difference for continuous variables. 




Table S6: Serious adverse events   
 PMC PMC-Placebo 





Incidence per 100 





Incidence per 100 
person-days (95% CI) 
Overall 245 319 0.29 (0.26-0.32) 354 581 0.40 (0.39-0.46) 
Blood and lymphatic system disorders 58 74 24.62 (20.20-30.01) 99 142 37.50 (32.91-42.68) 
Cardiac disorders 1 1 0.33 (0.05-2.35) 0 0  
Ear and labyrinth disorders 1 1 0.33 (0.05-2.35) 1 1 0.30 (0.04-1.87) 
Gastrointestinal disorders 3 3 1.00 (0.32-3.08) 5 5 1.30 (0.55-3.15) 
General disorders and administration site conditions 13 13 4.33 (2.54-7.36) 15 15 4.00 (2.41-6.50) 
Hepatobiliary disorders 1 1 0.33 (0.05-2.35) 1 1 0.30 (0.04-1.87) 
Immune system disorders 0 0  1 1 0.30 (0.04-1.87) 
Infections and infestations 124 180 59.89 (54.59-65.69) 172 347 91.60 (88.83-94.42) 
Metabolism and nutrition disorders 9 9 2.99 (1.57-5.70) 4 4 1.10 (0.40-2.80) 
Nervous system disorders 2 2 0.67 (0.17-2.65) 3 3 0.80 (0.26-2.44) 
Renal and urinary disorders 7 7 2.33 (1.12-4.84) 17 24 6.30 (4.30-9.33) 
Respiratory, thoracic and mediastinal disorders 24 26 8.65 (5.99-12.49) 36 38 10.00 (7.42-13.56) 
Skin and subcutaneous tissue disorders 1 1 0.33 (0.05-2.35) 0 0  
Musculoskeletal and connective tissue disorders 1 1 0.33 (0.05-2.35) 0 0  
PMC, post-discharge malaria chemoprevention; CI, confidence interval, MedDRA, Medical Dictionary for Regulatory Activities. 
  




Table S7: Cardiac monitoring; mean and mean change in QTcF at baseline and 4 to 6 hours after 
the third dose of each course 
PMC     













(SD) Range 95% CI p 
>60 
ms 
1st 0  33 400 (14) 377-431 0 (0) 0 (0) Ref   
 
 
1st 2+4h 33 422 (15) 396-456 0 (0) 0 (0) 22 (14) -6, 54 17, 27 <0.001 0 (0) 
2nd 0 33 401 (16) 363-431 0 (0) 0 (0) Ref   
 
 
2nd 2+4h 33 420 (17) 388-460 0 (0) 0 (0) 20 (15) -18, 44 14, 25 <0.001 0 (0) 
3rd 0 33 402 (15) 369-431 0 (0) 0 (0) Ref   
 
 
3rd 2+4h 33 416 (20) 384-458 0 (0) 0 (0) 14 (16) -14, 55 8, 20 <0.001 0 (0) 
            
Placebo     













(SD) Min-max 95% CI p 
>60 
ms 
1st 0  33 401 (14) 370-439 0 (0) 0 (0) Ref   
 
 
1st 2+4h 33 401 (14) 376-431 0 (0) 0 (0) 0 (13) -27, 31 -4, 5 0.87 0 (0) 
2nd 0 33 400 (13) 373-420 0 (0) 0 (0) Ref   
 
 
2nd 2+4h 33 395 (16) 367-420 0 (0) 0 (0) -4 (17) -46, 27 -10, 2 0.18 0 (0) 
3rd 0 33 400 (19) 358-433 0 (0) 0 (0) Ref   
 
 
3rd 2+4h 33 398 (20) 320-425 0 (0) 0 (0) -2 (22) -82, 47 -9, 6 0.68 0 (0) 
            
DP, dihydroartemisinin-piperaquine; ECG, electrocardiogram; QTc, QT interval on ECG corrected using the 
Fridericia method (QTcF); ms, milliseconds; SD, standard deviation; 2+4h, Day 2 plus 4 to 6 hours after the 
third (last) dose of each course of DP (Tmax), 
; CI, confidence interval. 
* Change in QTcF from baseline in ms. Baseline was the QTcF interval taken just before the first dose of each 
course of PMC with DP 
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Chapter 7: Discussions 
Main findings 
This thesis aimed to provide evidence of the burden of post-discharge mortality and morbidity 
among children less than five years of age who are admitted with all-cause severe anaemia and 
living in malaria-endemic areas of Africa. Following the impressive results from the previous trial in 
Malawi where artemether-lumefantrine was shown to provide substantial protection against 
morbidity and mortality post-discharge,1 we aimed to provide confirmatory evidence with a longer-
acting antimalarial to show that post-discharge malaria chemoprevention is an effective tool for the 
management of severe anaemia post-discharge in this setting. 
By analysing historical data collected between 2008 and 2013 within the KEMRI/CDC HDSS located 
in an area with intense year-round malaria transmission in western Kenya (chapter 3), we found 
that children admitted with severe anaemia have a 2-fold higher risk of death within the first six 
months post-discharge than children admitted with other syndromes, except for severe acute 
malnutrition (3-fold). Furthermore, it is well documented that severe anaemia is a leading cause of 
mortality and carries substantial in-hospital mortality risk ranging from 4 to 12% in different 
epidemiological settings.2,3 We found that children admitted with severe anaemia were more likely 
to die in the first six months after discharge than during their in-hospital stay. Similar findings were 
observed for children admitted with severe acute malnutrition. Severe anaemia and severe acute 
malnutrition commonly co-exist in this setting, and this was found to worsen the post-discharge 
mortality outcomes. These findings were further confirmed when we pooled the findings from 
similar studies conducted in comparable epidemiological settings in a systematic review and meta-
analysis (Chapter 4). Thus, the unrecognised risk of post-discharge mortality in children with severe 
anaemia likely contributes substantially to the overall burden of child mortality in malaria-endemic 
areas of Africa.  
The previous trial in Malawi provided the initial evidence that malaria chemoprevention is a 
promising intervention.1 This showed that a substantial reduction in all-cause deaths or 
readmission among children with severe malaria anaemia could be achieved with three months of 
post-discharge malaria chemoprevention with artemether-lumefantrine.1 In our current trial in 
Uganda and Kenya, which enrolled children with all-cause severe anaemia and which was designed 
to confirm the earlier finding from Malawi, three months of post-discharge chemoprevention with 
dihydroartemisinin-piperaquine (DP) was found to be highly efficacious (Chapter 6). PMC, 
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therefore, is a promising tool for the post-discharge management of children admitted with severe 
anaemia in malaria-endemic areas of Africa.  
Efficacy of post-discharge malaria chemoprevention with dihydroartemisinin-piperaquine 
Three monthly courses of DP administered to children living in a malaria-endemic area and recently 
discharged with severe anaemia was associated with a 35% reduction in all-cause death or all-cause 
readmission by six months. This was 70% during the three months intervention period. The effect 
was not sustained after the protective drug levels had waned (Chapter 6). The greatest reduction 
was seen in malaria-related re-admissions (i.e. severe malaria or severe malarial anaemia). With the 
multifactorial nature of the aetiology of severe anaemia in malaria-endemic areas, the results may 
vary in different epidemiological settings depending on the extent to which malaria contributes to 
the overall burden of severe anaemia visa vis other aetiological factors. These findings are better 
than those from the previous trial in Malawi which used artemether-lumefantrine and showed a 
36% reduction for the same primary outcome during the three months intervention period, and 
21% overall by 6 months (31% in multi-variate analysis).1 We used DP which provided complete 
prophylaxis between the 4-weekly doses because of the longer post-discharge chemoprophylactic 
effects of the piperaquine component as opposed to the lumefantrine component which provides 
about three weeks of post-treatment prophylaxis. As opposed to the 69% reduction found in our 
trial, monthly courses with AL, provided more modest protection against clinical malaria (50%) 
during the intervention period in the Malawi trial. This may be related to the shorter duration of 
post-treatment prophylaxis that is achieved with the lumefantrine component which allows 
infections to occur in the last week before the next monthly course of the intervention is due. Our 
observed reduction in clinical malaria is consistent with the findings from earlier SMC trials which 
reported a 71% reduction with the SP and amodiaquine combination in Burkina Faso,4 and a 93% 
reduction with the SP and piperaquine combination in The Gambia5 where the efficacy of SP is still 
high.6 
In the PMC trial (Chapter 6), we recruited children with all-cause severe anaemia as opposed to 
children with only severe malarial anaemia in the previous trial in Malawi.1 The reason was that 
subsequent observational studies showed that in malaria-endemic areas, children with severe 
anaemia were at an increased risk of post-discharge mortality irrespective of whether they had 
malaria on admission (Chapter 5). Indeed, this was confirmed in our PMC trial as we did not find a 
difference in the effect of the PMC between children who had evidence of malaria infection at 
baseline and those who did not (Chapter 6).  
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Nevertheless, because of the other similarities in the design and setting of the two studies, we 
pooled the results in an aggregate data meta-analysis which shows an overall reduction in the 
primary outcome of 33% by six months (HR=0.67, 0.56-0.78, p<0.001) and 66% during the 
intervention period (HR=0.34, 0.24-0.43, p<0.001). All cause-readmissions were also significantly 
reduced by 33% overall (HR=0.67, 0.56-0.78, p<0.001) and 63% during the intervention period 
(HR=0.37, 0.27-0.47, p<0.001). Similar findings were obtained for the pooled analyses for 
readmissions due to severe anaemia or severe malaria and clinic visits due to clinical malaria overall 
and during the intervention period. The pooled reduction in mortality was only significant during 
the intervention period (HR=0.09, -0.20-0.39, p<0.001) with no effect overall (HR=0.79, 0.28-1.29, 
p=0.530). None of the outcomes was affected in the post-intervention period when the protective 
drug levels had waned (Figure 1).  
Figure 5: Meta-analysis of the primary outcome (all-cause readmission /death) 
 
HR, hazard ratio; CI, confidence interval; AL, artemether-lumefantrine; DP, dihydroartemisinin-
piperaquine. 
 
There have been two previous trials in areas with highly seasonal malaria transmission in West 
Africa that looked at the impact of malaria chemoprevention when provided to children with 
severe anaemia during the malaria transmission season. Both were conducted in The Gambia.7,8 
The first was a prospective follow up of children between six months and nine years of age initially 
admitted and managed for severe malaria anaemia. They were randomised twenty-eight days later 
to receive either weekly chemoprophylaxis with the pyrimethamine and dapsone combination 
(Maloprim®) (n=98) or placebo (n=86) for a maximum of twelve weeks during the malaria 
transmission period. The intervention was found to reduce all-cause readmission (odds ratio 
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[OR]=0.19, 0.03-0.76, p=0.02) and clinical malaria (OR=0.36, 0.14-0.90, p=0.03), but protection 
against mortality or recurrence of severe anaemia was not reported.8 The second study was a 
placebo-controlled trial providing monthly SP post-discharge to children aged three months to nine 
years with moderate to severe anaemia (Hb <7g/dL).7 A total of 1200 children, equally divided 
between the intervention and placebo arms, were recruited and followed for the rest of the 
malaria transmission seasons. The duration of follow-up per child dependent on the timing of 
enrolment in the transmission season with children admitted early in the transmission season being 
followed for longer. Like our study, there was substantial protection against the recurrence of 
severe anaemia (PE=78%, -3%-95%, p=0.055) and clinical malaria (PE=53%, 37%-65%, p<0.001).  
Although the available evidence is restricted to four trials, it indicates that post-discharge malaria 
chemoprevention may be beneficial in both areas with intense year-round malaria transmission as 
seen in our trial (Kenya and Uganda) and Malawi,1 and in areas with highly seasonal malaria 
transmission when offered during the malaria transmission season.7,8 However, these PMC studies 
in the Gambia were conducted prior to the widespread introduction of SMC. Thus, today, PMC is 
unlikely to play a role in seasonal malaria transmission areas where SMC strategies are widely 
implemented as SMC may offer similar protection as PMC in the post-discharge period. 
Tolerance and safety of post-discharge malaria chemoprevention 
DP was well tolerated in our study (Chapter 6), consistent with reports from previous studies in 
children. The major safety concern with DP is its dose-related QT prolongation associated with the 
piperaquine component. Previous studies examining the safety of repeat dosing of DP when used 
on apparently healthy children did not report any clinical adverse events related to QTcF 
prolongation.9 However, no study in malaria-endemic areas has previously reported on the cardiac 
safety of repeat doses of DP in convalescent children recently discharged from hospital. In our 
nested cardiac monitoring study involving 33 children from the main trial (Chapter 6), we found a 
mean (SD) increase of 22ms (14) from baseline to 4-6 hours after the last dose of the first course 
and similar increases following administration of the second and the third courses. No child had 
QTc values exceeding 500ms using the Fridericia’s correction and one child (3%) had QTc values 
exceeding 500ms when using Bazett’s correction. No clinical cardiac adverse events occurred in any 
of the 1049 children enrolled. The lack of an increase in QTc prolongation following monthly 
courses of DP, despite the potential for dose accumulation of piperaquine due to its slow 
elimination, is consistent with the findings from a previous trial that provided monthly doses to 
apparently healthy children 6 to 24 months of age, some of whom received 18 monthly courses of 
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DP. In this study in Uganda, 145 ECGs were taken from 19 of these children showing no difference 
in the magnitude of QTcF prolongation between the monthly courses; i.e. the mean QTcF 
prolongation after 18 months was similar to the degree of QTcF prolongation observed with earlier 
courses.9 Similar findings were reported in a recent systematic review on the safety of repeat 
dosing of DP involving a total of 3935 individuals and 18,297 courses of DP (2-18 courses per 
individual).10 Although these findings are reassuring, our sub-study only included 33 children and it 
would be advisable to collect more safety data as part any Phase-IV studies if and when PMC 
become policy to provide further reassurance of the cardiac safety of DP in this vulnerable target 
group. 
The trial (Chapter 6) included an extended follow-up period until six months post-discharge. The 
rationale behind this related to the concerns about the interference in the development of anti-
malarial immunity in children exposed for prolonged periods of malaria chemoprevention. This 
could lead to a potential rebound of malaria-related morbidity and even all-cause mortality after 
the chemoprevention is stopped (Chapter 2), which could cancel out the initial benefits seen during 
the 3 months intervention period. Some studies have reported a significant rebound in malaria and 
anaemia in the periods immediately following cessation of the intervention.11,12 However, most IPTi 
and IPTc studies did not show a difference in the risk of malaria, anaemia or hospital readmissions 
between the intervention and placebo arms after the intervention was stopped.9,13,14 These 
conclusion from individual studies were consistent with those from a pooled analysis in a 
systematic review and meta-analysis on the safety and efficacy of IPTi using SP.15 In our study 
(Chapter 6), we found a statistically non-significant increase in the risk of mortality during the post-
intervention period (HR=2.67, 0.85-8.40) after the protective drug levels had waned approximately 
4 weeks after the third course of DP, i.e. by 15 weeks post-discharge; similar findings were obtained 
in the Malawi trial (HR=1.60, 0.52-4.89),1 and when the two studies were pooled (HR=1.87, -0.02-
3.76). it is unlikely that this reflects a decrease in malarial immunity as there was no corresponding 
increase in the number of clinical malaria events post-intervention (Chapter 6: HR=0.84, 0.67-1.05; 
Phiri et al, HR=1.10, 0.89-1.37). It is possible that this reflects artefactual increased mortality due to 
a frailty effect because the sub-group of the most vulnerable children in the placebo arm is no 
longer contributing to the post-intervention period because they died before, whereas in the PMC 
arm mortality is not avoided but delayed until the protective drug levels have waned. By six months 
the mortality was 26% lower in the PMC arm, but the confidence intervals were wide, and not 
statistically significant. Overall, it appears that, like the IPTi and IPTc studies, the interruption in the 
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acquisition of antimalarial immunity, if any, is small, and the benefits of the intervention outweigh 
the risks. Continued surveillance is inevitable for more conclusive information. 
Another concern with the use of malaria chemoprophylaxis is the risk of enhancement of the 
development of antimalarial drug resistance due to increased drug pressure (Chapter 2). During the 
PMC trial, we collected blood samples for host and parasite genetic analysis before and after 
completion of the study. However, these results were not yet available by the time of writing this 
thesis. Reports from IPTi and SMC trials have mixed findings (Chapter 2) on the effects of 
widespread use of antimalarials for chemoprevention on the development of drug resistance, 
hence the need for more evidence and continued surveillance. Therefore, it is important to 
establish the baseline prevalence of artemisinin16 and piperaquine17 markers of resistance before 
the deployment of PMC with DP. This is important to assess any changes in these molecular 
markers associated with the implementation of PMC if continuous surveillance is implemented.  
Aetiology of post-discharge morbidity and indirect benefits for malaria chemoprevention  
In highly malaria-endemic areas, post-discharge malaria has been reported in many studies as a 
likely cause for post-discharge morbidity and mortality,18-21 but this has not been adequately 
quantified, and other diseases and conditions contribute. Studies conducted to determine post-
discharge survival of children admitted with severe anaemia have mainly reported on all-cause 
mortality or all-cause morbidity or recurrence of severe anaemia,22 however, to the best of our 
knowledge, no reports on the aetiology of post-discharge mortality among children previously 
admitted with severe anaemia are currently available from malaria-endemic areas of sub-Saharan 
Africa. Other aetiologies which co-exist with malaria or whose effects are potentiated by malaria 
infections may be affected by reductions in the risk of malaria. Several studies have demonstrated 
that reductions in malaria can have indirect benefits as demonstrated by reductions in all-cause 
mortality rates following the aggressive deployment of malaria control interventions that were 
greater than could be expected from an effect of reductions in malaria-related deaths alone.23,24  
Persisting post-discharge bacteraemia could be a major cause of post-discharge mortality in 
children recently admitted with severe malaria in malaria-endemic areas of Africa. There is a strong 
positive correlation between malaria endemicity and invasive non-typhoidal salmonella infections 
(iNTS) (p=0.1; r=0.70)25 and on-going or recent Plasmodium falciparum infections are associated 
with iNTS with in-hospital case-fatality rates approaching 20% irrespective of treatment with 
suitable antibiotics.26 A systematic review and meta-analysis investigating the association between 
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invasive bacterial co-infection and falciparum malaria in Africa found that the outcome is even 
worse for children admitted with severe malarial anaemia and iNTS (24%) co-infection compared to 
children without malaria (10%).27 In Chapter 4, we also found a significant positive association 
between bacteraemia and post-discharge mortality. The clinical presentation of iNTS and malaria 
overlap and most facilities in malaria-endemic areas in sub-Sahara Africa have limited availability of 
blood culture services; thus, most of these infections go undiagnosed and untreated. This is 
reflected in our data collected routinely from a hospital within the KEMRI/CDC HDSS, where the 
number of children diagnosed with bacteraemia was too low for any analysis to be conducted. It is, 
therefore, likely that several children were discharged with persistent bacterial infections which 
worsened after discharge leading to post-discharge mortality. The WHO recommends the use of 
broad-spectrum antibiotics for all children with suspected severe malaria in moderate to high 
malaria transmission settings,28 however the current WHO guidelines for the identification of 
children with invasive bacterial infections fail to identify about a third of infected children and 
about 50% of bacterial isolates from these children are not susceptible to the currently 
recommended antibiotics.29 The more potent antibiotics like third-generation cephalosporins are 
not easily available or affordable for routine use in these malaria-endemic areas.30 Persisting post-
discharge bacteraemia, including iNTS and its contribution to the burden, needs to be quantified 
further. 
Severe malaria vs non-malarial anaemia and the post-discharge burden 
In Chapter 3 and 4, we found that the risk of six months post-discharge mortality was significantly 
higher among children admitted with non-malaria severe anaemia compared with those with 
severe malarial anaemia. One potential reason for this difference may be misclassification of 
uncomplicated malaria as severe malaria, which is very common in Africa, where as many as one-
third of admissions for ‘severe malaria’ do not fulfil WHO’s criteria for severe malaria.31 Another 
potential explanation is the challenge in diagnosing these non-malaria causes of severe anaemia 
relative to diagnosing malaria-associated anaemia, resulting in inadequate in-hospital management 
and children being discharged with persisting underlying conditions. In many lower-level facilities in 
malaria-endemic areas, anaemia and malaria are diagnosed clinically, and in-hospital treatment for 
severe anaemia, even non-malarial severe anaemia constitutes of blood transfusion and parenteral 
antimalarial treatment, which is instituted presumptively following the IMCI guidelines,32,33 without 
much further investigation to the cause of anaemia. Coupled with delays and poor health-seeking 
behaviour34 children with non-malarial severe anaemia are thus more likely to die in the post-
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discharge period without a diagnosis and proper treatment of the underlying condition than 
children where malaria was the primary cause of the severe anaemia.  
The WHO recommends the rational use of blood for transfusion to reduce unnecessary use and 
transfusion-transmitted infections. The adherence to these guidelines is poor leading to high rates 
of in-hospital mortality among severely anaemic children in sub-Saharan Africa,35 especially if they 
had severe malaria anaemia and respiratory distress.36 Due to frequent shortage and/or delay in 
transfusion,37 (also observed during the PMC trial) it is possible that some children are discharged 
with no or inadequate transfusion. These children are likely to be readmitted because of recurrence 
of severe anaemia or are exposed to a higher risk of post-discharge mortality as has been observed 
in previous studies,38,39 especially if they come from households with poor health-seeking 
behaviour.  
Vitamin A deficiency is a neglected cause of severe anaemia in sub-Saharan Africa, yet it is a 
widespread micronutrient deficiency in Africa.40 It has also been shown to potentiate the 
susceptibility of children to malaria infection and bacteraemia,40,41 both of which are possibly 
associated with post-discharge mortality. Vitamin A deficiency could be associated with severe 
acute malnutrition in children in malaria-endemic areas, a condition we found (Chapter 3 and 4) to 
worsen the post-discharge mortality outcomes in children with severe anaemia.  
Red cell production failure (RCPF) has been shown to be a common pathway in the pathogenesis of 
severe anaemia in sub-Saharan Africa and can be triggered by many aetiological factors discussed 
above. Other conditions which are known to cause RCPF are viral infections including HIV infections 
which is prevalent in malaria-endemic areas and a possible cause of post-discharge mortality and 
morbidity. HIV positive status has been shown to be positively associated with post-discharge 
mortality as shown by our study (Chapter 3) and others.42,43 However, like the Malawi study, we did 
not observe a difference in effect based on HIV status. Data may be insufficient to make any 
conclusions in each of the two studies, but since the HIV positive children were on co-trimoxazole 
prophylaxis, PMC may provide less additional antimalarial protection than in HIV uninfected 
children since co-trimoxazole is an effective anti-malarial drug.44 
Risk factors of post-discharge mortality and morbidity 
In addition to determining the aetiology of post-discharge mortality, identification of clinical or 
demographic predictors associated with post-discharge mortality present on admission or 
discharge could offer a cost-effective option for identifying children who are at greatest risk of 
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post-discharge mortality and may benefit from targeted management. Most countries in malaria-
endemic sub-Saharan Africa are resource-constrained and therefore following all children after 
discharge may not be feasible in the routine healthcare system. Although this thesis did not include 
a detailed study of the clinical risk factors and other predictors of post-discharge re-admission or 
mortality, in Chapter 3, we provided the risk factors associated with post-discharge mortality as 
identified on admission, but our data was limited and did not include the clinical parameters on 
admission to hospital. To date, we are aware of two studies; one in Uganda45 and a more recent 
one in Mozambique, which developed risk scoring algorithms for predicting post-discharge 
mortality using simple variables collected on admission. These models are intended to provide 
more targeted post-discharge care. The primary models in the two studies identified about 80% of 
children who are at risk of post-discharge mortality.42,45 According to these models, poor 
anthropometric measurements and younger age are predictive of post-discharge mortality, 
characteristics which were also identified in our study to be associated with post-discharge 
mortality (Chapter 3). Other risk factors commonly identified and included in the primary prediction 
models in the two studies were HIV positive status, hypoxia and abnormal conscious levels. These 
models are likely to provide a more objective and reliable means of identifying children at risk of 
post-discharge mortality, but the low specificity and positive predictive values reported in the 
models in the two studies are likely to compromise the effectiveness of post-discharge 
management.  
Implications for future research 
This thesis raises several important gaps in the overall management of severe anaemia in malaria-
endemic areas of Africa, which is currently focussed on in-hospital care. Post-discharge mortality is 
a major burden in this setting in children previously admitted with severe anaemia. Post-discharge 
malaria infection has been shown to be an important underlying condition leading either directly or 
in-directly to morbidity and mortality. This study did not assess the aetiology of post-discharge 
morbidity and further studies to determine this, and the magnitude of malaria versus non-malaria 
conditions leading to morbidity or mortality post-discharge are warranted. There is a need to assess 
the contribution of poor adherence to the current standard guidelines for the in-patient 
management of severe anaemia in-hospital and their link to post-discharge mortality. A recent 
study in Uganda showed that strict adherence to clinical guidelines was associated with a significant 
reduction of in-hospital deaths associated with severe anaemia.46 As discussed above, 
improvement of the discharge process through the identification of children most at risk may 
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reduce the burden of post-discharge mortality through improved and focused management 
restricted to the highest risk population. More data, however, is needed to develop more robust 
prediction models by incorporating data from varied settings in malaria-endemic sub-Sahara Africa, 
possibly through a systematic review and meta-analysis of relevant studies in this setting. 
Based on the possible breath of aetiologies for post-discharge mortality and morbidity in children 
with severe anaemia in malaria-endemic areas, additional post-discharge interventions to cover a 
broader range of aetiologies may improve the efficacy of PMC on all-cause post-discharge mortality 
and morbidity. As discussed above, aggressive deployment of malaria control interventions has 
been linked to substantial reductions in all-cause mortality at levels higher than can be attributed 
to reductions in malaria alone. The contribution of non-malaria causes of post-discharge morbidity 
and mortality has not been fully quantified, but malaria remains a common underlying factor in this 
setting.18-20 Several factors have been postulated to increase the hosts’ susceptibility to other 
infections following clinical malaria, including prolonged neutrophil impairment and immunological 
dysregulation.47,48 Inflammatory processes from bacterial and other infections lead to disruption of 
surface receptors on endothelial walls which forms the pathological basis for many infections 
including sepsis and plasmodium falciparum malaria.49,50 It has been shown that endothelial 
inflammation persists for more than a months following Plasmodium falciparum infection, even 
after the parasites have been eliminated,51 a situation which may persist for longer in malaria-
endemic areas because of repeat malaria infection and other infectious agents prevalent in this 
settings. This would be consistent with the finding that most post-discharge deaths occur in the 
immediate post-discharge period; this was >50% in the first one month in other studies,42,45,52 
although it was only about 60% in the first three months in our study. 
The addition of a broad-spectrum antibiotic to PMC may have more beneficial effects than PMC 
alone. For example, the association of iNTS and malaria and its associated high in-hospital mortality 
in children with severe anaemia has been confirmed in several studies 26,27 and is possibly 
associated with high post-discharge mortality if not adequately managed. Azithromycin is a potent 
broad-spectrum antibiotic, also with well documented, although modest, antimalaria 
properties.53,54 It has been widely used for mass drug administration for the control of Trachoma in 
West Africa with over 100 million doses being distributed annually with no serious safety 
concerns.55 An observational study during a mass drug administration exercise in Ethiopia for the 
control of Trachoma using a single dose of azithromycin found a significant reduction in all-cause 
mortality among children one to five years of age who received the intervention 26 months earlier 
Chapter 2: Discussions 
212 
 
(OR=0.35, 0.17-0.74)56 and similar findings were reported in the same setting among children 1 to 
9-year-old in a cluster-randomised trial.57 These findings were further confirmed in a large cluster-
randomised trial (Mortality Reduction After Oral Azithromycin [MORDOR]) which involved more 
than 190,000 children in three sub-Saharan African countries. Azithromycin was distributed half-
yearly for two years, and a significant reduction in all-cause mortality was reported among the 
communities that received the intervention with the greatest reduction being in children between 
1 to 5 years of age (RR=0.75, 0.63-0,89, p<0.001).58 However, the addition of azithromycin to 
monthly SP and amodiaquine combination for SMC in Mali and Burkina Faso did not result in a 
reduction in mortality or hospital readmissions.13 The authors of this SMC trial attributed the no-
effect findings to several reasons including that the mortality in MORDOR trial may have been due 
to the antimalaria effects of azithromycin which were cancelled out in their trial since all children 
received SP and amodiaquine combination which is a more efficacious antimalarial than 
azithromycin. Furthermore, the antimicrobial effects of SP may have reduced the benefits of 
azithromycin and lastly, the coverage of pneumococcal conjugate vaccine was high in their trial 
sites. Nevertheless, the incidence of the gastrointestinal, upper respiratory tract and other febrile 
infections were significantly reduced in the azithromycin arm. Therefore, because of the high 
incidence of iNTS infections in children with severe anaemia in malaria-endemic areas, the addition 
of azithromycin to PMC may have greater beneficial effects than those observed in SMC 
participants who are generally healthy individuals at risk of malaria. Studies to determine further 
benefits of adding azithromycin to PMC are warranted, however because of safety concerns due to 
the concomitant administration of DP and azithromycin, both of which are known to cause QT 
prolongation, an alternative broad-spectrum antibiotic or alternative antimalarials may be 
considered, or studies to determine the safety of DP and azithromycin co-administration may be 
needed. 
DP has been evaluated in several trials looking for alternative drugs for IPTp because of the 
widespread resistance of plasmodium falciparum to SP.6 It has been shown to have better anti-
malaria prophylactic effects than SP. However, despite the high resistance, SP has been associated 
with better or similar pregnancy outcomes compared to DP possibly because of the additional non-
malaria properties of SP; e.g. through its antibiotic effects or potential anti-inflammatory effects as 
were demonstrated for cotrimoxazole. An individual participant data meta-analysis of three 
recently completed trials comparing the efficacy of IPTp with DP and SP shows that SP has a potent 
non-malaria effect on birth weight (ter Kuile et al, personal communication), which explains the 
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higher mean birth weight in the SP arms relative to IPT with DP observed in these trials. The 
combination of DP plus SP would possibly result in better outcomes among severely anaemic 
children because of the antibiotic/anti-inflammatory effects of SP in addition to the significant 
outcome of a reduction in post-discharge mortality and morbidity due to the anti-malarial effects of 
DP seen in our trial in this setting. 
Another possible regimen is an azithromycin-chloroquine combination, both of which have anti-
malarial and anti-inflammatory properties with well-established safety profiles. Co-administration 
of azithromycin and chloroquine has been shown to have synergistic effects against Plasmodium 
falciparum infections. Azithromycin-1000mg and chloroquine 600mg base combinations 
administered once daily for three days has been shown to achieve 28 days malaria-free periods of 
>98% in adults in two clinical trials in sub-Saharan Africa. Chloroquine monotherapy was previously 
evaluated in a clinical trial with the hypothesis that the anti-inflammatory effects of chloroquine 
against Plasmodium falciparum induced prolonged inflammation may potentiate erythropoietic 
recovery, but the findings were indifferent with the placebo arm, possibly because of the low dose 
of chloroquine used and recruitment of participants during a low malaria transmission season.59 
Because of the anti-malarial and antibiotic effects of chloroquine and azithromycin, use of a 
treatment dose of chloroquine in combination with azithromycin merits an evaluation among 
children admitted with severe anaemia in malaria-endemic areas to reduce post-discharge 
mortality and morbidity. 
Another possible intervention worth exploring in the addition of vitamin A into the PMC regiment 
(or Vitamin A bolus on discharge) to improve on Vitamin A associated causes of severe anaemia. As 
discussed above, Vitamin A deficiency has been shown to be a major factor leading to severe 
anaemia in sub-Sahara Africa40 and Vitamin A supplementation has been shown to reduces the 
incidence of malaria infection and parasite densities.60 Another randomised controlled trial in 
Tanzania also found that the addition of Vitamin A and C to monthly SP for management of children 
with mild malarial anaemia was associated with improvements in the mean serum transferrin 
receptor levels compared to children who received SP alone.61  
PMC Delivery mechanism 
The studies described in this thesis were part of the activities of a PMC Consortium. This included a 
delivery mechanism trial in Malawi. This cluster-randomised controlled trial in Malawi compared 
community-based delivery mechanisms of PMC (drugs for all PMC courses were given to caretakers 
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at the time of discharge) versus facility-based approaches (drugs collected monthly by caretakers at 
the facility) with and without SMS reminders. It was found that community-based delivery achieved 
higher adherence (Nkosi-Gondwe, unpublished). A nested study among the caregivers showed that 
PMC was highly acceptable and home-based delivery together with SMS reminders was preferred 
to the health-facility collection of drugs or reminders from healthcare workers due to convenience 
and economic reasons.62 No conclusions could be made regarding the addition of SMS reminders 
because very few were delivered to the intended participants due to low mobile phone usage and 
coverage in Malawi. SMS reminders have been deployed in the management of various health 
issues in Africa with mixed results,63 therefore further studies to evaluate the addition of SMS 
reminders in the delivery of PMC are warranted. 
The WHO recommends the utilisation of existing community platforms for the delivery of SMC.64 
Randomised-controlled trials have shown that the delivery of SMC by community health workers 
(CHWs) can achieve high coverage and is cost-effective.65 However, utilisation of CHWs in existing 
routine programmes has been shown to achieve less coverage. In a study in Mali, 84% of eligible 
children received the first course of SMC and only 54% completed the four recommended 
courses.66 In Ghana, there was no difference in the completion rates of all the three doses of IPTc 
when it was delivered at the community by CHWs or at the health facilities (91.6% and 91.7%).67 In 
Malawi, less than half of the CHWs made the required reminder home visits mainly due to high 
workload, inadequate training, low community acceptance and other organizational challenges.68 
PMC may be another addition to the workload, therefore, further evaluation of delivery options for 
PMC are warranted. 
Policy implications  
The current standard practice for the post-discharge management of severe anaemia in malaria-
endemic areas entails the provision of artemether-lumefantrine at discharge if malaria was 
suspected and a short course of iron and folate (Chapter 5). PMC offers a potential strategy to 
reduce the high post-discharge morbidity and mortality observed in this population. Similar 
strategies which have been successfully deployed for the control of malaria including IPTp, IPTi and 
SMC (Chapter 2). Therefore, PMC is a potential new strategy to reduced childhood mortality and 
morbidity if found to be acceptable and cost-effective and if a sound delivery mechanism for the 
delivery of the intervention can be found.  
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Furthermore, the epidemiologic and geographical areas where PMC would be a cost-effective 
strategy needs to be determined. This involves identification of the optimal target population of 
children, the proportion that access hospital care and get adequate management, and their 
geographical location in the malaria-endemic setting. A similar strategy to identify these targets 
group and geographical areas were used to identify the appropriate areas for SMC deployment.69 
To support this process we conducted the systematic review and meta-analysis of studies reporting 
the burden of severe anaemia and the post-discharge risk of morbidity and mortality in malaria-
endemic areas of Africa (Chapter 4). A next step is to combine the results of our trial (Chapter 6) 
with the three previous efficacy trials in Malawi1 and the Gambia7,8 using a formal individual-level 
participant data meta-analysis to obtain a summary effect measure overall and by transmission 
strata (perennial vs highly seasonal) This information would then be used in a spatially-stratified 
mathematical model to simulate the impact of the intervention on morbidity in the presence of the 
existing malaria control interventions (e.g. ITN, IRS, mass drug administration, malaria vaccine etc.) 
at various levels of deployment. These activities are currently being conducted by other groups as 
part of the PMC consortium. 
In order to facilitate the adoption of PMC as a management strategy for severe anaemia, the 
consortium included a policy taskforce as one of its major objectives. Local senior paediatricians 
and health managers were involved in the protocol development. In addition to ethical and 
regulatory approvals, the study protocol was reviewed and approved by the Ministry of Health and 
the regional referral hospitals in both countries. Some senior hospital staff also supported the 
training of study personnel and facilitated other aspects of the study, such as laboratory tests and 
sample storage before shipment to the research laboratories. We conducted sensitization meetings 
in all study hospitals and to regional/County health management teams before and after the study 
was concluded. During these meetings, the study rationale was shared in detail; we realised that, 
outside of a research setting, the hospital staff have limited awareness of the burden of the post-
discharge burden of severe anaemia in this malaria-endemic setting. We stressed that this study is 
designed to complement the efforts of reducing under-five mortality, a struggle which has mainly 
concentrated on reducing in-hospital mortality in the past decade. The study findings will be 
presented to the Kenya National Malaria Control Programme in the second quarter of 2020. The 
Ugandan National Malaria Control Programme is already considering including PMC in their Malaria 
strategy because of the impressive study findings. The study findings have been presented to the 
WHO and further discussions are ongoing. 




Most of the limitations identified in this thesis have been discussed in the respective chapters, and 
further limitations will be highlighted in this section. 
In Chapter 3, we used data from one hospital within the KEMRI/CDC HDSS, and this being the major 
referral hospital there is a possibility that only the most severe cases were considered in this 
retrospective analysis. There are other lower-level hospitals within the HDSS area that provide in-
patient care, but no paediatric in-patient surveillance was on-going in these other hospitals. It is 
thus possible that mortality rates are underestimated in our studies if they were referred to these 
other hospitals. By contrast, it is also possible that the overall mortality rates are overestimated if 
the most severe cases were referred to the study hospital from these lower-level facilities. A 
retrospective cohort analysis of HDSS data in Mozambique found a significant positive association 
between transfer from other facilities and post-discharge mortality.42  
In Chapter 3 and 4, we excluded children with sickle cell anaemia and other haemoglobinopathies, 
trauma, surgical conditions and malignancies in estimating the risks of post-discharge mortality and 
morbidity. A recent post-discharge mortality study in Tanzania among the general paediatric 
population reported that chronic conditions such as cancer, cardiovascular diseases and sickle cell 
anaemia were significantly more associated with post-discharge mortality than other conditions.52 
It was also not clear if these may have been included under `undefined conditions` in the studies 
included in Chapter 4 because they were not expressly mentioned. The burden of post-discharge 
mortality may, therefore, be underestimated. Further, the determination of the post-discharge 
risks of mortality associated with chronic conditions in malaria-endemic areas is worth exploring 
because of their associations with severe anaemia. In Chapter 4, we did not find sufficient data on 
post-discharge morbidity and mortality for children admitted with diarrhoea, yet it is a common 
cause of paediatric admission in resource-poor countries.70 The limited focus on post-discharge 
mortality associated with diarrhoea in sub-Saharan Africa was highlighted in a recent publication 
where they noted that since 2013, 17 more studies on diarrhoea have been published with none 
reporting on post-discharge mortality.71 This paucity of data on follow-up studies on paediatric 
diarrhoea precluded any comparative analysis of post-discharge mortality risk of children admitted 
with diarrhoea and anaemia or other conditions in our systematic review. Similar challenges were 
faced with data on bacteraemia, possibly because of inadequate diagnostic and culture facilities in 
most facilities in this setting.  
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The search for studies included in the systematic review and meta-analysis in Chapter 4 was closed 
in October 2018, and since then, more studies have been published in sub-Sahara Africa on post-
discharge mortality and morbidity and thus are not included in this thesis.42,71,72 The new evidence 
which has come up will be included in future updates of our systematic review and meta-analysis. 
A limitation in the PMC trial is the relatively short duration of the intervention period. We observed 
a 70% reduction in the incidence of the primary outcome during the intervention period and the 
effect was absent in the subsequent post-intervention period. A significant number of events 
occurred between 15 and 26 weeks, 47% (126/184) of all events post-randomisation; 34% 
(107/316) in the placebo arm and 68% (233/500) in the PMC arm. It is thus likely that more events 
would have been prevented had the intervention period been longer. Studies to determine the 
optimum duration for the PMC intervention are warranted. 
Conclusions  
This study shows that children admitted with acute conditions in malaria-endemic areas in sub-
Saharan Africa are at a high risk of post-discharge mortality and morbidity in the first few months 
during the post-discharge period. Admission with all-cause severe anaemia in this setting is 
associated with a doubling of the risk of post-discharge mortality compared to other acute 
conditions. Coexistence of severe acute malnutrition further worsens this risk. Malaria 
chemoprevention with three monthly courses of DP is a promising tool for post-discharge 
management of children recently admitted with severe anaemia in malaria-endemic areas. Further 
studies of effective delivery mechanisms are now warranted. 
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